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ABSTRACT 
Encephalitis lethargica affected a large number of people in the pandemic in the early 
1900s (von Economo, 1930). Histological and biochemical data suggest that autoimmune 
mechanisms play an important role in this disorder and recently serum anti-basal ganglia 
antibodies (ABGA) have been detected in affected sporadic cases associated with evidence 
of recent streptococcal infection (Dale et al., 2004a). ABGA are also associated with other 
neuropsychiatric disorders including Sydenhams chorea, paediatric autoimmune 
neuropsychiatric disorders associated with streptococcal infections, Tourettes syndrome 
and obsessive compulsive disorder. The precise frequency, presentation, disease course, 
treatment response and causes of these disorders are still unknown. As ABGA are strongly 
associated with recent streptococcal infection, these disorders represent a potentially good 
model for the study of molecular mimicry and autoimmunity. 
The present study focussed on various aspects of this group of disorders. Profiling  of group 
A streptococcus isolates from both patients with postulated post-streptococcal disorders of 
the CNS and controls was done which highlighted differences in virulence factors like M 
protein and superantigens between the two groups. Also in the present study we 
demonstrated the pathogenicity of anti-neuronal antibodies found in patients in both an in 
vivo and in vitro setting.  An animal model of the disorders was produced by passive 
transfer of antibodies from patients which resulted in symptoms reminiscent of diseases 
like encephalitis lethargica and dystonia. An active immunization animal model using 
GABHS proteins and recombinant proteins (putative autoantigens) was also developed. 
Furthermore, the autoantibodies from patients and animal models were analysed on both 
neuronal and non-neuronal cells where they demonstrated to have a functional effect on 
cytotoxicity, apoptosis, calcium flux and enolase activity. N-methyl D-aspartate glutamate 
receptor and voltage gated potassium channel have been recently been implicated in a 
16 
 
range of neurological disorders, hence we also tested the patient sera for antibodies 
against these receptors and found a group of patients to be positive.  
In summary, EL and other ABGA-associated disorders are still an emerging entity, with 
major implications for neuropsychiatry. As auto-antibody mediated diseases respond to 
immunomodulatory therapy, identifying and defining the pathogenesis of these disorders is 
important so that patients can be appropriately treated. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 THE BASAL GANGLIA 
1.1.1 Background 
The basal ganglia are large subcortical gray matter masses in the brain comprising of the 
caudate nucleus, the putamen, the globus pallidus and the nucleus accumbens (Ringwood 
and Serra-Mestres, 2002).  The basal ganglia have been considered an important area in 
motor control of musculature since the 19th century (Ferrier et al., 1876). They are also 
involved in psychomotor behaviour including motor learning, sequencing and movements, 
attention allocation and filtering, working memory and implicit learning and memory 
(Alexander et al., 1986; Brown et al., 1999; Nakano, 2000; Ringwood and Serra-Mestres, 
2002). The basal ganglia do not have direct output connections to the spinal cord so the 
motor functions are mediated though the pyramidal system of neurones (Percheron et al., 
1994). 
The neurones comprising the basal ganglia are arranged in a complex system but the 
efferent neurones are GABAergic medium spiny neurones (Parent et al., 1993). These 
neurones contain the inhibitory neurotransmitter gamma-amino-butyric acid (GABA) and 
can be typed depending on the dopamine receptor type they contain (Albin et al., 1989; 
Ribak et al., 1979). Neuronal function within the basal ganglia is modulated by 
dopaminergic innervations from both within and outside the striatum, especially from the 
substantia nigra (Cossete et al., 1999). The main transmission system of the basal ganglia 
originates in the neocortex and the basal ganglia receive inputs from the associative areas 
of the neocortex and sensori-motor cortex (Gerfen, 1984; Haber et al., 1995). The cortex 
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utilises glutamate as the neurotransmitter and interact with the medium spiny neurones in 
the striatum (Bouyer et al., 1984; Cherubini et al., 1998).  
1.1.2 Basal Ganglia Disorders 
 
The consequences of disorders affecting the basal ganglia are not completely understood 
but include hypo and hyperkinetic movement abnormalities and a range of 
neuropsychiatric symptoms (Dale and Brilot, 2012). The neurotoxin, 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) has given some insights into the relationship of the basal 
ganglia to Parkinsons disease (PD), a classical hypokinetic movement disorder characterised 
by rigidity and slow movements. MPTP causes extensive neuronal dopaminergic 
degeneration and a Parkinsonian phenotype due to over-reactivity of the neurones in the 
striatum and dysregulation of dopaminergic neurones (Dale and Brilot, 2012, Herrero et al., 
1993).  
Overt damage to the basal ganglia resulting in tissue lesions results from infections, 
tumours, vascular disorders, genetic disorders and trauma. Such lesions commonly result in 
apathy and loss of self-initiative (abulia) (Bhatia et al., 2004). The movement disorder 
dystonia, an extrapyramidal movement disorder with slow and sustained muscle 
contractions, is also common (Bhatia et al., 1994). The other common outcomes of basal 
ganglia lesions are chorea (fast, purposeless movements-hyperkinetic disorder) and 
athetoid-type movement disorder (slow, sinuous movements), (Destée et al., 1990; Denny-
Brown., 1968). Disease of the basal ganglia associated with progressive neuronal loss and a 
genetic pathology or association, include Huntingtons disease (HD). This is typically a 
progressive hyperkinetic movement disorder with associated cognitive loss and dementia 
(Graveland et al., 1985). Wilson’s disease is another genetic disorder associated with 
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abnormal copper metabolism and results in degeneration of the putamen and globus 
pallidus causing tremor and rigidity (Wilson, 1912; Giagheddu et al., 2001). 
Psychiatric symptoms such as obsessive-compulsive disorder (OCD) and behavioural 
abnormalities have also been described associated with basal ganglia lesions (Laplane et al., 
1989). The reason for the psychiatric abnormalities is that basal ganglia circuits have 
functional roles in oculomotor, pre-frontal, and cingulate pathways which are central to 
attention, learning and behavioural control (Brown et al., 1999; Gerfen, 1984; Haber et al., 
1995; Yamashiro et al., 1997). Disruption in these circuits can therefore result in a range of 
extrapyramidal movement disorders and neuropsychiatric symptoms of which Sydenham’s 
chorea (SC) is a good example. This disorder has been proposed as having an immune 
mediated pathogenesis (Kiplan et al., 2003). 
Movement disorders (such as Huntingtons and Parkinsons diseases) occur due to damage 
to the basal ganglia and therefore it is proposed that Tourettes syndrome (TS) is linked to 
the basal ganglia (Peterson et al., 2003). In support of this hypothesis, studies have shown 
tic like behaviours in humans and animals are associated with electrochemical 
manipulation and lesions of the basal ganglia. Furthermore, neuroleptic drugs which treat 
tic disorders, work by blocking dopamine receptors in the basal ganglia (Peterson et al., 
2003). Despite this strong circumstantial evidence, investigations into basal ganglia 
abnormalities in TS patients have produced conflicting results. Some studies have shown 
that the caudate nucleus is significantly reduced in size across all age groups with TS and 
that the left lenticular nucleus, putamen and globus pallidus are significantly smaller in TS 
adults (Peterson et al., 1993; Peterson et al., 2003). Other studies disagree and claim basal 
ganglia volumes are not significantly different in TS patients compared to controls (Singer 
et al., 2005). 
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1.1.3 Anti-basal Ganglia Antibodies  
Anti-basal ganglia antibodies (ABGA) are anti-neuronal autoantibodies directed against the 
basal ganglia. They have been associated with movement disorders and psychiatric 
disturbances in adults and children postulated to be occurring as a result of infection, 
particularly with group A beta-hemolytic streptococcus (GABHS). Autoimmune mechanism 
involving molecular mimicry has been proposed. These antibodies have been shown to bind 
to common neural autoantigens of molecular weight 40, 45, 60 and 98 kDa (Church et al., 
2003). Studies have shown that ABGA are specific for several antigens in TS and obsessive 
compulsive disorder (OCD) patients, including putamen and proteins of molecular weight 
60, 67 and 83 kDa (Singer et al., 1998; Church et al., 2003; Hoekstra et al., 2003). ABGA 
antigens have also been identified in SC, with molecular weights of 40, 45 and 60 kDa 
(Church et al., 2002). Subsequent studies have identified these as the glycolytic enzymes 
aldolase C, neuronal enolase and pyruvate kinase M1 respectively (Dale et al., 2004). In 
addition, ABGA have also been observed in patients with acute disseminated 
encephalomyelitis (ADEM), an autoimmune inflammatory disorder of the nervous system 
(Dale et al., 2001). This study demonstrated that ABGA are significantly elevated in ADEM 
patients compared to controls and that they bind to basal ganglia antigens with molecular 
weights of 60, 67 and 80 kDa (Dale et al., 2001). This study suggested that ADEM should be 
included within the post-streptococcal sequelae group and also supports other studies 
which propose that the 60kDa antigen could be a critical factor in anti-neuronal 
autoimmune responses (Singer et al., 1998; Singer et al., 1999; Trifiletti and Bandele, 2000; 
Church et al., 2003). As mentioned earlier, one study reported this to be pyruvate kinase 
M1, however a different study suggests it could also be human heat shock protein 60 
(hsp60) (Hoekstra et al., 2003).  This latter study observed higher anti-hsp60 titres in 
patients with tics but not with attention deficit hyperactivity disorder (ADHD) and OCD. 
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Hsp60 is ubiquitously present in tissue, where it functions as a molecular chaperone 
protein, involved in protein assembly and folding. It can be released extracellulary where it 
is thought to protect cells and prevent damage in response to toxic agents. Antibodies to 
hsp60 are extremely common and bacterial and parasitic hsp60 show a high degree of 
homology with human hsp60. Indeed several rheumatic autoimmune diseases are linked 
with abnormal reactivity to hsp60, including severe coronary heart diseases, juvenile 
chronic arthritis and carotid (Hoekstra et al., 2003).  
The blood-brain barrier (BBB) results from the selectivity of the tight 
junctions between endothelial cells  in CNS vessels that restricts the passage of solutes. 
Normally, the CNS would be inaccessible to leukocytes due to this barrier, however, in 
various diseases the barrier function is compromised examples of which include epilepsy, 
multiple sclerosis, meningitis, Alzheimer’s disease and progressive multifocal 
leukoencephalopathy (PML) (Luissint et al., 2012). It has been suggested that rather than 
being a disease of the immune system these might be diseases of the BBB. In epilepsy 
studies have implicated the interactions between albumin, a common blood protein and 
astrocytes (Ivens et al., 2007). Similarly loss of function of vascular P-glycoprotein an ATP-
binding cassette transporter which is highly expressed at the BBB has been reported during 
neuroinflammation in models of multiple sclerosis (Kooij et al., 2011). Notably, lymphocyte 
interaction via endothelial intracellular adhesion molecule -1 (ICAM-1) caused the 
activation of a nuclear factor kappa B (NF-kappaB) signalling pathway, which resulted in 
endothelial P-gp malfunction (Kooij et al., 2010).  
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1.2 AUTOIMMUNITY  
1.2.1 What is Autoimmunity? 
Autoimmununity is a condition triggered by the immune system initiating an attack on self-
molecules due to deterioration of immunologic tolerance to auto-reactive immune cells 
(Atimal and Shoenfeld, 2004).  Some examples of autoimmune diseases include Coeliac 
disease, rheumatoid arthritis (RA), diabetes mellitus type 1 (IDDM), systemic lupus 
erythematosus (SLE), Sjögrens syndrome, Churg-Strauss Syndrome, Graves disease, 
idiopathic thombocytopenic purpura (PubMed Health) . Although autoimmune disorders 
can affect an individual of any gender, age or race certain people are more susceptible 
taking into account certain risk factors associated with these disorders (figure below). For 
example it is known that females, young to middle-aged individuals, individuals with a 
family history and individuals from African American/American Indian/ Latino ethnicity are 
at an increased risk of developing an autoimmune disorder (Page et al., 2012, Gleicher and 
Barad, 2007). Also exposure to certain medications (e.g. procainamide) or metals (e.g. 
mercury) and bacterial and viral infections in a genetically susceptible individual could 
contribute towards an increased risk (Bernstein, 1985).  
                                         
25 
 
                        
Figure 1.1: Risk factors associated with autoimmune disorders.The figure above depicts 
some of the risk factors found to be associated with the development of an autoimmune 
disorder. 
The exact aetiology of autoimmune diseases is not known. However, various theories have 
been proposed that include sequestered antigen, escape of auto-reactive clones, loss of 
suppressor cells, cross reactive antigens including altered self antigens (chemical and viral 
infection)  and exogenous antigens (pathogens) (Ghaffar and Ngarkatti, 2010, Gleicher and 
Barad, 2007). 
Witebsky's postulates 
Autoantibodies and to some extent self-reactive T cell clones have been detected in 
patients with a variety of diseases. However, a causative role in disease development has 
not always emerged and a set of criteria had to emerge to distinguish bona fide 
autoimmune diseases from other diseases in which some feature of autoimmunity is 
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present but in which a causative role is lacking, these are termed as Witebsky's postulates 
(Rose and Bona, 1993): 
- Direct evidence from transfer of pathogenic antibody or pathogenic T cells. 
- Indirect evidence based on reproduction of the autoimmune disease in experimental 
animals. 
- Circumstantial evidence from clinical clues. 
1.2.2 Bacteria and Autoimmunity 
In addition to viruses, a number of other pathogens including bacteria have been 
associated with autoimmune diseases involving chronic inflammation and demyelination. 
Extensive research is being done to better understand the possible mechanisms of bacterial 
involvement as aetiological agents or in the exacerbation of these diseases. Variety of 
bacterial infections have been linked with rheumatoid conditions (Sherbet, 2009). Infection 
by Mycoplasma pneumoniae, M. salivarum, and M. fermentans, has been strongly 
associated with rheumatoid arthitis (Furr et al., 1994; Haier et al., 1999). Proteus mirabilis 
has also been implicated in the pathogenesis of RA and in osteoarthitis (OA) (Tiwana et al., 
1997; Wanchu et al., 1997). Borrelia burgdorferi, which is transmitted by tics, typically 
causes cutaneous disease, encephalitis and arthitis (Steere, 2001). Borrelia burgdorferi 
sensu stricto infection is usually associated with a reactive arthitis, but 10% of these 
patients also develop an autoimmune form of Lymes disease arthitis. This form of arthitis is 
associated with constant inflammation and is treatment resistanct (Guerau-de-Arellano et 
al., 2002; Steere, 2001).   
Bacterial infections have been found to be associated with autoimmune conditions besides 
RA. Certain members of the Enterobacteriaceae family are linked with Kawasaki syndrome 
27 
 
and Graves’ disease (Sherbet, 2009). Haemophilus influenzae, Campylobacter jejuni, and M. 
pneumoniae have been highlighted as the possible causative agents of a demyelinating 
neuropathy called Guillain-Barre (GB) syndrome (Yuki, 2007). Recently studies involving 
serology and PCR have provided evidence of Chlamydophila pneumoniae, Mycoplasma 
species, Borrelia burgdorferii and human herpesvirus-1 and -6 in multiple sclerosis (MS), 
amyotrophic lateral sclerosis (ALS) Alzheimers and Parkinsons disease (Nicolson, 2008; 
Sherbet, 2009).  
Group A beta-haemolytic streptococcus (GABHS) or Streptococcus pygogenes has been 
linked with autoimmune disease in humans with particular involvement of the heart, joints, 
and brain.  
               
 
Figure 1.2: Postulated autoimmune aetiology of post-streptococcal disorders. GABHS 
infection in a susceptible host leads to molecular mimicry thereby raising autoantibodies 
leading to disorders such a rheumatic fever characterized by carditis, neuropsychiatric 
disorders like Sydenhams chorea (SC) and rheumatoid arthitis. 
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1.3 GROUP A BETA-HAEMOLYTIC STREPTOCOCCUS (GABHS) 
1.3.1 Background 
Streptococcus is a genus of spherical Gram-positive bacteria. The bacteria is non-motile and 
non-sporeforming and characteristically forms pairs or chains during growth (Todar, 2008). 
Streptococci are oxidase and catalyse negative and many are facultative anaerobes. They 
are generally strong fermenters of carbohydrates resulting in the production of lactic acid, 
a property employed in the dairy industry (Greenwood et al., 2007). Some streptococci are 
important ecologically as part of the normal microbial flora of animals and humans, while 
others are associated with important human diseases ranging from subacute to acute or 
even chronic, attributable in part to infection by the bacteria and in part to sensitization to 
them (Brooks et al., 2007).  
Lancefield group A streptococci consists of a single species, Streptococcus pyogenes which 
typically produces a large zone of beta-haemolysis when cultured on blood agar plates, and 
is therefore also called Group A beta-haemolytic Streptococcus (GABHS) (Ryan and Ray, 
2004). It is associated with a wide range of supparative infections in the skin and 
respiratory tract, life theatening soft tissue infections and certain types of toxin- associated 
reactions (Hayes et al., 2001). Acute S. pyogenes infections may take the form of 
pharyngitis, impetigo, cellulitis or scarlet fever (Cunningham, 2008). Invasive infections can 
result in streptococcal toxic shock syndrome, necrotizing fasciitis or myositis (Hahn et al., 
2005).  
GABHS express a number of cell surface components and extracellular products that play 
an important role in its pathogenesis and in the immune response of the host as discussed 
previously. Although the pathophysiology of post-streptococcal disorders is not completely 
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understood, antigenic mimicry is proposed to be the triggering cause of autoimmunity 
(Hahn et al., 2005; Greenwood et al., 2007). 
Evidence suggests that GABHS contain antigens which are similar enough to host antigens 
and can stimulate B and T cells to respond to self. The streptococcal M protein, N-
acetylglucosamine, and group-specific carbohydrate contain antigenic epitopes that mimic 
those of mammalian muscle and connective tissue. Of all the streptococcal antigens 
involved in molecular mimicry, the M protein has been best investigated and characterized 
(Bordeur, 2003). 
1.3.2 Virulence factors 
GABHS elaborates a number of cell surface components and extracellular products that 
play a central role in the pathogenesis of infection and the immune response of the host 
(Stevens et al., 2012). Although some factors are expressed by all clinical isolates others are 
variably present among S. pyogenes strains. This variation is owed to the horizontal transfer 
of virulence genes among the strains primarily by transduction. This explains the temporal 
variations in the prevalence of severe infections and sequelae together with differences in 
the virulence of individual strains (Lamagni et al., 2008). 
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Figure 1.3: GABHS virulence factors. Schematic diagram showing some of the virulence 
factors associated with GABHS.  
1.3.2.1 Streptolysins  
GABHS expresses two distinct streptolysins, Streptolysin O and S both of which lyse 
erythocytes, polymorphonuclear leucocytes and platelets by forming pores in their 
membrane (Bisno et al., 2003).  
Streptolysin O (SLO) 
Streptolysin O (oxygen labile) is a protein that is haemolytically active in the reduced state 
(available –SH groups) but rapidly inactivated in the presence of oxygen (Thelestam and 
Molby, 1980). Cytolysin-mediated translocation (CMT) of GABHS uses streptolysin O to 
translocate the bacterium’s nicotinamide adenine dinucleotide-glycohydrolase (SPN) into 
the host cell cytosol, resulting in cell death (Magassa et al., 2010). Analysis of GABHS 
virulence factor mutants, heterologous expression, and purified toxin studies identified the 
pore-forming streptolysin O both necessary and sufficient for the apoptosis-inducing 
phenotype (Timmer et al., 2009). Streptolysin O is also capable of affecting the immune 
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response by impairing neutrophil function and inducing monocytes to produce tumour 
necrosis factor (TNF) and keratinocytes to produce a host of inflammatory cytokines 
(Bremm et al., 1987; Hackett et al., 1993; Ruiz et al., 1998). 
Streptolysin S (SLS) 
The molecular identity of Streptolysin S was revealed only recently and characterization of 
partially purified preparation has suggested it to be 2.8 kDa protein (Betschell et al., 1998; 
Nizer et al., 2000; Wessels MR, 2005). SLS is known to be responsible for the beta-
haemolysis around streptococcal colonies on blood agar plates and plays a role in inhibition 
of neutrophil recruitment during the early stages of infection (Lin et al., 2009). It is known 
to be produced by a vast majority of GABHS strains however, SLS negative strains (non-
haemolytic)have been more associated with human infections which suggests that SLS 
might not be essential for virulence (Sierig et al., 2003; Wessels et al., 2005). 
1.3.2.2 C5a Peptidase 
Virulent strains of S.pyogenes are found to produce a C5a peptidase (SCPA) which is bound 
to their surface and specifically cleaves human C5a one of the principle chemo-attractants 
of the phagocytic cell (Brown et al., 2005). Activation of the complement system by either 
the classical or alternative pathway generates C5 convertase that proteolytically liberates 
C5a, a 74-residue chemotactic peptide (O’Connor and Cleary, 1987). A chemical gradient of 
C5a attracts phagocytic polymorphonuclear leukocytes to the site of infection to form the 
first line of defence against persistent colonization and invasion of deeper tissues (Cleary et 
al., 1992). 
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1.3.2.3 Hyaluronic Acid Capsule and Hyaluronidase 
Some strains of GABHS form a capsule made up of hyaluronic acid (Sugahara et al., 1979; 
Schager et al., 1996). The capsule presenting strains grow as mucoid colonies on blood agar 
plates and the capsule of GABHS has been shown to enhance virulence in systemic and 
intranasal challenge models (Sugahara et al., 1979; Schager et al., 1996). The encapsulated 
strain has been shown to be highly virulent, producing extensive local tissue necrosis and 
secondary bacteraemia, compared to the un-encapsulated strain that produced fewer and 
less severe local lesions with no animals developing bacteraemia (Blank et al., 2005). The 
capsule is identical to the hyaluronic acid of the host connective tissue and is not 
immunogenic. In this way the bacteria disguise themselves with an immunological self 
substance (Schrager et al., 1996). Secreted hyaluronidase is released by the bacterium to 
degrade hyaluronic acid the ground substance of host connective tissue. During infections 
of the skin, serum antibody titres to hyaluronidase show a significant rise (Harris et al., 
1950).  
1.3.2.4 F Protein 
F protein has been shown to be surface-expressed and to bind tightly to fibronectin, the 
extracellular matrix protein to which GABHS bind (Hanski et al., 1992).  M protein is not 
expressed under conditions that promote expression of F protein (high O2 and low CO2), 
and vice versa.  The interaction between the streptococcal F protein and host cell 
fibronectin also mediates internalization of the bacteria into the host cells (Stevens et al., 
2000; Greenwood et al., 2007).  
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1.3.2.5 Streptokinase (Fibrinolysin) 
Streptokinase is produced by many strains of GABHS. It transforms the plasminogen of 
human plasma into plasmin an active proteolytic enzyme that digests fibrin and other 
proteins (Tewedros et al., 1995). GABHS uses host plasmin to hinder the build-up of fibrin 
barriers resulting in soft tissue infections that are more diffused and often spread readily 
than well localized abscesses (Bardia, 2007). 
1.3.2.6 Superantigens (SAg) 
Microbial superantigens (SAg) are a family of protein exotoxins that cause non-specific 
activation of T-cells resulting in polyclonal T cell activation and massive cytokine release 
(Llewelyn and Cohen, 2002). These extracellular pyogenic exotoxins are important as they 
cause direct tissue damage by initiation of apoptotic pathways or disruption of mammalian 
cell-walls (Hallas, 1985; Saouda et al., 2001). These immunostimulatory molecules activate 
large numbers of T cells by binding simultaneously to both major histocompatibility (MHC) 
class II molecules and T cell receptors (TCR) (Brouillard et al., 2007). However, binding of 
superantigens to MHC class II molecules requires no prior processing and occurs outside 
the antigen-binding groove (Pullen et al., 1990). Compared to a normal antigen-induced T-
cell response where 0.001-0.0001% of the T-cells are activated, SAg are capable of 
activating up to 20% of the T-cells (Li et al., 1998). Conventional antigens, when presented 
to the major histocompatibility complex (MHC) on antigen-presenting cells, require 
recognition by all five variable elements (Vβ, Dβ, Jβ, Vα, Jα) of the TCR in contrast to SAg 
which are primarily recognized by only the Vβ chain of the TCR (Davis and Bjorkman, 1988). 
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Figure 1.4: Bioactivity of Superantigens (SAg). Diagrammatic representation of non-
specific activation of T-cells caused by streptococcal SAg. Once secreted SAg require no prior 
processing to interact with the antigen-presenting cell (APC). The activity of SAg depends on 
its ability to bind both the MHC class II and TCR outside the antigen binding groove. 
To date eleven distinct superantigens have been identified to be produced by GABHS 
including the pyrogenic exotoxins (Spe) A, C, G, H, I, J, K, L, M, ssa and smez (Norrby-
Teglund et al., 2001). The distribution of these superantigens varies between different 
streptococcal strains except exoproteins SpeB and SpeF  which are chromosomally encoded 
and function as a cysteine protease and DNase, respectively, however neither  of the two is 
a true SAg (Sriskandan et al., 2007). 
Microbial superantigens are medium size proteins (molecular weight 22-29 kDa) 
characterized by high resistance to proteases and to denaturation by heat (Papageorgiou 
and Acharya, 2000). Comparison of those structures already solved indicates conserved 
two-domain architecture (N terminal β-barrel domain and C-terminal β-grasp domain) and 
a long, solvent-accessible α-helix spanning the centre of the molecule (Baker et al., 2004, 
Bulliard et al., 1997). A common feature of several superantigens is the presence of a highly 
flexible disulphide loop within the N-terminal (Reda et al., 1994). Interestingly, this loop has 
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been implicated in the emetic properties of these bacterial toxins (Reda et al., 1994). Key 
regions interact with host major histocompatibility complex (MHC) class II molecules and 
the variable region of the T cell receptor (TCR) beta (TCRVβ) chain, thereby bringing MHC 
class II molecule and TCR together (Sriskandan et al., 2007). Despite this large amount of 
crystallographic information, many questions regarding the exact mode of superantigen 
function remain unanswered (Solanki et al., 2008). 
Binding affinity of superantigens for human leucocyte antigen (HLA) class II is believed to 
underlie the magnitude of superantigen induced T cell activation (Michaelson et al., 2011). 
Bacterial superantigens are known to exhibit a clear binding preference for human MHC 
class II molecules compared to murine (Faulkner et al., 2005). The difference between mice 
and human response to SAg is most likely related to the difference in the MHC class II 
structures (Sriskanadan et al., 2001). Mice expressing HLA class II transgenes 
(C57BL/10.DQ8) exhibit greater sensitivity to superantigen SPEA both in vitro and in vivo as 
compared to wild-type mice (Sriskanadan et al., 2001). Some earlier studies have also 
shown that immunization of mice with bacterial SAg lead to polyclonal expansion of 
specific Vβ T cell subsets approximately 2 days later followed by clonal deletion and a 
period of superantigen specific T cell anergy that eventually recovers (MacDonald et al., 
1991). Despite these findings it is difficult to extrapolate these immunological observations 
to the clinical setting as mice are comparatively resistant to superantigens and 
immunization with SAg cannot mimic the continuous release of the toxin into the tissue 
that occurs during an infection (Vabulas et al., 1996).  
Sub-lethal doses of superantigen and lipopolysaccharide (LPS) can induce a synergistic 
shock in rodents if co-administered (Bohach et al., 1990). The mechanism underlying this 
phenomenon is not completely understood. A recent study using human monocytes pre-
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exposed to superantigens SpeA, SmeZ, SEA, SEB for 3 hours showed a significantly 
exaggerated TNF-α response following LPS exposure (Hopkins et al., 2005). It is 
hypothesised that the synergy between LPS and superantigens is due to enhanced pattern 
recognition of LPS as superantigens presenting via MHC class II complex which leads to 
increased expression of toll like receptor 4 (TLR4) the pattern recognition receptor of LPS 
(Hopkins et al., 2005). In the HLA-DQ8 transgenic model described above (Sriskandan et al., 
2001) the mice pre-exposed to D-galactosamine (D-gal) demonstrated an enhanced 
sensitivity to SPEA. D-gal is used to sensitize mice to acute lethal effects of LPS and more 
recently to the effects of injected staphylococcal superantigens (Miethke et al., 1992). 
Further research into the structure-function relationships of bacterial superantigens is vital 
for a number of reasons. Firstly to identify potential new treatments for the growing list of 
diseases in which these toxins are implicated. Superantigens can down regulate the 
immune response following acute exposure resulting in anergy and /or deletion of T cells, 
this potential of SAg can be exploited to eliminate specific populations of T cells involved in 
autoimmune disorders (Sriskanadan et al., 2001; Michaelson et al., 2011). SAg or 
superantigen toxoids might also be suitable vaccine targets (Sriskandan et al., 2007). 
Delivered in such a way as to trigger only MHC class II antigen signalling, SAg may prove to 
be excellent vaccine adjuvants or stimulants (Hopkins et al., 2005). 
1.3.2.7 Emm gene and M protein 
Emm gene 
The emm gene is located on the chromosome near the GABHS multiple gene regular and 
encodes the M protein. A single strain may express up to three distinct emm genes with skin 
and throat serotypes distinguished by genetic markers located in the 3’ end. This portion 
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encodes the cell-associated regions of the M protein and is highly conserved between 
different serotypes. The nucleotide sequences of the 3’ ends are divided into 4 phylogenetic 
lineages, each representing a subfamily of emm genes (SF1 –SF4). The content and relative 
chromosomal arrangement of the SF genes exists in 5 patterns (A-E) with patterns A, D, and 
E the most common. Strains with patterns A-C are most likely to be isolated from the 
throat, whereas D pattern strains are associated with impetigo. Strains with pattern E 
belong in a third group of GAS types but it is unclear which tissue sites these streptococci 
prefer (Bessen and Lombroso, 2001). 
An international protocol for amplifying and sequencing the emm gene has been developed 
at the centre for disease control and prevention (CDC).  Sequences can be compared 
against those in the CDC emm sequence database using their basic local search alignment 
tool (BLAST).  This database only includes sequences that have been obtained by the CDC 
streptococcal genetics laboratory. BLAST searches can be performed at 
http://www.cdc.gov/ncidod/biotech/strep/strepblast.htm. An emm sequence is defined as 
a particular serotype if it shares 95% identity with a database sequence over the first 160 
bases, or as many bases close to this figure. 
M Protein 
Streptococcal M protein is a major surface protein and virulence factor of group A, C and G 
-haemolytic streptococci (BHS) (Cunningham MW, 2000; Anand et al., 2012). It plays a 
central role in the pathogenesis by virtue of its anti-phagocytic properties. The M protein is 
attached to the cell membrane via an LPSTGE motif and consists of 2 polypeptide chains 
arranged in a -helical coiled coil configuration (Anand et al., 2012). These polypeptide 
chains pass through the cell wall and appear as fibrils on the cell surface (Cunningham MW, 
2000; Bisno et al., 2003). The primary structure of the M protein comprises 4 repeat 
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regions (A-D) which differ in amino acid sequence and size. Within these repeat blocks are 
7 residual repeats of non-polar amino acids. The carboxy-terminal region corresponds to 
the portion located within the cell wall and cell membrane, while the amino-terminal 
region extends from the cell wall into the environment (Cunningham, 2000; Bisno et al., 
2003). The carboxy-terminal portion is highly conserved between group A, C and G BHS, 
whereas the hypervariable region in the amino-terminal portion varies significantly 
between isolates. This hypervariable region corresponds to repeat region A (also known as 
the N terminal) and is used to serotype group A, C and G BHS (Cunningham, 2000; Bisno et 
al., 2003). Approximately a 124 types of M proteins have been discerned by serological 
means and gene sequencing, which could lead to recurrent infection in the individual with 
strains expressing different versions of this protein (Bisno et al., 2003; Ryan, 2004).  
 
 
 
 
 
 
 
 
 
 
39 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Structure of a streptococcal M protein. A typical streptococcal M protein 
showing the repeat regions (A-D), the proline and glycine rich peptidoglycan region and a 
hydrophobic portion. 
The primary function of the M protein is to inhibit phagocytosis, which enables GABHS to 
survive in host infected tissues (Zartash Zafar Khan, 2009). Some strains produce two 
different M proteins with anti-phagocytic activity and some an additional structurally 
related M –like protein. All of these can bind to various host plasma proteins like fibrinogen, 
plasminogen, albumin, IgA, IgG and factor H (Greenwood et al., 2007, Madigan et al., 2008). 
Hypervariable 
Variable 
Conserved 
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Binding of fibrinogen to streptococci expressing M proteins blocks complement disposition 
on the bacterial cell surface (Anand et al., 2012). Factor H, a complement regulatory protein 
binds to the C repeat region of the M protein, and a factor H–like protein binds to the 
hypervariable region (Fischetti et al., 1995). These 2 events both inhibit the deposition of 
soluble opsonic C3b to the bacterial surface and the net effect is inhibition of opsonisation 
by the alternate complement pathway (Fischetti et al., 1995). GABHS can release some of 
the M proteins with its own cystine protease (Raeder et al., 1998). If shed in the circulation 
the protein forms complexes with fibrinogen which by indirect pathways induces the 
release of inflammatory mediators from neutrophils. This process plays an important part in 
the leakage of plasma into the tissues and lungs (Lamagni et al., 2008). 
1.3.3 Anti-streptococcal antibodies as surrogate markers of infection 
 
Due to the delayed clinical manifestations in some of the post-streptococcal syndromes 
identification (culturing) and serotyping of the GABHS is not always possible as the 
infection may have cleared. In addition to a clinical history of pharyngitis or skin infection, 
surrogate markers can be used instead to assess recent infection. Surrogate markers 
measure the concentrations of host antibody levels against the extracellular antigens of 
GABHS. An increase or decrease in the antibodies can give some indication of the course of 
infection (acute, chronic, relapse or recovery) and hence the indication for treatment.   
1.3.3.1 Anti-Streptolysin O titre (ASOT) 
Neutralising antibodies are produced by the host as a protective measure against SLO and 
are termed anti-streptolysin O (ASO) antibodies (Todd, 1932; Wannamaker, 1958). 
Antibody titres against SLO (ASOT) rise during GABHS infection and usually peak between 3 
and 6 weeks after acute infection before falling (Todd, 1932). ASOT values where there is 
no clinical suspicion of rheumatism are less than 200 units in adults and less than 300 units 
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in children. Upper limit of normal ASOT values are known to vary with respect to site of 
infection, geographical locations and even season (Shet and Kaplan, 2002). A raised ASOT 
has been observed in 64% of children with TS as compared to 15% of paediatric 
neurological disease controls (p< 0.0001) (Church et al., 2003). Measurement of ASOT has 
its limitations, since over diagnosis of acute rheumatic fever (ARF) based on a raised ASOT 
is not uncommon (Kotby et al., 2012).  
1.3.3.2 Anti-deoxyribonuclease B titre (Anti-DNase B) 
Streptococcus also produces a number of deoxyribonucleases (DNAses A, B, C and D) which 
can break down deoxyribonucleic acid (DNA) and also elicit an immune response (Ayoub et 
al., 1962; Wannamaker., 1958).  Due to the limitations of ASOT, measuring antibodies 
against DNAse is also a useful indicator of GABHS as it is raised in skin infections and is 
elevated for longer than ASOT (Ayoub et al., 1962). Neutralising antibodies against DNAse B 
rather than A, C or D result in the strongest response during streptococcal infections 
(Wannamaker, 1959). Normal range of anti-DNAse B considered by most laboratories in the 
United Kingdom is <300 IU/mL. The benefit of anti-DNAse B is that the antibody response is 
still detectable later on in the disease course compared to ASOT and is more pronounced 
(Tiesler et al., 1976). Anti-DNAse titres are not thought to reach their maximum titre until 6 
to 8 weeks after acute infection (Kaplan et al., 1974). Other surrogate markers exist such as 
anti-hyaluronidase, although it closely mirrors that of anti-DNAse B and adds little to the 
diagnostic utility of the anti-DNAse B test (Hederstedt et al., 1978). 
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1.3.4 Molecular Mimicry Model  
 
Acute GABHS infections may take the form of pharyngitis, scarlet fever, cellulitis, or 
impetigo. Invasive infections can result in streptococcal toxic shock syndrome necrotizing 
fasciitis and myositis (Cunningham, 2000, Cunningham, 2008). Patients may also develop 
immune-mediated sequelae such as acute rheumatic fever and acute glomerulonephitis 
(Cunningham, 2000; Cunningham, 2004). S. agalactiae may cause meningitis, neonatal 
sepsis, and pneumonia in neonates; adults may experience vaginitis, puerperal fever, 
urinary tract infection, skin infection, and endocarditis (Lindahl et al., 2005). 
GABHS express a number of cell surface components and extracellular products that play 
an important role in its pathogenesis and in the immune response of the host as discussed 
previously. Although the pathophysiology of post-streptococcal disorders is not completely 
understood, antigenic mimicry is proposed to be the triggering cause of autoimmunity 
(Hahn et al., 2005, Greenwood et al., 2007) 
Evidence suggests that GABHS contain antigens which are similar to host antigens and can 
stimulate B and T cells to respond to self (Cunningham, 2000). The streptococcal M protein, 
as well as peptidoglycan, N-acetylglucosamine, and group-specific carbohydrate, contain 
antigenic epitopes that mimic those of mammalian muscle and connective tissue (Bordeur, 
2003). Of all the streptococcal antigens involved in molecular mimicry, the M protein has 
been best investigated and characterized (Cunningham, 2000; Tewodros and Kronvall, 
2005). Opsonophagocytosis, mediated by serum opsonins, such as antibodies or 
complement, is a key mechanism for host protective immunity against streptococcal 
infection (Baker et al., 1982). M protein has been shown to contribute to virulence, 
conferring resistance to phagocytosis under non-immune conditions by interfering with the 
complement pathway (Carlsson et al., 2005) . 
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The pathogenic response by a susceptible host most likely involves induction of cross-
reactive autoantibodies and the recognition of microbial epitopes by the major 
histocompatibility complex (MHC) proteins which present these epitopes to inflammatory 
(Th1, CD4
+) and cytotoxic (CD8+) T cell subsets (Cunningham, 2004). In studies to 
understand the mechanisms by which streptococcal antigens lead to autoimmune and 
post-infectious sequelae, production of human monoclonal antibodies and T cell clones 
have been utilized (Ellis et al., 2005, Kirvan et al., 2006) 
     
Figure 1.6: Molecular Mimicry Model. The current molecular mimicry hypothesis for the 
pathology of PANDAS is that streptococcal infection occurring in a vulnerable host leads to 
production/activation of immune cells that cross-react with the cellular components in the 
CNS eventually leading to neurological impairment.   
 Infection with GABHS 
Activation of antigen specific T and B-cells 
     Passive transfer of IgG/ Migration of T- cell clones into the CNS 
Focal cytotoxicity/ IgG mediated immunological cascade 
  Neurological Impairment 
  
44 
 
1.4 POSTULATED POST-STREPTOCOCCAL DISORDERS 
An understanding of the diverse nature of disease complications attributable to this 
organism is an important cornerstone of paediatric medicine. The following sections briefly 
detail some of the prevalent clinical entities in which molecular mimicry of GABHS is 
believed to lead to immunopathogenic tissue damage even after the successful elimination 
of the eliciting organism. 
1.4.1 Acute Rheumatic Fever (ARF) 
1.4.1.1 Background 
Acute rheumatic fever (ARF) is an autoimmune inflammatory process that develops as 
sequelae of GABHS infection (PubMed Health; Carapetis et al., 2005). ARF is characterized 
by non-suppurative inflammatory lesions of the joints, heart, subcutaneous tissue and CNS 
(Madden and Kelly, 2009). It is most prevalent in children between 5 and 15 years of age, 
although it can also develop in adults (Cunningham, 200; Crapetis et al., 2005). The 
recurrence of rheumatic fever is relatively common in the absence of maintenance of low 
dose antibiotics, especially during the first three to five years after the first episode. Heart 
complications may be long-term and severe, particularly if valves are involved (Carapetis et 
al., 2005). Disease symptoms include abdominal pain, fever, cardiac problems which may 
not have symptoms, or may result in shortness of breath and chest pain, joint pain and 
swelling, arthritis, nosebleeds, skin nodules, skin rash and Sydenhams chorea (emotional 
instability, muscle weakness and quick, uncoordinated jerky movements that mainly affect 
the face, feet, and hands) (Binotto et al., 2002; Carapetis et al., 2005). 
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1.4.1.2 Pathophysiology 
Molecular mimicry between streptococcal and human proteins has been proposed as the 
triggering factor leading to autoimmune humoral and cellular responses towards the 
human tissue in rheumatic fever and rheumatic heart disease (RHD) (Hahn et al., 2005, 
Guilherme et al., 2005). Streptococcal M protein has been found to be structurally and 
functionally similar to the most prominent of heart antigens cardiac myosin. Cross 
reactivity between the streptococcal M protein and cardiac myosin have been observed 
using affinity purified antibodies from ARF sera or sera from rabbits immunized with 
streptococcal pep M-5 protein (Cunningham et al., 1988). Results indicate three M5 regions 
that cross react with heart protein fractions, residues 1-25, 81-103 and 163-177 
(Cunningham et al., 1988).  
Autoantibodies against the heart were associated with RF by Cavelti in 1943. The first 
indication that anti-heart antibodies cross reacted with GABHS was found in 1963 by 
Kaplan et al. (1963) when they showed that anti-heart antibodies present in the human 
sera could be absorbed by group A streptococci or their cell wall (Kaplan, 1963). The role of 
cross-reactive and polyspecific antibodies in the pathogenesis of RF is not yet clear, 
however two monoclonal antibodies (MAb) namely human MAb 1.H9 and mouse MAb 
36.2.2 were found to be cytotoxic to heart cells in culture in the presence of complement 
(Adderson et al., 1998). Various studies have also investigated T cell responses to 
streptococcal M proteins. T cells with high affinity for self-antigens are normally removed 
from the repertoire during intrathymic deletion; those that escape to the periphery most 
likely have low to intermediate affinity for self-antigens. These T cells are subject to 
peripheral tolerance control but may be activated under certain conditions and 
subsequently contribute to autoimmune disease (Ellis et al., 2005). Cytotoxic T cells were 
46 
 
found to be stimulated by M protein with their presence detected in the blood of patients 
with ARF (Dale and Beachey, 1987, Cunningham, 2004).  In a study by Gorton et al. (2009) 
rats immunized with streptococcal M5 protein developed valvular lesions, distinguished by 
infiltration of CD3+, CD4+, and CD68+ cells into valve tissue, consistent with human studies 
that suggest that RF/RHD are mediated by inflammatory CD4+ T cells and CD68+ 
macrophages (Gorton et al., 2009) 
1.4.1.3 Treatment 
Management and prevention of ARF includes: Treatment of the GABHS infection that is the 
identified cause of the disease with intramuscular penicillin G benzathine, oral penicillin V 
potassium, and oral amoxicillin (Brook and Doah, 2006; Armstrong, 2009). Anti-
inflammatory agents like salicylates and steroids are used to control the arthritis, fever, and 
other acute symptoms (Kleinerman et al., 1981), Intravenous immunoglobulin (IVIG) is also 
performed although it has not been shown to reduce the risk of rheumatic heart disease or 
to substantially improve the clinical course (Voss et al., 2001). Treatment of chorea though 
IVIG, steroids, and plasmapheresis has have been successfully used in refractory chorea, 
although conclusive evidence of their efficacy is also limited (Crapetis et al., 2005; Weiner 
et al., 2007). Bed rest is essential in patients with cardiac involvement. Carditis resulting in 
heart failure is treated with conventional measures like corticosteroids although digoxin 
and diuretics are the mainstay of therapy (Feldman and McNamara, 2000; Crapetis et al., 
2005).  
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1.4.2 Sydenhams chorea (SC) 
1.4.2.1 Background 
Sydenhams chorea is the principle neurological manifestation of rheumatic fever. The 
symptoms of SC can vary from a halting gait and slight grimacing to involuntary movements 
that are frequent and severe enough to be incapacitating (Moore, 1996; Dale, 2003). SC 
results from childhood infection with GABHS and is reported to occur in 20-30% of patients 
with RF. The disease is usually latent, occurring up to 6 months after the acute infection, 
but might occasionally be the presenting symptom of RF. SC is more common in females 
than males and most patients are children, below 18 years of age (Walker and Wilmshurst, 
2010). Adult onset of SC is comparatively rare and most of the adult cases are associated 
with exacerbation of chorea following childhood SC (NINDS, WeMove.org, Moore, 1996). 
Symptoms of SC include fever, arthritis, carditis, subcutaneous nodules and choreic 
movements (rapid, uncoordinated jerking movements affecting primarily the face, feet and 
hands) like deterioration in handwriting, difficulties feeding and walking, facial grimacing 
and slurred speech (dysarthia) (Dale, 2003, Walker and Wilmshurst, 2010). Several 
emotional or behavioral disturbances are also associated with SC like attention deficit 
hyperactivity disorder (ADHD), age-regressed behaviors, frequent mood changes and 
excessive emotional reactions including uncontrollable crying and transient psychosis 
(Moore, 1996, Dale, 2003). 
1.4.2.2 Pathophysiology 
Evidence of molecular mimicry with mechanism of pathogenesis similar to ARF has been 
proposed in SC. A study demonstrated the presence of cross reactive autoantibodies in 
human hybridoma cell lines derived from SC patients. These monoclonal antibodies 
recognized N-acetyl-β-D-glucosamine (GlcNAc), the major epitope of GABHS surface 
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carbohydrate and were seen cross reacting with lysoganglioside , a central nervous system 
ganglioside which is known to play a role neuronal signal transduction (Kirvan et al., 2003). 
Binding of autoantibodies to the brain lysoganglioside activated calcium/calmodulin 
dependent protein kinase II (CAMKinase II) which is proposed to regulate functions like 
neurotransmitter synthesis and release. Antibodies to N-acetyl-β-D-glucosamine bound to 
tissue sections derived from the human basal ganglia (Fujinami and Sweeten, 2003, Kirvan 
et al., 2007).  
Further evidence that SC is a basal ganglia disorder comes through evidence derived from 
magnetic resonance imaging (MRI) volumetric studies that have shown increased sizes of 
the caudate, putamen, and globus pallidus in the Sydenham's chorea group with no 
increase seen in total cerebral, prefrontal or midfrontal volumes or thalamic area (Giedd et 
al., 1995). Pathological findings by Colony et al. (1956) (Colony and Malamud, 1956) have 
also revealed specific changes to the basal ganglia, including cellular infiltration and 
neuronal loss with relative sparing of other brain areas in SC (Church et al., 2002, Dale and 
Heyman, 2002). These results indicated the selective involvement of the basal ganglia in SC. 
In an attempt to gain a more precise understanding of chorea antibody specificities, 
monoclonal antibodies derived from SC patients were studied for reactivity with brain 
proteins. These antibodies were found to react with the cytoskeletal α-helical protein 
tubulin in addition to GlcNAc. Competitive inhibition studies have shown that the tubulin 
reactivity of the chorea mAbs was blocked by three gangliosides with lysoganglioside GM1 
as the potent inhibitor (Kirvan et al., 2007). Anti-GlcNAc autoantibodies from RF and 
uncomplicated pharyngitis cases have been found to be cross reactive to different 
cytoskeletal and microbial proteins like human cardiac myosin, epidermal keratin, 
streptococcal recombinant M6 and pepM5 in contrast to SC mAb which exhibit mAbs which 
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appear to have unique antigen specificity (Adderson et al., 1998). This difference in the 
antigen cross reactivity profile may be an indication for the presence of different subsets of 
anti-GlcNAc mAbs contributing towards the different clinical manifestations of ARF. 
1.4.2.3 Treatment 
Therapeutic interventions in patients with SC are based on the aetiology, pathology, 
pathophysiology and clinical presentation Primary treatment with penicillin is considered 
mandatory to eliminate the streptococcus (Walker, 2010). Secondary prophylaxis with long-
term penicillin is prescribed to protect the heart, however, whether it prevents relapses of 
SC is still debatable (Berrios et al., 1985). The increased understanding of the 
pathophysiology of SC has led to the use of agents which affect the neurotransmitters 
dopamine (e.g. halperidol) (Shenker et al., 1973) and GABA (e.g. benzodiazepines) (Edgar, 
2003). Immunomodulatory therapies like corticosteroids, IVIGs and plasma exchange are 
used to shorten the course of the illness and to prevent complications (Garvey et al. 2005). 
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1.4.3 Paediatric Autoimmune Neuropsychiatric Disorders Associated with 
Streptococcal Infections (PANDAS) 
1.4.3.1 Background 
Swedo and colleagues proposed the existence of subgroup paediatric autoimmune 
neuropsychiatric disorders associated with streptococcal infections (PANDAS) that included 
a subset of children with tic disorder and/or obsessive compulsive disorder who have an 
abrupt onset or exacerbations of symptoms temporally related to streptococcal infection 
(Swedo et al., 1998). They proposed five diagnostic criteria that needed to be fulfilled for 
inclusion in the PANDAS subgroup: 
(1)      Presence of OCD or a tic disorder  
(2)      Childhood onset 
(3)      Abrupt onset of symptoms 
(4)      Exacerbations of symptoms temporally related to a preceding GABHS infection 
(5)      Association of neurological abnormalities including hyperactivity and choreiform 
movements 
Host vulnerability for PANDAS might be the result of a combination of genetic 
susceptibility, developmental factors and abnormal immune responsivity (Swedo, 2002). 
Genetic factors may play a greater role in childhood-onset cases as rates of tic disorders 
and OCD in first-degree relatives of children in the PANDAS subgroup are found to be 
higher than those in the general population (12% total; 15% in parents; 5% in siblings) 
(Lougee et al., 2000). Similarly development vulnerability is suggested because of the high 
rate of disease occurrence among grade school age children with 6-7 years being the peak 
age for the onset of symptoms (Swedo et al., 1998). 
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 Figure 1.7: Clinical course of PANDAS. The graph above depicts the clinical course of 
PANDAS with periods of symptom quiescence, followed by exacerbations with abrupt onset 
and gradual resolution. Neuropsychiatric exacerbations in PANDAS begin at the time of 
GABHS infection or within one to two weeks after infection. 
1.4.3.2 Pathophysiology 
Most of the knowledge about PANDAS has been obtained by studying patients with a 
known tic disorder or long-standing OCD (Murphy et al., 2010).  Neuroimaging studies have 
revealed an increased basal ganglia volumes and the proposed mechanism involving the 
cross-reaction of streptococcal antibodies with basal ganglia tissue (Murphy et al., 2010). 
The hypothesis of a possible involvement of the immune system seems justified from 
quantitative alterations of TNF-alpha, IL-6 and IL-1 in the patients' serum with such 
syndromes (Marconi et al., 2009). However, the role of autoimmunity in PANDAS has been 
controversial. Reports of response to treatment with immune-modifying therapies, such as 
glucocorticoids, IVIG, and plasma exchange have supported for a role of autoimmunity 
(Allen et al., 1995; Perlmutter et al., 1999). However, the response to plasma exchange 
appears to be specific for children with OCD or a tic disorder with a preceding GABHS 
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infection as in an open trial it provided no benefit for children with OCD whose symptom 
exacerbation did not follow GABHS infection (Nicolson et al., 2000). 
An autoimmune mechanism for PANDAS is also supported by studies demonstrating 
increased anti-neuronal antibodies in patients diagnosed with PANDAS as compared to 
patients with OCD or tic disorders but no evidence of GABHS infection and patients with 
GABHS infection but without OCD or tic disorder (Church et al., 2003; Hoffmann et al., 
2004). However some other studies looking at autoantibody profiles have not been able to 
distinguish patients with PANDAS or TS from control patients (Singer et al., 2005; Morris et 
al., 2009). Methodologic differences might explain the conflicting results of these studies 
(Rippell et al., 2005). Failure of microinfusion of PANDAS serum into rodent striatum to 
produce behavioural changes (Loiselle et al., 2004) and failure of immunologic markers to 
correlate with clinical exacerbations in PANDAS patients in a longitudinal case-control study 
(Singer et al., 2008) provide some conflicting evidence against the hypothesis that PANDAS 
is caused by anti-neuronal antibodies (Kaplan et al., 2011). 
1.4.3.3 Treatment 
The management of PANDAS centres on providing standard therapies for GABHS infection 
and OCD/tic disorder. There have been no randomized controlled trials of antibiotic 
treatment in children suspected of having PANDAS. In a prospective study that identified 12 
children with abrupt onset of neuropsychiatric symptoms and evidence of recent GABHS 
infection, anti-streptococcal therapy using penicillin or cephalosporin was associated with 
prompt symptom resolution in all cases (Murphy et al., 2002). Immunomodulatory 
therapies include glucocorticoids, plasma exchange, and intravenous IVIG provided 
PANDAS is an autoimmune disorder as this still remains controversial.  
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1.4.4 Tourettes syndrome (TS) 
1.4.4.1 Background 
Gilles de la Tourette’s syndrome (TS) is a neuropsychiatric disorder characterised by the 
presence of motor and phonic tics (Robertson MM, 2000; Leckman, 2002; Church et al., 
2003). A tic is an involuntary, repetitive, rapid, sudden, non-rhythmic, stereotyped 
movement or sound, which begins in childhood or early adolescence (Hoekstra et al., 2004).  
They occur in bouts though the day and wax and wane in severity over time, changing in 
frequency, number and complexity (Robertson, 2000; Leckman, 2002). Symptoms begin in 
children between the ages of 3 and 8 years, usually with simple motor tics (Leckman, 2002). 
These involve only 1 muscle group and include movements such as eye blinking and head 
jerking (Singer, 2005). More complex motor tics involve a co-ordinated sequence of 
movements or group of simple movements such as body or facial contortions, smelling, 
licking, spitting, jumping, touching, squatting and echopraxia (imitating other people’s 
actions) (Robertson, 2000; Singer, 2005). The most extreme forms of TS also involve forceful 
bouts of self-harmful actions including hitting and biting but these only occur mainly in 
adults (Robertson, 2000). Phonic tics develop later in patients with a mean onset of 11 
years, although some cases have reported them in children as young as 3 years old 
(Robertson, 2000; Leckman, 2002). Simple phonic tics include sniffing, throat clearing, 
barking and grunting. Complex expressions include syllables, palailia (repeating one’s owns 
words), echolalia (repeating words of others) and coprolalia (uttering obscene words) 
(Singer, 2005). These occur in a substantial number of patients except for coprolalia which is 
only present in 10% of patients with a mean onset of 15 years (Robertson, 2000; Singer, 
2005). Tics can be fast and brief with an abrupt onset (clonic) or sustained and slow 
(dystonic) (Leckman, 2000).  Studies have shown that TS has a prevalence of 5 per 10,000 
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and is more common in males. About 50% of patients do not express tics by 18 years of age 
and in adulthood tics gradually become less severe (Church et al., 2003).  
                                         
Figure 1.8: Tourette’s syndrome and related disorders. A substantial proportion of TS 
patients have comorbid neuropsychiatric disorders including obsessive compulsive disorder 
(OCD), attention deficit hyperactivity disorder (ADHD) and depression (Robertson, 2002; 
Church et al., 2003). It has been suggested that TS and OCD are actually part of the same 
disease spectrum (Church et al., 2003). 
1.4.4.2 Pathophysiology 
The aetiology of TS is unknown but it is proposed that both genetic disposition and 
environmental factors are involved (Garvey et al., 1998; Church et al., 2003). There is little 
doubt that TS has a genetic background but the precise inheritance pattern has yet to be 
determined. Preliminary studies have suggested an autosomal dominant inheritance and 
genome screening has revealed two regions, 4q and 8p with increased lod scores. It is 
proposed that TS susceptibility genes might be located at these loci (Church et al., 2003).  
Basal ganglia involvement in TS is supported by the presence of ABGA in TS patients. One 
study reported a correlation between ASOT and ABGA and observed elevated titres in 91% 
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of ABGA-positive patients and in 57% of ABGA-negative patients (Church et al., 2003). They 
concluded that for some TS patients the presence of ABGA was related to GABHS infections.  
The surprising result however, was the relatively high prevalence of GABHS in ABGA-
negative patients, which suggested ABGA reactivity could wax and wane similar to clinical 
symptoms. This hypothesis was supported by follow-up clinics 3 months later, where 3 out 
of 4 patients who were previously ABGA negative, were now ABGA positive with reduced 
ASOT (Church et al., 2003).  
Other studies disagree about the significance of ABGA in TS and OCD patients and claim 
healthy subjects can also have relatively high anti-neuronal titres (Hoekstra et al., 2003). 
One particular study did detect a relationship between ABGA and an 83 kDa antigen in TS-
OCD patients but also suggested that these antibodies were not a direct consequence of 
GABHS infection alone (Pavone et al., 2004). Another explanation for ABGA in SC, TS and 
OCD is that antibodies are produced due to an “epiphenomenon secondary to basal ganglia 
damage” (Hoekstra et al., 2003). This theory however is thought unlikely as studies have 
shown patients with inflammatory, ischemic and metabolic basal ganglia diseases rarely 
produce ABGA (Church et al., 2003).  In addition, tics have also been observed in rats after 
IgG from TS patients was micro infused into the brain striatum, further supporting a 
pathological role for ABGA (Taylor et al., 2002; Church et al., 2003). 
Apart from basal ganglia dysfunction the other source abnormality in TS is thought to be 
inappropriate regulation of neurotransmitters, especially dopamine (Singer et al., 1991). 
Strong evidence has indicated dopamine excess or supersensitivity of the postsynaptic 
dopamine receptors as the underlying pathophysiological mechanism of TS (Singer et al., 
1982; Singer et al., 1998). Another hypothesis of dysfunction is a neurophysiologic deficit 
secondary to neurotransmitter abnormalities that results in failure of inhibition of the 
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frontal-subcortical motor circuits an area that has prominent interconnections with the 
basal ganglia (Singer, 1997; Bagheri et al., 1999). 
1.4.4.3 Treatment 
The management of TS is multifaceted with the treatment primarily aimed at frequent or 
disabling tics, coexisting behavioural symptoms, and patient/family education. The alpha2-
adrenergic drugs clonidine and guanfacine both of which decreases plasma norepinephine 
levels are first-line agents in treating mild to moderate tics (Bagheri et al., 1999; King et al., 
2005). Neuroleptics which block the D2 dopamine receptor e.g. haloperidol and pimozide 
are the most effective medications for treating tics, and are used by many experts 
(Guilliano et al., 1998; Bagheri et al., 1999). However, their side effect profile, which 
includes extrapyramidal symptoms and tardive dyskinesia, limits their use as first-line 
therapy (Guilliano et al., 1998; Bagheri et al., 1999). More recently atypical neuroleptics 
that interact with both serotonin and dopamine receptors have been shown to be effective 
and have less extrapyramidal side effects. Within this group risperidone has shown efficacy 
equal to that of clonidine (Bruun and Budman, 1996; Scahill et al., 2003). Furthermore, 
botulinum toxin-A has been effective in treating motor and vocal tics in some patients 
(Aguirregomozcorta et al., 2008). Additionally anteromedial globus pallidus interna deep 
brain stimulation (DBS) is found to be an effective and well-tolerated treatment for a 
subgroup of patients with severe TS (Bajwa et al., 2007; Cannon et al., 2012). Selective 
serotonin reuptake inhibitors (SSRIs) and clomipramine are predominantly used to treat 
OCD symptoms (Kellner, 2010). 
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1.4.5 Dystonia 
1.4.5.1 Background 
Dystonia is a movement disorder characterized by directional, patterned and sustained 
muscle contractions leading to repetitive twisting movements, and abnormal postures of 
the trunk, neck, face, or arms and legs (Stamelou et al., 2011, Fahn, 1987).  Neuroimaging 
studies have provided insight into the systems-level disturbances that are responsible for 
dystonia which indicate a central role for abnormal plasticity leading to distortion of 
sensory fields in the sensorimotor cortex and abnormal signalling in the basal ganglia 
(Breakefield et al., 2008). Current treatment options of dystonia rely on drugs acting on 
cholinergic, dopaminergic and γ-aminobutyric acid (GABA)ergic receptors (Breakefield et 
al., 2008). Although considered a third-line treatment certain forms of dystonia are known 
to respond well to deep brain stimulation of the globus pallidus, indicative of the fact that 
movement abnormalities are potentially reversible (Krauss, 2007). 
In the recent years there has been a rationalisation of the classification of dystonia and a 
much deeper understanding into the causes though the study of genetics, neurophysiology, 
and functional imaging (Phukan et al., 2011). Dystonia has been classified based on 
topographic distribution, age of onset, aetiology and genetics (Tarsy and Simon, 2006; 
Donaldson et al., 2012). Topographic classification of dystonia includes: focal (single 
region), segmental (two or more adjacent regions), multifocal (two or more nonadjacent 
regions), generalized (leg or legs, trunk and one other region) and hemidystonia (ipsilateral 
arm and leg) (Geyer and Bressman, 2007). Classification according to the age of onset 
includes early onset dystonia (≤ 25 years) and late onset dystonia (>25 years). Age of onset 
is closely related to anatomical distribution early onset dystonia usually progresses from 
focal limb to severe generalized form as opposed to late onset which remains localized or 
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segmental, and is usually not progressive (Berardelli et al., 1998; Bressmann, 2004). 
Genetically determined dystonias is a rapidly evolving group based on the loci of genes 
involved. Loci DYT1 though DYT13 include autosomal dominant, autosomal recessive and X-
linked causes of primary dystonia and dystonia-plus syndromes (Doheny et al., 2004). 
Etiological classification of dystonia includes primary, secondary, paroxysmal and dystonia 
plus syndromes (Schneider and Bhatia, 2010, Fahn et al., 1998). Primary dystonia occurs in 
patients who have no signs of structural abnormality in the central nervous system (CNS) 
(Berardelli et al., 1998). The precise cause of primary dystonia is unknown hence it was 
originally described as ‘idiopathic’ as there was no neurophysiological, neurochemical or 
pathological clues to the underling aetiology, but many are now known to have a genetic 
basis (Nemeth, 2001; Donaldson et al., 2012). Cervical dystonia is known to be the most 
common primary dystonia (Defazio et al., 2004). Secondary dystonia on the other hand is 
associated with an inherited neurological disorders or exogenous insult. Dystonia-plus 
syndrome is a sub-category of secondary dystonia in which dystonia is accompanied by a 
neurological condition but as in primary dystonia there is no neuropathological evidence 
(Fahn et al., 1998). Lastly paroxysmal dystonia are rare disorders characterized by episodic 
dystonia and other involuntary movements without symptoms or neurologic findings 
between episodes. They bear an uncertain relation to other dystonias as they clinically 
overlap with other episodic disorders such as epilepsy and ataxia (Tarsy and Simon, 2006).  
1.4.5.2 Pathophysiology 
Most cases of dystonia do not have a specific demonstrable cause. Primary dystonia is 
often inherited (Geyer and Bressman, 2007). Neurophysiological studies of patients with 
dystonia and animal models have shown abnormalities of cortical and basal ganglia 
function (Berardelli et al., 1998). Basal ganglia abnormality could be a result of tumour, 
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stroke, oxygen deprivation, drug reaction or infection (Geyer and Bressman, 2007). 
Although the classic post-streptococcal neuropsychiatric disorder is Sydenham chorea 
recent studies have suggested that the spectrum of postulated post‐streptococcal CNS 
disease is broader, including hyperkinetic movement disorders like dystonia and tics (Dale, 
2003; Karagulle-Kendi et al., 2008). Infantile bilateral striatal necrosis (IBSN) is an 
abnormality of the basal ganglia associated with acute dystonia in children is also known to 
fall under the post-streptococcal autoimmune neuropsychiatric spectrum (Dale et al., 2002; 
Karagulle-Kendi et al., 2008). Additionally, there are high rates of behavioural sequelae, 
particularly that of psychiatric disorders such as OCD, anxiety and depression. All these 
findings have led to the hypothesis that similar immune‐mediated basal ganglia processes 
may be operating in all these neuropsychiatric disorders (Dale, 2003).   
1.4.5.3 Treatment 
Pathogenesis-targeted treatment is still elusive however currently available symptomatic 
treatment strategies are fairly effective for certain types of dystonia. Botulinum toxin A (or 
type B if there is resistance to type A) is regarded as first-line treatment for primary cervical 
dystonia and blepharospasm and is probably effective in other types of upper limb 
dystonias (Costa et al., 2005). However it is not licensed for use in children. Drug 
treatments for dystonia include levodopa (Hwang et al., 2001), anti-cholinergic agents and 
tetrabenazine/benzodiazepines (Marino et al., 1993; Albanese et al., 2006). The absolute 
and comparative efficacy and tolerability of anticholinergic agents is found to be poorly 
documented in children and there is no proof of their efficacy in adults either (Albanese et 
al., 2006). Pallidal DBS is found to be very effective in primary generalized or segmental 
dystonia (Kupsch et al., 2006; Haridas et al., 2011). It is found to be less effective in 
secondary dystonia with the exception of tardive dystonia (Kupsch et al., 2006). Intrathecal 
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baclofen has been employed in patients with severe generalized dystonia particularly the 
ones with concomitant severe spasticity (Albanese et al., 2006). 
1.4.6 Encephalitis Lethargica (EL) 
1.4.6.1 Background 
Encephalitis lethargica also known as sleeping sickness was first described by neurologist 
Constantin von Economo in 1917 (Dourmashkin, 1997). An epidemic of the disease swept 
around the world between 1915 and 1926. The disease is highly polymorphic with 
fluctuating signs and symptoms however prodromal symptoms include headache, double 
vision, high fever, delayed physical and mental response, and lethargy (Triarhou LC, 2006). 
In acute cases, patients may enter coma-like state termed akinetic mutism (Triarhou, 
2006). They may also experience Parkinsonism, abnormal eye movements, upper body 
weakness, tremors, and behavioural changes. Pathological findings have localized the 
encephalitis to basal ganglia and midbrain structures (Triarhou, 2006, Vilensky et al., 2007). 
1.4.6.1 Pathophysiology 
Although the exact cause of EL is still unknown it is postulated to be an autoimmune 
disease. Because the EL epidemic occurred around the same time as the 1918 influenza 
pandemic the two were thought to be related (Ravenholt and Foege, 1982). However, the 
failure to find the identified influenza ribonucleic acid (RNA) in the archived EL brains 
dismissed this association (Taubenberger et al., 1997, McCall et al., 2008). However a 
recent study has found 27 nm virus-like particles (VLP) in the cytoplasm and nuclei of 
midbrain neurons in four classical EL cases. Additionally large 50nm VLP and 27nm 
intranuclear VLP were observed in two modern EL cases and a post-encephalitic 
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Parkinsonism (PEP) CASE. The VLPs were identified as enterovirus by sequence analysis 
(Dourmashkin et al., 2012).  
All the recent sporadic cases of EL-like syndrome have presented with pharyngeal 
infections. GABHS being the most common cause of pharyngitis and a recognized cause of 
immune mediated basal ganglia dysfunction in SC (Church et al., 2002) has hence, been 
implicated in EL. It is hypothesized that antibodies induced after GABHS infection cross-
react with components of the basal ganglia, resulting in movement and psychiatric 
disorders (Dale et al., 2004). A study by Dale et al. examining 20 cases of EL was able to 
demonstrate autoantibodies reactive against discrete basal ganglia autoantigens in 95% of 
the patients. Rather than polyspecific binding, reactivity was seen against several common 
basal ganglia antigens 40, 45 and 60 and 98 kDa (discussed later). Out of these the first 
three have are important Sydenham’s neuronal antigens but the 98 kDa antigen was novel 
to the EL phenotype. The CSF examination confirmed that the autoantibodies are present in 
the CNS, although whether these antibodies are mainly produced intrathecally or 
peripherally (with transfer into the CNS) has not been examined (Dale et al., 2004). 
1.4.6.3 Treatment 
Treatment of EL is symptomatic. There is little evidence so far of a consistent effective 
treatment for the initial stages, though some patients given steroids have seen 
improvement (Blunt et al., 1997). Levodopa and other anti-parkinson drugs often produce 
dramatic responses in people with this condition (McAuley et al., 1999). However, in most 
of the patients who were given L-DOPA in the 1960s, the amelioration of the disease was 
short lived (McAuley et al., 1999). Some other drugs used to treat EL post 1940 included 
neuroleptics, anti-cholinergics, anti-depressants, e.g. imipramine, corticosteroids and 
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antibiotics. However the efficacy of these drugs for EL is still controversial due to 
insufficient or contradictory data (Vilensky, 2011).  
1.4.7 NMDAR Encephalitis 
 
1.4.7.1 Background 
The N-methyl-D-aspartate receptor (NMDAR) is a specific type of ionotropic receptor 
belonging to the glutamate receptor superfamily together with α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) and kainate receptors (Dingledine et al., 1999). 
Both NMDA and non-NMDA receptors are activated by the endogenous transmitter, L-
glutamate, however, L-aspartate, a putative endogenous transmitter appears to activate 
NMDA only (Patneau and Mayer, 1990). NMDAR are inactive at resting membrane 
potential this is due to a voltage dependent block of the pore by magnesium ions (Mayer et 
al., 1984) and their activation is secondary to kainate or AMPA receptor activation that 
depolarises the neuron leading to the release of the Mg+ blockade (Ascher and Nowak, 
2009). The NMDAR is most abundant in the cortex, basal ganglia, and sensory pathways of 
the nervous system, but have also been identified in a variety of non-neuronal and 
peripheral locations (Bolton and Paul, 2006). 
The NMDAR have been associated with a wide variety of neurological disorders including 
ischemic brain damage,  epilepsy and more speculatively, neurodegenerative disorders 
such as Parkinsons, Alzheimers, Huntingtons chorea, and amyotrophic lateral sclerosis (ALS) 
(Waxman and Lynch, 2005; Ghasemi and Schachter, 2011). 
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1.4.7.2 Pathophysiology 
Anti-NMDA receptor encephalitis has been recently identified as treatment responsive 
encephalitis associated with anti-NMDA receptor antibodies (Iizuka and Sakai, 2008). These 
antibodies bind to the NR1/NR2 heteromers of the NMDA receptors and antibody levels 
are known to correlate with the clinical severity of the disease (Irani and Vincent, 2011).  
Recent studies have demonstrated that these antibodies cause a reversible reduction in the 
numbers of cell-surface NMDA receptor clusters in postsynaptic dendrites, suggesting 
antibody mediated decreased NMDA receptor function (Iizuka, 2009).  
NMDAR encephalitis is highly characteristic occurring in five stages: the prodromal phase 
with viral infection like symptoms, psychotic phase, unresponsive phase, hyperkinetic 
phase, and gradual recovery phase (Iizuka et al., 2010). Psychiatric manifestations are 
observed that upon progression lead to decrease of verbal output, catatonia, seizures, 
dyskinesias, hypoventilation and frequent autonomic instability (Florence et al., 2011). In 
some cases it is a paraneoplastic syndrome usually affecting childbearing-age female with 
ovarian tumors, however, recent reports suggest a much higher incidence of 
nonparaneoplastic cases in males and children (Lebas et al., 2010; Hung et al., 2011).  
Clinical features seen in EL coincide with the NMDA receptor encephalitis which might 
make it a part of the spectrum of anti-NMDAR disorders. Dale et al. (2009) studied sera 
from paediatric patients with contemporary EL and found 10 sera out of 20 (from 2 males 
and 8 females, aged 1.3–13 years) and 6/6 cerebrospinal fluid samples positive for 
antibodies against the NMDA receptor. Different disease phenotypes were observed 
between the NMDA receptor positive and negative patients suggestive of different 
pathogenic targets. The antibody concentration in all cases was found to be higher in the 
serum than CSF (Dale et al., 2009).  
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1.4.7.3 Treatment 
Treatment of anti-NMDAR encephalopathy includes immunotherapy and/or tumour 
removal. Anecdotal reports have shown that recovery might be spontaneous without 
tumour resection , however, tumour resection together with aggressive immunotherapy 
facilitates early functional recovery and 65% of patients with anti-NMDAR encephalopathy 
exhibit full or near-full recovery (Suzuki et al., 2008). Most patients receive IVIG, plasma 
exchange or corticosteroids as first-line of immunotherapy (Dalmau et al., 2011). It is likely 
that patients who don’t respond to one form of immunotherapy might respond to other 
regimens like plasmaphoresis, cyclophosphamide, and rituximab (Irani and Vincent, 2011). 
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1.5 CANDIDATE AUTOANTIGENS 
 
It has been identified that patients presenting with an encephalitic illness with a subsequent 
clinical course reminiscent of EL with ABGA and evidence of recent streptococcal infection 
(Dale et al., 2001; Dale et al., 2004a). ABGA is shown to recognise four main protein bands 
of 40kDa (aldolase C), 45kDa (neuron specific gamma enolase), 45 kDa (non-neuronal alpha 
enolase) 60 kDa (pyruvate kinase M1) and 98 kDa (neuron specific alpha/gamma dimer) 
which have been purified and successfully identified using 2-D gel electrophoresis and mass 
spectrometry (Dale et al., 2006). All the above antigens are glycolytic enzymes and are 
involved in energy homeostasis and as expected are found in the cytosol. However, these 
proteins have also been shown to be located on the neuronal surface (Lim et al., 1983; 
Nakajima et al., 1994), where they appear to have “moonlighting” or have alternative 
functions (explained below). These glycolytic enzymes/putative autoantigens have probable 
roles in energy metabolism, neurotransmission, cell health, maintenance of ion channels, 
and the control of cellular metabolism. All these roles are plausible and it is possible that 
autoantibodies could interfere with these roles either directly or indirectly (i.e. via a cell 
mediated response).                  
1.5.1 Aldolase C (Ald C) 
 
Glycolytic enzyme aldolase (ald) catalyzes the production of glyceraldehyde phosphate 
from fructose 1, 6-bisphosphate. Aldolase has 3 isoforms: aldolase A is expressed largely in 
the muscle, aldolase B in the liver and aldolase C in the brain and neuroendocrine cells 
(Buono et al., 2001). Ald C mRNA is greatest in cerebellar neurons but is found to a lesser 
degree albeit in the striatum, medulla and occipital lobe (Ignaki et al., 1988). 
Fructose 1,6 Bisphosphate Glyceraldehyde 3-phosphate
Aldolase
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Aldolase may have functions beyond glycolysis and has been implicated in the functioning 
of Vacuolar proton- translocating ATPases (V-ATPases). These are  a family of highly 
conserved proton pumps that couple hydrolysis of cytosolic adenosine triphosphate (ATP) 
to proton transport out of the cytosol (Forgac, 1999). Residing on the intracellular 
membrane these pumps are central to pH homeostasis in organelles. Some cells express V-
ATPases at the plasma membrane, where they carry out cell-specific functions such as renal 
acidification, bone reabsorption, homeostasis of cytoplasmic pH and sperm maturation 
(Forgac, 2007). The direct binding interaction between V-ATPase and aldolase might be a 
new mechanism for the regulation of the V-ATPase and may underlie the proximal tubule 
acidification defect in hereditary fructose intolerance (Lu et al., 2001). 
Ald C gene has been identified as a candidate hypoxia-regulated gene in mouse lung 
epithelial (MLE) (Jean et al., 2006). Aldolase associates with the actin cytoskeleton and can 
provide a local source of ATP production that is important for cytoskeletal integrity 
(Schindler et al., 2001). In addition, ald C has been found in tight association with a plasma 
membrane oxidoreductase complex in brain cells. The plasma membrane oxidoreductase 
complex is believed to function as an extracellular membrane redox sensor that induces 
cellular responses to external oxidant stress (Bulliard et al., 1997).  
It is the C isoform of aldolase that has been identified as one of the putative autoantigens 
in post-streptococcal disorders. Aldolase C-positive cerebellar Purkinje cells are observed to 
be resistant to delayed death after cerebral trauma and AMPA-mediated excitotoxicity 
which highlights its role in neuroprotection (Slemmer et al., 2007). Glucose metabolism has 
been indicated to play an important role in the pathogenesis of rheumatoid arthritis (RA) 
and evidence indicates that RA synovial tissues have increased glycolytic activity which 
leads to an acidic microenvironment that further induced the transformation of normal 
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synovial cells. Enolase and aldolase are the two key enzymes of the glycolysis pathway that 
are observed to promote RA autoimmunity by acting as autoantigens (Goëb et al., 2009; 
Chang and Wei, 2011). Furthermore, Ald A has been identified as a candidate autoantigens 
in Alzheimer’s disease with sera IgG of >50% of 45 AD patients binding to it. However, 
immunization of rats and mice with Ald A in complete Freund’s adjuvant was found not to 
be pathogenic (Mor et al., 2005). Significantly higher autoantibodies against Ald B have 
been determined in sera of patients with chronic hepatitis and liver cirrhosis as compared 
to healthy subjects with anti-aldolase B antibody titer indicating the severity of liver 
dysfunction (Maniratanachote et al., 2005).  
1.5.2 Enolase (Eno) 
 
The enzyme enolase also known as phosphopyruvate dehydratase was discovered by 
Lohmann and Meyerhof in 1934 (Lohman.K 1934). It is responsible for the catalysis of 2-
phosphoglycerate (2-PG) to phosphoenolpyruvate (PEP), the penultimate step of glycolysis.  
The structure of enolase is highly conserved with a homology of 40-90% between different 
species (Pancholi V, 2001). There are three subunits of enolase namely α, β, and γ, each 
encoded by a separate gene that can combine to form five different isoenzymes: αα, αβ, αγ, 
ββ, and γγ. In mammals there is 82% homology between the amino acid sequences of -, -
and -enolase monomers (Witkowska et al., 2005). Alpha-enolase (also called non-neuronal 
enolase) is ubiquitously expressed in the early stage of embryonic development, beta-
enolase is expressed in adult skeletal and cardiac muscles, and gamma-enolase (also called 
neuron-specific enolase (NSE)) is expressed in mature neuron and neuroendocrine cells 
(Marangos and Schmechel, 1987, Deloulme et al., 1997). Using sensitive immunoassays, 
2-Phosphoglycerate Phosphoenolpyruvate
Enolase
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significant levels of NSE have been found  in differentiated tissues other than nervous 
tissues (Haimoto et al., 1985).  
Enolase apart from being involved in glycolysis has additional roles as plasminogen binding 
receptor, heat shock protein, Myc-binding protein, eye -crystallin protein, and an 
endothelial stress protein. It acts as a plasminogen receptor on neuronal membranes 
mediating interactions between microglia and dopaminergic neurons (Nakajima et al., 
1994). The enolase binding to plasminogen induces plasminogen transformation into 
plasmin and is thought to be a virulence factor by preventing the generation of fibrin clots 
and thus enabling tissue invasion, as described for S. pyogenes and S. Pneumonia (Fontan et 
al., 2000). NSE can form complexes with other glycolytic enzymes (e.g. aldolase C) which 
monitor oxidative stress levels at the cell surface (Bulliard et al., 1997). In addition, α-
enolase when located in the nucleus is a Myc-binding protein (MBP-1) playing a vital and 
crucial role in cell growth and differentiation (Terrier et al., 2007).  
Studies have reported the presence of enolase-specific autoantibodies in a range of 
psychiatric, degenerative and inflammatory disorders, including discoid lupus 
erythematosus, autoimmune polyglandular syndrome type 1, primary and secondary 
membranous nephopathy, cancer-associated retinopathy, autoimmune hepatitis type 1, 
mixed cryoglobulinemia with renal involvement, cystoid macular oedema and 
endometriosis (Gitlits et al., 2001). In addition, autoantibodies which cross react with 
GABHS and human -enolase have been observed ARF patients (Fontan et al., 2000). In 
recent study involving anti-optic nerve autoantibodies, 55% of 209 patients showed specific 
neuronal autoantibodies. Some of the major antigenic targets for these antibodies were 
found to be classical glycolytic enzymes α and γ enolase and glyceraldehyde 3-phosphate 
dehydrogenase (Adamus et al., 2011). Furthermore in a recent study patients with OCD 
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were tested for the presence ASOT and ABGA. Positivity for ABGA was observed in 19/96 
(19.8%) patients and the majority of positive OCD sera (13/19) had antibodies against the 
enolase antigen (Nicholson et al., 2012).  
Citrillunation is the enzymatic conversion of arginine to citrulline in situ on proteins. This 
form of post-translational protein modification creates novel epitopes on common 
proteins, providing ‘neoantigens’ that are now known to be important in autoimmune 
diseases like rheumatoid arthritis (Fischer and Venables, 2012). In a perspective study by 
Lundberg et al., 2010  the hypothesis of molecular mimicry in the aetiology of RA has been 
explored with citrullinated enolase being the specific antigen involved. Both RA and 
periodontitis which is largely caused by Porphyromonas gingivalis infection have similar 
pathophysiology, characterized by inflammation. The citrullination of proteins by P. 
gingivalis and the subsequent generation of autoantigens that drive autoimmunity in RA 
might be representative of a causative link between these two diseases (Lundberg et al., 
2008; Lundberg et al., 2010). Also numerous studies have demonstrated the presence of 
antibodies against citrullinated α-enolase in the serum samples from patients with RA 
(Kinloch et al., 2005; Montes et al., 2012). 
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1.5.3 Pyruvate kinase (PK) 
 
Pyruvate kinase catalyses the transfer of a phosphate group from phosphoenolpyruvate 
(PEP) to ADP, yielding one molecule of pyruvate and one molecule of ATP, the final step of 
glycolysis. The PKM gene in humans is 32,315 kb long and consisting of 12 exons and 11 
introns. Pyruvate kinase isoenzymes type M1 and M2 are splicing products of the PKM 
gene (exon 9 for M1-PK and exon 10 for M2-PK) (Noguchi et al., 1986; Dombrauckas et al., 
2005). 
Findings by Kostanyan and Nazaryan, 1996 demonstrate how pyruvate kinase induced 
glycolysis occurs in rat brains in response to oestradiol which may explain sex-specific 
phenomena such as chorea gravidarum and chorea whilst on the oral contraceptive pill 
(Kostanyan and Nazaryan, 1996). In addition monomeric pyruvate kinase acts as a 
T3/thyroid binding protein, with inhibition of the glycolytic enzymes activity occurring on 
binding (Kato et al., 1989, Ashizawa et al., 1991). This suggests that glycolytic enzymes are 
involved in the control of cellular metabolic effects that are induced by thyroid hormones. 
This could explain the association between hyperthyroidism and chorea (Cretel et al., 1998; 
Isaacs et al., 2005). Recent findings have shown that the expression and activity of PK is 
reduced in lymphocytes, polymorphic neutrophils (PMN) and leucocytes of normal 
pregnant women in comparison with those of non-pregnant women and pre-eclampsia 
patients which may explain why during pregnancy, many women experience remission of 
autoimmune diseases like multiple sclerosis and uveitis (Xu et al., 2010). 
Pyruvate kinase M1/M2, the putative autoantigen in post-streptococcal disorders is 
expressed in differentiated tissues, such as lung, fat tissue, retina, pancreatic islets as well 
Phosphoenolpyruvate Pyruvate
PK
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as in all cells with a high rate of nucleic acid synthesis, which include all proliferating cells 
such as, embryonic cells, adult stem cells and tumour cells (Tsutsumi et al., 1988). This 
isoenzyme is known to be found mainly in the cytosol and to some extent in the nucleus. 
PK is associated with other glycolytic enzymes, i.e. glyceraldehyde 3-P dehydrogenase,  
hexokinase, phosphoglyceromutase, phosphoglycerate kinase, enolase and lactate 
dehydrogenase in a so-called glycolytic enzyme complex (Campanella et al., 2005). 
Immunoreactivity to PK in patients with exacerbated symptoms with a recent streptococcal 
infection was 7-fold higher compared to patients with exacerbated symptoms without  
evidence of a streptococcal infection (Church et al., 2002). Antibodies to PK were the most 
predominant amongst the glycolytic proteins identified as antigenic targets in the sera of 
patients with Sydenham’s chorea (Church et al., 2002; Kansy et al., 2006). Additonally, the 
sera from patient with dementia and striatal hypermetabolism has been shown to 
selectively detected a 60 kDa protein (Léger et al., 2004). 
1.6 CONCLUSION 
As ABGA are strongly associated with recent streptococcal infection this group of disorders 
is a good model for the study of molecular mimicry and autoimmunity. Preliminary data 
suggest that ABGA have effects on neuronal function and may therefore be directly 
involved in the pathogenesis of basal ganglia dysfunction. As auto-antibody mediated 
diseases respond to immunomodulatory therapy, identifying and defining the pathogenesis 
of these disorders is important so that patients can be appropriately treated.  
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1.7 HYPOTHESIS 
 Variation in the virulence factors (M protein and SAg) associated with GABHS might 
coexist between patients diagnosed with postulated post-streptococcal disorders 
and healthy controls.  
 Inoculating mice with putative autoantigens (aldolase C, enolase and pyruvate 
kinase) in complete Freund’s adjuvant will induce the development of ABGA in 
mice and result in stereotypical movements similar to those seen in human 
subjects with ABGA-associated neuropsychiatric disorders. 
 Autoantibodies from patients with postulated post-streptococcal disorders 
including TS, EL, SC and dystonia will have functional effects in vitro, e.g. in the case 
of our identified putative autoantigens ABGA will affect neuronal function and 
survival. 
 The transfer of these antibodies to animals will result in stereotypical movements 
similar to those seen in human subjects with ABGA-associated neuropsychiatric 
disorders. 
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1.8 AIMS 
 To screen GABHS samples for emm type and SAg from patients diagnosed with 
postulated post-streptococcal disorders like TS, SC, EL and dystonia and healthy 
controls. 
 To investigate the functional effects of ABGA from patients diagnosed with 
postulated post-streptococcal disorders like TS, SC, EL and dystonia in neuronal cell 
cultures. 
 To produce an animal model of postulated post-streptococcal disorders by active 
immunization with putative autoantigens including and aldolase C, enolase and 
pyruvate kinase. 
 To produce an animal model of postulated post-streptococcal disorders by active 
immunization with group A-beta haemolytic streptococcal proteins. 
 To produce an animal model of postulated post-streptococcal disorders by direct 
intra-cerebral infusion of autoantibodies from patients. 
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CHAPTER 2 
GROUP A BETA-HAEMOLYTIC STREPTOCOCCUS (GABHS) 
 
2.1 INTRODUCTION 
2.1.1 GABHS Background 
Lancefield group A streptococci consists of a single species, S. pyogenes which typically 
produces a large zone of beta-haemolysis when cultured on blood agar plates, and is 
therefore also called GABHS (Ryan and Ray, 2004). It is associated with a wide range of 
supparative infections in the skin and respiratory tract, life threatening soft tissue 
infections and certain types of toxin- associated reactions (Hayes et al., 2001). Acute S. 
pyogenes infections may take the form of pharyngitis, scarlet fever, cellulitis or impetigo. 
Invasive infections can also result in necrotizing fasciitis myositis and streptococcal toxic 
shock syndrome (Hahn et al., 2005).  
The spectrum of post-streptococcal disease of the CNS includes movement disorders 
(chorea, tics, dystonia and Parkinsonism), psychiatric disorders like OCD and ADHD and 
associated sleep disorders (Dale, 2005). The classical post-streptococcal disorders are 
known to be rheumatic fever and Sydenham’s chorea which is a neurological manifestation 
of RF (Dale and Heyman, 2002; Dale, 2005). 
 GABHS express a number of cell surface components and extracellular products that play 
an important role in its pathogenesis and in the immune response of the host as discussed 
previously. Evidence suggests that GABHS contain antigens which are similar enough to 
host antigens and can stimulate B and T cells to respond to self. Of all the streptococcal 
antigens involved in molecular mimicry, the M protein has been best investigated and 
characterized (Bordeur, 2003). In addition streptococcal SAg cause non-specific activation 
of T-cells resulting in polyclonal T cell activation and massive cytokine release (Llewelyn and 
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Cohen, 2002). These extracellular pyogenic exotoxins are important as they cause direct 
tissue damage by initiation of apoptotic pathways or disruption of mammalian cell-walls 
(Watson, 1960; Hallas, 1985; Saouda et al., 2001). Although the pathophysiology of post-
streptococcal disorders is not completely understood, antigenic mimicry is proposed to be 
the triggering cause of autoimmunity (Hahn et al., 2005, David Greenwood, 2007).  
2.2 HYPOTHESIS AND AIMS   
 
The major virulence factors determining the pathogenicity of streptococcal strains include 
M protein encoded by emm and emm-like (emmL) genes and superantigens. The main 
hypothesis behind this study was that a differential pattern of emm type and superantigens 
might exist in the patients suffering from TS and dystonia as compared to neurological 
controls which might better explain the role of these two virulence factors in the disease 
pathogenesis. The aim of this study therefore was to investigate the emm types and 
superantigen profiles of GABHS isolates from patients diagnosed with suspected post-
streptococcal movement disorders, mainly Tourette’s syndrome, and neurological controls. 
I also wanted to see if there is a link between emm types and superantigens presented.  
In addition to the main aims above I wanted to select a sample that exhibited the most 
diverse range of SAg for creating an active immunization animal model (Chapter 3).    
2.3 MATERIALS AND METHODS 
All the work described in this chapter was performed at Great Ormond Street Hospital for 
Children, London, UK under direct supervision of Dr. Kathryn Harris (Clinical Scientist, 
Microbiology Unit, GOSH). 
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2.3.1 GABHS Samples 
GABHS frozen on beads from 21 patients and 8 controls were assessed in this study. All 
samples were collected at Great Ormond Street Hospital, London during a cross-sectional 
and longitudinal study. The isolates were from patients diagnosed with TS with an age 
range of 11- 46 years. All controls samples came from healthy children with age ranging 
from 10- 16 years.  
2.3.2 GABHS Culturing  
GABHS samples frozen on beads were streaked onto solid agar plates supplemented with 
5% horse blood. The plates were then incubated for 18-24 hours at 37°C aerobically with 
the addition of 5% CO2.  GABHS typically formed colonies 0.5mm in diameter surrounded 
by a zone of complete haemolysis. A swab of bacterial colonies was used to inoculate Todd- 
Hewitt broth for liquid cultures needed for preparation of bacterial homogenate and 
protein fractions. 
2.3.3 Latex Agglutination Test 
PROLEX™ streptococcal grouping latex kit (Pro-lab Diagnostics, UK) was performed for 
definitive serological identification of the cultured bacteria as GABHS. This streptococcal 
grouping method involves chemical extraction of group specific carbohydrate antigens 
using nitrous acid extraction reagents. The extraction reagents 1 and 2 provided in the kit 
contain a chemical substance to extract the streptococcal group specific antigens at room 
temperature. Extraction Reagent 3 contains a neutralizing solution. The neutralized 
extracts can be easily identified using latex particles sensitized with purified group specific 
rabbit immunoglobulins (IgG). These latex particles agglutinate strongly in the presence of 
homologous antigen and will not agglutinate when homologous antigen is absent. 
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1-4 beta-haemolytic colonies were selected using a disposable loop and suspended in one 
drop of Extraction Reagent 1 in a test tube. A drop of Extraction Reagent 2 was then added 
to the tube. The reaction was mixed by tapping for 5-10 s and approximately five drops of 
Extraction Reagent 3 was then added to the above reaction mix. One drop of group A 
streptococcal latex was dispensed onto a circle on the test card. A second streptococcal 
group specific latex was used as a negative control. Using a Pasteur pipette, one drop of 
colony extract was placed beside the group A streptococcal latex. The latex and the extract 
were then mixed with the sticks provided, using the complete area of the circle. The card 
was gently rocked allowing the mixture to flow slowly over the entire test ring area. At one 
minute, under normal lighting conditions, agglutination was observed. 
2.3.4 Emm Typing  
2.3.4.1 DNA isolation 
GABHS samples from TS patients frozen on beads were streaked onto horse blood agar 
plates and incubated overnight at 37°C. A swab of each culture was put into a tube 
containing AE buffer (Qiagen, West Sussex, UK) and 0.1mm silica spheres (MP Biomedicals, 
UK). The samples were ribolysed at 6.5m/s for 40 seconds using the FastPrep®-24 
Instrument (MP Biomedicals, UK) and centrifuged for 2 min at 17,500 x g. The supernatant 
was then transferred to clean Eppendorf tubes and the DNA was stored at 4°C until used. 
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2.3.4.2 Polymerase Chain Reaction (PCR) 
Amplification of the emm gene was performed using the following primers: 
Emm (Forward) - tatt (c/g) gcttagaaaattaa 
Emm (Reverse) - gcaagttcttcagcttgttt  
1µL (20pmol) of each primer was added to a PCR tube containing 1µL Q-BioTaq (5 units/µL, 
QBiogene Inc., UK), 5µL of 10x NH4 buffer (Bioline Ltd., UK), 1.5 µL of 50 mM MgCl2 and 
0.4µL of 25 mM deoxynucleoside triphosphates (dNTPs). The final volume was adjusted to 
50µL with PCR grade water. The reaction mixture was then amplified using the following 
PCR cycle in a T3000 thermocycler. The PCR products were analyzed on a 2% agarose gel 
with ethidium bromide and DNA hyper ladder II (Bioline Reagents Ltd., UK). 
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PCR Cycle 
Step Temperature (°C) Time (in seconds) 
1)Initialization  94 60 
10 Cycles 
2)Denaturing 
3)Annealing 
4)Extension/Elongation 
 
94 
46.5 
72 
 
15 
30 
75 
20 Cycles 
2)Denaturing 
3)Annealing 
4)Extension/Elongation 
 
94 
46.5 
72 
 
15 
30 
75  
With a 10 s increment for 
each of the subsequent 19 
cycles. 
5)Final Elongation 
6)Final Storage 
72 
4 
600 (10 minutes) 
Short term storage 
Table 2.1: PCR cycle used for emm typing of GABHS islates.  
2.3.4.4 Sequencing 
The PCR products were purified using Illustra microspin S400H (GE Healthcare Life Sciences, 
Buckinghamshire, UK). The sequencing PCR mixture contained 2µL Big dye terminator 
(Applied Biosystems, California, USA), 1µL Sequencing buffer (Applied Biosystems, 
California, USA), 2.5µL (2pmol) of each primer, 1.5µL PCR grade water (Molzym, Germany) 
and 3µL of purified PCR product. The sequencing reactions were cleaned up by ethanol 
precipitation. 2µL EDTA (125mM) and 80µL of 96% ethanol were then added to the 
sequence reaction. The samples were incubated for 15 minutes at room temperature, 
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followed up by incubation on ice for 5 minutes. The mixture was then centrifuged for 15 
minutes at 17,500 x g. 
The supernatant was discarded and the pellet was washed with 200µL of 70% ethanol, 
spun for 5 min at 17,000 x g, the supernatant was discarded again and the pellet was air 
dried for 10 minutes. The pellet was resuspended in 10µL High Dye formamide (Applied 
Biosystems, California, USA), transferred to a 96-well plate and denatured for 5 min at 95°C 
in the PCR machine. The sequencing plate was then loaded into the genetic analyzer (ABI 
3130, Applied Biosystems, California, USA). 
Consensus sequences of the forward and reverse strands were generated with Seqman 
(Lasergene 8, DNAstar). Phylogenetic analysis was performed with MegAlign (Lasergene 8, 
DNAstar) using the ClustalW algorithm. 
2.3.5 Superantigen Screening 
2.3.5.1 PCR 
DNA was extracted from the streptococcal cultures as described before. Individual PCR 
amplifications were undertaken to detect the genes for 13 known superantigens namely 
spe A, B, C, F, G, H, I, J, K, L, M, ssa and smeZ. 
Superantigen primer sequences (Eurofins MWG Operon, Germany): 
1)   speA-up - 5'-ACTTAAGAACCAAGAGATGG-3'   
        speA-dn - 5'-CCTTATTCTTAGGTATGAAC-3'   
                      
 
2)   speB-up - 5'-GGATCCCAACCAGTTGTTAAATCTCT-3'   
        speB-dn - 5'-AACGTTCTAAGGTTTGATGCCTACAA-3'    
                     
 
3)   speC-up - 5'-AAGTGACTCTAAGAAAGACA-3'                        
        speC-dn - 5'-TTGAGTATCAATGTTTAATG-3'  
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4)   speF-up  - 5'-CGAAATTAGAAAAGAGGAC-3'                        
        speF-dn  - 5'-GGCTGAGCAAAAGTGTGTG-3'   
 
        
               
 
5)   speG-up - 5'-CTGGATCCGATGAAAATTTAAAAGATTTAA-3'                        
        speG-dn - 5'-AAGAATTCGGGGGGAGAATAG-3'   
                      
 
6)   speH-up - 5'-TTGGATCCAATTCTTATAATACAACC-3'                        
        speH-dn - 5'-AAAAGCTTTTAGCTGATTGACAC-3'   
                      
 
7)   speI-up - 5'-GGATCCATGAGTAGTGTGGGAGTTATTAA-3'                        
        speI-dn - 5'-AAGCTTTTATTTATTAAATTTAACTAAG-3'   
                 
 
8)   speJ-up - 5'-GGATCCGATAGTGAAAATATTAAAGCG-3'                        
        speJ-dn - 5'-GAATTCGCTCCTATCTTATTTAGTCC-3'     
                    
 
9)   speK-up - 5'-GCGGATCCGATACGTACAATACAAATG-3'                        
        speK-dn - 5'-GCGAATTCAATAGCATTCAACCA-3'   
 
 
10)  speL-up- 5'-GCAGCCATATGGAAGAGACTATTCCTCTTAAGGATATATACTCTC-3'   
        speL-dn  - 5'-GGGGATCCTTAATTTTCTTTGTTTGTGAATAAATAGAC-3' 
                     
 
11)  speM-up - 5'-GCAGCCATATGTTTTCAGATGCTGTGTTGG-3'                        
        speM-dn - 5'-GGGGATCCTTAATTTTTAGAAAAATCTTCGTTTAAGTA-3' 
 
                      
12) smeZ-up - 5'-TGGGATCCTTAGAAGTAGATAATA-3'   
 smeZ-dn - 5'-AAGAATTCTTAGGAGTCAATTTC-3'                        
 
 
13) ssa-up  - 5'-AGTCAGCCTGACCCTAC-3'   
 ssa-dn  - 5'-TAAGGTGAACCTCTAT-3'                        
 
                                       
Each 50 µL reaction contained 20 pmol of each of the forward and reverse primers, PCR 
buffer (10 mM Tris/HCl, pH8.3; 50 mM KCl), 1.5 mM MgCl2, 200 µM
 each dNTP, 2.5 U 
AmpliTaq Gold DNA polymerase and 10µL genomic DNA. The reaction mixture was then 
amplified using the below PCR cycle in a T3000 thermocycler. The PCR products were 
analyzed on a 2% agarose gel with 10 µL ethidium bromide and DNA hyper ladder II. 
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PCR cycle 
 
Step Temperature (°C) Time (seconds) 
1)Initializing 95 600 (10 minutes) 
35 Cycles 
2)Denaturing 
3)Annealing 
4)Elongation 
 
94 
50 
72 
 
30 
30 
60 
5)Final Elongation 
6)Storage 
72 
4 
120 
Short term storage 
Table 2.2: PCR cycle used for screening SAg in GABHS isolates.  
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2.4 RESULTS 
2.4.1 Emm typing 
GABHS DNA extracts from 21 patients and 8 child controls were emm typed using PCR 
followed by gene sequencing. In the patient cohort emm type 4 was the most predominant 
emm type and was found present in 8 out of 21 samples analysed (38%). This was followed 
by emm11 (19%), emm3 (14%) and emm1 (14%). Both emm1 and emm3 have been 
associated with invasive GABHS diseases. Another emm type exclusive to the isolates from 
the patient population was emm12. In the control samples emm types observed were 
emm4 (25%), emm78 (25%) and emm5, 6, 75 and 77 at low percentages. In both cohorts 
except for emm4 no other common emm types were observed 
             
Figure 2.1: Emm typing PCR image. The above is an image of a PCR carried out as a first 
step for emm typing of GABHS isolates. The PCR product was then sequenced to assign an 
emm type. A negative control was also employed which came from Group B streptococcus 
isolate.   
 
 
            M Wt.          Samples 
2000 bp 
1000 bp 
 
300 bp 
1          2      3          4           5         6           7           8         9           -ve       10
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Figure 2.2: Emm types found in GABHS isolates from patients and controls. The pie chart 
above shows the emm types found in GABHS isolates from patients and controls as 
analysed though PCR and gene sequencing. The only common emm type found in both 
patients and control was emm type 4. (A) Emm types found in patient GABHS isolates 
consisted predominantly of emm type 4 followed by emm3 and emm11. (B) Emm 
typesfound in GABHS isolates from healthy controls presented with a high percentage of 
emm4 and emm78.  
 emm3 (14%) 
emm1 (14%) 
emm4 (39%) 
emm11 (19%) 
 emm12 (9%) 
emm87 (5%) 
emm types (%) in GABHS isolates from Patients 
emm78 (25%) 
emm77 (12.5%) 
emm75 (12.5%) 
emm6 (12.5%) 
emm5 (12.5%) 
emm4 (25%) 
emm types (%) in GABHS Isolates from Contols 
A 
B 
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2.4.2 Superantigens  
The same cohort of isolates was screened for the presence of superantigens speA, speB, 
speC, speF, speG, speH, speI, speJ, speK, speL, speM, ssa and smeZ using PCR.                 
 
Figures 2.3: PCR image for SAg screening (speK, L, M and smeZ) in GABHS isolates. PCR 
above shows the presence of superantigens speK, L, M and smeZ in some of the GABHS 
isolates analysed. speL and speM can be seen occurring in the same samples. The above 
PCR is representative of the PCRs carried out for SAg screening in the present study. The 
bands at the bottom of the PCR images show the formation of primer dimer.  
SpeB was found in all 29 samples whereas speF was found in 28 out of the 29 samples with 
one control isolate not expressing it. SAg smeZ was present in 23 out of the 29 samples 
(79%) occurring in both cohorts. speL and speM were always co-detected which was 
expected, as the genes are in adjacent positions on the same bacteriophage (Smoot et al., 
2002a). Both these SAg were observed in 5 isolates all belonging to the patient population. 
speA (14%), speJ and speK (19%) were found only in patients isolates. Only a single patient 
isolate showed the presence of speH and I. speC was seen in all but 5 isolates and was 
                  smeZ 
                    speK                      speL 
                     speM 
M wt.        1       2         3       4         5       6 7        8      9      10     -ve      1        2       3         4        5       6        7      8       9        10   -ve 
M wt.        1       2         3       4         5       6 7        8      9      10    -ve      1        2       3         4        5       6        7      8       9       10   -ve 
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present in both cohorts. To conclude speA, H, I, J, K, L and M were completely absent in the 
isolates from the control group.  
     
    
Figure 2.4: Superantigens present in GABHS isolates from patients and controls. The 
graphs above show the percentage of superantigens (speA, B, C, F, G, H, I, J, K, L, M, smeZ 
and ssa) that were detected in GABHS isolates from patients and neurological controls using 
PCR. (A) The percentage of each of the 13 known SAg in 21 GABHS isolates from patients. 
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speB and F were seen in all samples; speH and I were always co-detected as were speL and 
M. (B) The percentage of each of the 13 known SAg in 8 GABHS isolates from controls. SAg 
speA, H, I, J, K, L and M were found to be completely absent from these GABHS samples; 
speB and speC were seen in all samples; speF was missing in 1 out of 8 samples. 
2.4.3 Correlation: emm type and superantigens 
In addition to the known linkage between the T serotype, serum opacity factor production, 
and the emm type, several studies also indicated correlations between emm types, disease 
manifestations, and other virulence factors, especially the superantigens. Therefore all the 
samples that were emm typed were also analysed for the presence of SAg to study the co-
relation between the two and the following was observed: 
 SpeL and speM were always found in samples with emm4. Interestingly this was 
the case in GABSH isolates only from the patients as they were absent in emm4 
control isolates. 
 Largest numbers of SAg were found to be present with emm4 patient cases (B, C, F, 
G, J, L, M, smez and ssa). In contrast the control cases with the same emm type 
displayed a small number of SAg (B, C, F, smeZ, ssa). However, in both cohorts speG 
was found absent. 
 SpeA was seen only with emm1 and emm3 isolates in the patients. 
 SpeH and speI were the two superantigens present in emm12 patient sample. 
 All emm3 samples did not have SAg smeZ. 
 All emm11 patient cases presented with the same SAg B, C, F, G, smeZ. Similarly, 
this was the case with emm1 samples A, B, F, G, J, smeZ. In common to the above 
two emm type isloates was that they both lacked ssa. 
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PATIENTS 
   
Emmtypes SAg 
  
emm1 A, B, F, G, J, smeZ 
 
emm3 A, B, F, G, K, ssa 
 
emm4 B, C, F, L, M, smeZ, ssa 
 
emm11 B, C, F, G, smez 
 
emm12 B, F, G, H, I, smeZ 
 
Others B, C, F, G, smeZ, ssa 
 
    
CONTROLS 
   
Emmtypes SAg 
  
emm4 B, C, F, smeZ, ssa 
 
emm78 B, C, F, G, smeZ 
 
Others B, C, F, G, smeZ, ssa 
 
Table 2.3: Observed co-relation between GABHS emm types and SAg. The table above 
shows the observed co-relation between emm types and SAg in both GABHS isolates from 
patients and controls. speA was only seen with emm1 and 3; speL and M only with emm4 
but only in the isolates from patients and not controls; speH and I were only present in 
emm12 sample and speJ in emm1 and speK only in emm3. Most SAg that showed 
preference for a particular emm type like speA, H, I, J, K, L and M were absent in the control 
cohort.  
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2.5 DISCUSSION  
GABHS is one of the most important pathogens encountered in clinical practice. Acute 
infections may take the form of pharyngitis, scarlet fever, impetigo, cellulitis, or erysipelas 
(Anand et al., 2012). Arrays of neurological and neuropsychiatric disorders have also been 
linked to GABHS like SC, TS, and OCD. GABHS express a number of cell surface components 
and extracellular products that play an important role in its pathogenesis. The 
pathogenicity of streptococcal strains is determined by major virulence factors like the M 
protein encoded by emm and emm-like (emmL) genes and superantigens. Although the 
pathophysiology of post-streptococcal disorders is not completely understood, antigenic 
mimicry is proposed to be the triggering cause of autoimmunity (Hahn et al., 2005, David 
Greenwood, 2007, Greenwood et al., 2007).  
In the present study GABHS samples were typed for the emm gene that encodes the M 
protein which is known to evoke cross-reactive antibodies, specific for human tissue 
including the brain. Also the aim was to determine if certain emm types were more 
prevalent in patients diagnosed with suspected post-streptococcal neuropsychiatric 
disorders as compared to neurological controls. In the 21 patient samples analyzed emm4 
(38.8%) seemed to be the most prevalent followed by emm11 (19%) and emm3 (14%). 
During 2002–2010, emm4 was found to be the third most common emm type causing 
pharyngitis, and in 2007 and 2008, it was the most common emm type (Shia et al., 2011). In 
a study performed by Chiou et al., 2009 emm4 (23.2%) again was found to be one of the 
prevalent emm type after emm12 (50.4%) in patients with scarlet fever which is associated 
with immune complications including acute glomerulonephitis, rheumatic fever and 
erythema nodosum (Chiou et al., 2009).  
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In the current study emm11 was the second most prevalent emm type found in the isolates 
recovered from patients. Su and colleagues emm typed GABHS isolates from both invasive 
and non-invasive cases and observed that all other emm types were linked to both invasive 
and non-invasive infections except for type 11, which was uniquely associated only with 
invasive diseases (Su et al., 2009). emm type 3 found in 14% of the cases was the third most 
prevalent emm type found in patients  followed by emm1. Both emm1 and emm3 have 
been established to be associated with the most severe GABHS diseases (Harari et al., 
2009; Turner et al., 2012).  
Different emm types tend to predominate in different age groups. In a study conducted by 
Meisal and colleagues in 2010 looking at S. pyogenes isolates causing severe infections in 
Norway between 2006 and 2007, emm12 was found to be common in 1- to 9-year-old 
patients, while emm4 was overrepresented in patients over 60 years of age (Meisel et al., 
2010). These two emm types were found predominant as a cause of invasive infections in 
children (0 to 17 years) in Europe (Harari et al., 2009) and are also known to be common in 
noninvasive infections in children (Jaggi et al., 2005; Darenberg et al., 2007).  
Predominant emm types in distinct geographic areas, often vary in frequency from year to 
year for reasons not fully understood. For instance the isolates from ARF patients in Hawaii 
presented with a completely different range of emm types (emm types 65/69, 71, 92, 93, 
98, 103, and 122) than those in the United States (1, 3, 5, 6, 14, 18, 19, 24, 27, and 29) 
(Erdem et al., 2007).   
Despite the considerable diversity of emm types of GABHS isolates, epidemiologic studies 
have found that relatively few emm types tend to predominate within a local population 
(Shulman et al., 2004; Shulman et al., 2009). These findings suggest that GABHS strains 
associated with a single disease may be quite different in geographical regions complicating 
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designing and customizing candidate vaccines to induce type-specific immunity. In addition, 
sizeable outbreaks can be caused by strains of a single emm type or of a small number of 
emm types. Overall, this combination of factors results in a complex epidemiologic 
situation for GABHS infections requiring a deeper understanding of geographic and 
temporal variation in emm types.  
Next the superantigen profiles of the GABHS isolates from both patients and controls was 
analysed to determine whether there is any variation between the two cohorts. The results 
showed a range of superantigens to be only present in the patient isolates like speA, H, I, J, 
K, L and M which might be enhancing the immunopathogenicity of these isolates. Of these 
speL and M were discovered after the sequencing of genome of strain MGAS8232, a 
serotype M18 strain recovered from a patient with ARF (Smoot et al., 2002). Recombinant 
SPE-L (rSPE-L) and rSPE-M are seen to be highly mitogenic for human peripheral blood 
lymphocytes. Both SPE-L and SPE-M are shown to bind MHC class II antigens exclusively to 
the β-chain in a zinc-dependent binding mode and Vβ1.1 TcR appeared to be the primary 
target of both the toxins and T cells carrying the Vβ1.1 TcR being stimulated >80 times than 
with ConA (Proft et al., 2003). Other SAg uniquely seen in patient isolates was speA and 
GABHS that produce this exotoxin are known to be associated with severe infections 
characterized by rash, hypotension, multiorgan failure and a high mortality rate 
(Papageorgiou et al., 1999). It has also been linked to outbreaks of streptococcal toxic 
shock syndrome (STSS) in the United States and Europe. SpeA stimulates V beta 2.1, 12.2, 
14.1, and 15.1-positive T cells, and the lymphokine production from the activated T cells is 
believed to result in the symptoms associated with STSS (Kline and Collins, 1997). SpeJ 
which was again found exclusively in the patient isolates has been found to be lethal in 
models of STSS. Purified recombinant speJ (rSPE J) expressed in E. coli stimulated the 
expansion of both human peripheral blood lymphocytes and rabbit splenocytes. The SAg 
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preferentially expanded human T cells displaying Vβ2, -3, -12, -14, and -17 on their T-cell 
receptors (McCormick et al., 2001). SAg speJ was not found in all the samples in our study, 
this contrasts with the results of Proft and co-workers who observed a 100% prevalence 
suggesting this superantigen to be chromosomally encoded (Proft and Fraser, 2003; Proft 
et al., 2003). 
Superantigen genes are thought not to be randomly distributed amongst GABHS isolates. 
Certain combinations of superantigen genes are found to be more common and the 
majority of emm types showed restricted superantigen profiles. Previous studies have also 
suggests that there might be a geographical variation in the association between 
superantigen gene possession and emm type (Ikebe et al., 2002). So in the present study I 
analysed any possible link between the two virulence factors and made a few observations 
like speL and M were found only in emm type 4 patient samples and not controls. This 
finding is consistent with those by Proft and colleagues who also found speL and speM in 
emm4, emm22, emm28 and 73% of emm89 isolates (Proft et al., 2003).  
Next speG was found to be to be absent from emm4 isolates which has been in observed in 
some previous studies too (Murakami et al., 2002; Vlaminckx et al., 2003; Common et al., 
2008). This might suggest that emm4 isolates may contain an allele with mutations in the 
primer-binding sites (Commons et al., 2008). Also in accordance with all the previous 
studies it was found that smeZ was not present in emm3 isolates (Schmitz et al., 2003; 
Vlaminckx et al., 2003; Commons et al., 2008). A disparity in binding sites in emm3 isolates 
would be constant with evidence that smeZ alleles are linked to emm type (Proft et al., 
2000). Interestingly, both smeZ gene and emm3 isolates have been linked independently to 
STSS (Beres et al., 2002; Vlaminckx et al., 2003). Previous studies (Descheemaeker et al., 
2000; Vlaminckx et al., 2003) have suggested that majority of emm type 1 isolates contain 
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speA, speG, speJ and smeZ but do not possess speC, ssa and speH which is once again 
consistent with findings reported here.   
From the above observations it is clear that streptococcal SAg show emm-type-specific 
associations. The pattern seen in our study has been consistent with previous findings in 
the field making it possible for us to draw certain definitive conclusions about the co-
relation between the two virulence factors. However, the importance and relevance of 
these relationships needs further investigation by clarifying their role in the outcome of 
infection with GABHS. 
To conclude emm types display variability in virulence gene profiles as well as differences in 
gender and age group preferences. The distribution of emm types in cases of invasive 
diseases also tends to vary over time and within different geographic regions. Same holds 
true for superantigens where no single unifying superantigen has been implicated. 
Accumulating evidence however is suggesting that these diseases are in response to one or 
many of a variety of superantigens in genetically susceptible individuals. 
The patient and control streptococcal isolates were collected at Great Ormond Street 
Hospital for Children, London as part of a cross-sectional and longitudinal UK based study. 
The emm profile of GABHS can vary between different age groups, seasons and 
geographical locations. In the present study the patient and control cohorts were matched 
on the basis of season and geographical location but not for age which forms the biggest 
shortcoming of this study together with a small sample size. To take this study further I will 
be collaborating to work on a much larger cohort of TS and healthy children (approximately 
100 per group). In addition, I aim to introduce an additional cohort consisting of siblings of 
TS patients as they share the same micro-environment. In the present work unfortunately, 
a large number of GABHS DNA extracts stored previously from both patients and controls 
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could not be analysed for emm and SAg as the DNA was not extractable. This could be due 
to sub-optimal long-term storage conditions or problems with the extraction itself. From 
the small number of samples analysed it appears that the SAg gene repertoire of the 
isolates correlate with the emm type in a complex pattern, preventing the formation of 
definite conclusions on the role of individual SAg in disease. The data presented should 
hence be taken forward analysing a large group of samples as it could be of value for 
preventive work, including ongoing attempts at creating vaccine prophylaxis against GA. 
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CHAPTER 3 
ANIMAL MODELS 
 
3.1 INTRODUCTION 
In the present study it was attempted to create an animal model of postulated post-
streptococcal neuropsychiatric movement disorders by active immunization with various 
putative antigens which are described below. Additionally a passive transfer model was 
created involving direct insertion of antibodies from patients in to the CNS. 
3.1.1 Putative Antigen:  GABHS Proteins 
GABHS is a bacterium responsible for numerous human disorders because of its ability to 
induce immune-mediated sequelae. The M protein on the surface of GABHS has been 
identified as a possible antigen that ABGA may cross-react with (Dale et al., 2001).  In 
support of this hypothesis, the M protein has been reported to induce antibodies that 
cross-react with -helical human proteins. Furthermore, particular GABHS serotypes are 
associated with several post-streptococcal immune disorders, including SC (M types 5, 6, 19 
and 24), ARF (M types 1, 3, 5, 6, 14, 18, 19, 24, 29) and glomerulonephritis (M types 1, 4, 
12, 49, 55, 57, and 60) (Brandt et al., 2001; Church et al., 2002). In TS patients, increased 
titres of M12 and M19 serotypes have been observed; while antibodies from chorea 
patients have been shown to cross react with neuronal cells and M6 and M12 serotypes 
(Bronze et al., 1993; Müller et al., 2001). Similarly, antibodies from SC patients have been 
reported to cross-react with M types 5, 6 and 19 and several brain proteins ranging in size 
from 28kDa to 200 kDa. These neuronal proteins were not present in one particular 
anatomic region but the basal ganglia observed the most intense antibody interactions 
(Bronze and Dale, 1993).  
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Although streptococcal M protein is the most well characterized virulence factor a fairly 
complex picture is involved in host-pathogen crosstalk that involves a high number of 
proteins. Three categories of GABHS extracellular proteins have been recognized (Fischetti 
et al., 2000; Benfang et al., 2000). First category includes proteins that are actively secreted 
into the extracellular environment. Examples of these proteins include potent 
superantigens such as speA and C (Commons et al., 2008). The second category of proteins 
includes molecules with a secretion signal sequence and a conserved hexapeptide 
sequence (Leu-Pro-X-Th-Gly) that anchors the protein to the bacterial cell membrane 
(Fischetti et al., 2000). These cell surface-anchored proteins include known virulence 
factors such as M protein and C5a peptidase. In recent years, evidence has been presented 
a third category of GABHS extracellular proteins that lack apparent secretion signal 
sequences and the LPXTG membrane anchor motif. These proteins are found in the culture 
supernatants in high concentrations in the logarithmic phase of growth which may be 
related to passive release from the intracellular compartment via an unknown transport 
mechanism (Pancholi and Fischetti, 1992; Pancholi and Fischetti, 1998). Interestingly, two 
proteins in this class are glyceraldehyde-3-phosphate dehydrogenase and α-enolase both 
enzymes involved in the glycolytic pathway (Pancholi and Fischetti, 1993; Winram et al., 
1996; Pancholi and Fischetti, 1998; Zhang et al., 2007). 
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3.1.2 Putative Antigen: Glycolytic Enzymes 
 
Patients have been identified presenting with an encephalitic illness with a subsequent 
clinical course reminiscent of EL with ABGA and evidence of recent streptococcal infection 
(Dale et al., 2001; Dale et al., 2004a). ABGA have also been associated with other 
neuropsychiatric disorders including SC, PANDAS, TS and OCD. These autoantibodies are 
shown to recognise four main protein bands of 40kDa (aldolase C), 45kDa (neuron specific 
gamma enolase), 45 kDa (non-neuronal alpha enolase), 60 kDa (pyruvate kinase M1) and 98 
kDa (neuron specific alpha/gamma dimer) that have been purified and successfully 
identified using 2-D gel electrophoresis and mass spectrometry (Dale et al., 2006). All the 
above antigens are glycolytic enzymes involved in energy homeostasis and as expected are 
found in the cytosol. However, these proteins are also shown to be located on the neuronal 
surface (Lim et al., 1983; Nakajima et al., 1994), where they appear to have “moonlighting” 
or alternative functions. These glycolytic enzymes/putative autoantigens have probable 
roles in energy metabolism, neurotransmission, cell health, maintenance of ion channels, 
and the control of cellular metabolism. All these roles are plausible and it is possible that 
autoantibodies could interfere with these roles either directly or indirectly (i.e. via a cell 
mediated response). 
 
 
 
 
 
98 
 
3.1.3 Animal Models  
Autoimmunity has been postulated as the cause of at least some cases of a number of 
human diseases, including ankylosing spondylitis (Klebsiella), multiple sclerosis, Graves’ 
disease, systemic lupus erythematosis (SLE), diabetes mellitus, rheumatoid arthitis, and 
atherosclerosis (Samarkos and Vaiopoulos, 2005). But the human disease with the best 
support for an autoimmune aetiology remains ARF (Bessen, 2001). Experimental allergic 
encephalomyelitis (EAE) provided some of the earliest evidence for the phenomenon of 
microbial-induced autoimmunity (Oldstone, 2000). Although research into autoimmune 
mechanisms is advancing at a rapid pace, the immune system response is still largely 
unexplained at the molecular level (Swedo and Grant, 2005). 
Till date very few animal models have been set up to understand the aetiology and 
mechanisms of speculated post- streptococcal neuropsychiatric disorders the prototype 
being SC and TS. Briefly reviewed below are some of the animal models established so far 
to better understand the pathophysiology of these disorders and their link with GABHS.  
3.1.2.1 Stereotypies models 
TS and OCD are comorbid behavioral disorders, suggesting a shared but still unknown 
neuronal basis. Stereotypies and episodic utterances in animals have been proposed as a 
model of motor and vocal tics.  
In an animal model developed by Taylor et al. (2002) sera from TS patients with high levels 
of anti-neural Abs, TS patients with low levels of autoantibodies and normal subjects were 
infused bilaterally into the ventrolateral striatum of male Sprague-Dawley rats. Rates of 
oral stereotypies (analogous to involuntary movements seen in TS) significantly increased 
in the rats infused with sera from the patients with high levels of autoantibodies. There was 
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also a marked increase in genital grooming in the rats infused with high-antibody TS sera, 
compared with the other groups. These results suggest that it is the presence of 
autoantibodies or other serum factor(s) lead to the observed stereotypies (Taylor et al., 
2002). A similar study was carried out by Hallett et al. (2000) and their 
immunohistochemical analysis confirmed the presence of IgG that selectively bound to 
striatal neurons. These data support the hypothesis that binding of an anti-neuronal 
antibody from some children with TS induced striatal dysfunction and suggest a possible 
cause for the basal ganglia alterations observed in children with TS with the molecular 
mimicry hypothesis proposed for aetiology of a subgroup of TS cases (Hallett et al., 2000).  
A study by Nordstorm and Burton (2002) used transgenic mice expressing a 
neuropotentiating protein within a subset of dopamine D1-receptor expressing (D1+) 
neurons that are known to trigger glutamatergic excitation of orbitofrontal, sensorimotor, 
limbic and efferent striatal circuits. These circuits are thought to be affected in OCD and TS. 
These mice exhibited OCD-like behaviors including generalized behavioural perseveration 
and compulsion-like leaping and grooming-associated pulling and biting (Nordstrom and 
Burton, 2002). Additionally, the animals also exhibited comorbid TS-like behaviors, 
including juvenile-onset tics, increased tic number, complexity and flurries, increased tic 
severity in males, voluntary tic suppression. The importance of hormonal gender 
differences was highlighted in the study as this may be a factor sufficient to aggravate tic 
severity in human TS males compared to females (Nordstrom and Burton, 2002). 
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3.1.2.2 Active Immunization models 
Only a limited number of animal models have been set up using GABHS to confirm its link 
with the onset of a spectrum of neuropsychiatric disorders in children.  
The first animal model to test the hypothesis that an immune response to GABHS can result 
in behavioural abnormalities was carried out by Hoffman et al. (2004). Female SJL/J mice 
were immunized and boosted with a GABHS homogenate in Freund’s adjuvant. Sera from 
GABHS immunized mice was then tested for immunoreactivity to mouse brain and a subset 
was found to be immunoreactive to several brain regions, including deep cerebellar nuclei 
(DCN), globus pallidus, and thalamus. GABHS-immunized mice also exhibited increased 
rearing behaviour in open-field and hole-board tests compared with controls and with 
GABHS-immunized mice lacking serum anti-DCN antibodies (Hoffman et al., 2004).  
Another study was carried out by Yaddanapudi et al. (2009) in which they attempted to 
create a PANDAS mouse model following immunization with GABHS homogenate. Anti-CNS 
antibodies were seen directed against GABHS matrix (M) protein and cross-reacting with 
molecular targets complement C4 protein and alpha-2-macroglobulin in brain. They 
observed deficits in motor coordination, learning/memory and social interaction in PANDAS 
mice, replicating more complex aspects of human disease. Furthermore, they 
demonstrated that naive mice were transfused with IgG from PANDAS mice developed all 
the deficits listed above. This highlights that humoral immunity is necessary and sufficient 
to induce the syndrome. Their work provides an insight into PANDAS pathogenesis and may 
lead to new strategies for identification and treatment of children at risk for autoimmune 
brain disorders (Yaddanapudi et al., 2009). 
101 
 
A model of SC has been recently described by Brimberg et al. (2012) using male Lewis rats 
which when exposed to GABHS antigen exhibited motor symptoms (impaired food 
manipulation and beam walking) and compulsive behaviour (increased induced-grooming). 
Consistent with the known pathophysiology of these neuropsychiatric disorders antibody 
deposition was found in the striatum, thalamus, and frontal cortex. Concomitant 
alterations in dopamine and glutamate levels were seen in the cortex and basal ganglia. 
Furthermore, the motor symptoms were found to improve by the D2 blocker haloperidol 
and the selective serotonin reuptake inhibitor paroxetine, respectively, these are the drugs 
used to treat motor symptoms and compulsions in streptococcal-related neuropsychiatric 
disorders (Brimberg et al., 2012). These results were consistent with the hypothesis that an 
immune response to GABHS can cause motor and behavioural disturbances and suggest 
that anti-GABHS antibodies cross-reactive with brain components may play a role in their 
pathophysiology.  
3.2 HYPOTHESIS AND AIMS 
Inoculating mice with GABHS proteins or recombinant proteins (putative autoantigens) in 
complete Freunds adjuvant will induce the development of anti-neuronal antibodies in 
mice and result in stereotypical movements similar to those seen in human subjects with 
ABGA-associated neuropsychiatric disorders. 
Induction of autoantibodies from patients with postulated post-streptococcal 
neuropsychiatric disorders like EL in mice should result in stereotypical movements similar 
to those seen in human subjects. If enolase is indeed a target autoantigen in this group of 
disorders then injecting mice with monoclonal antibody (mAb) against neuron specific 
enolase (NSE) should also result in stereotypical movements similar to those seen in human 
subjects. 
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The main aim of this study was develop a mouse model that resembled the behavioural 
and locomotor deficits associated with TS and other proposed streptococcal-related 
neuropsychiatric disorders by: 
(1) Active immunization with a cocktail of the putative autoantigens aldolase C, α-enolase, 
γ-enolase and pyruvate kinase. (2) Active immunization with GABHS protein fractions 
(soluble + insoluble). (3) Intra-cerebral induction of autoantibodies purified from patients 
and controls and mAb against enolase. 
3.3 MATERIALS AND METHODS 
3.3.1 GABHS Protein Fractions  
GABHS isolate used for protein extraction belonged to a TS patient and was emm type 4 
presenting with a range of superantigens speB, C, G, F, L, M, smeZ and ssa. The isolate 
frozen on beads was streaked onto a solid agar plate supplemented with 5% horse blood. 
The plate was then incubated for 18-24 hours at 37°C aerobically with the addition of 5% 
CO2.  GABHS typically formed colonies 0.5mm in diameter surrounded by a zone of 
complete haemolysis. A swab of bacterial colonies was used to inoculate Todd-Hewitt 
broth (Sigma-Aldrich, UK) for liquid cultures needed for preparation of insoluble and 
soluble protein fractions. 
GABHS colonies were extracted from the Todd-Hewitt broth using successive rounds of 
centrifugation to form pellets in the bottom of 25mL falcon tubes. The bacterial pellet was 
re-suspended using 1mL of 20mM Tris-HCL buffer (pH7.5) with 20µL of protease inhibitor 
cocktail (Sigma-Aldrich, UK). To remove the soluble proteins, 0.1mm beads were added to 
each re-suspension which was then put in a bead beater for 90 s. The suspension was then 
centrifuged at 10,000 x g for 30 min and the supernatant collected. This supernatant 
formed the soluble (membrane) fraction and was stored at -80oC until required. The 
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remaining bacterial pellet were re-suspended in 1mL of 20mM Tris-HCL buffer (pH 7.5) and 
centrifuged at 10,000 x g for 15 min. The supernatant was removed and discarded. The 
pellet was then re-suspended in 8M urea and rocked for 1 h followed by centrifugation at 
10,000 x g for 30 min. The supernatant was collected which formed the insoluble protein 
fraction and was stored at -80oC until required.  
3.3.2 Production of Recombinant Proteins  
 
3.3.2.1 pQE30 Vector  
The pQE-30 expression vector from the The QIAexpress® System (Qiagen, UK) used in our 
study as it provides a high-level expression of 6xHis-tagged proteins in E. coli. It is based on 
the T5 promoter transcription–translation system. The pQE plasmids belong to the pDS 
family (Bujard et al., 1987) and offer some important features like: 
 Optimized promoter–operator element consisting of phage T5 promoter and two 
lac operator sequences. 
 Synthetic ribosomal binding site, RBSII, for high translation rates 
 6xHis-tag coding sequence either 5' or 3' to the cloning region 
 Nickel-nitrilotriacetic acid (Ni-NTA) metal-affinity chomatograph matrices for 
biomolecules which have been tagged with 6 consutive histidine residues 
 
 Multiple cloning site and translational stop codons in all reading frames for 
convenient preparation of expression constructs 
 Two strong transcriptional terminators: t0 from phage lambda (Schwarz et al. 
1987), and T1 from the rnB operon of E. coli, to prevent read-though transcription 
and ensure stability of the expression construct. 
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 3.3.2.2 Transformation using XL1-Blue Competent cells 
XL1-blue competent cells (Agilent Technologies, UK) were used for transformation. These 
are ready to use bacterial cells (E.coli) chemically treated to allow incorporation of foreign 
DNA/plasmid. This strain allows blue-white color screening for recombinant plasmids and is 
an excellent host strain for routine cloning applications using plasmid or lambda vectors. 
Two 14-mL BD Falcon polypropylene round-bottom tubes were pre-chilled on ice. (One 
tube was for the experimental transformation and one tube was for the pUC18 control). 
The SOC medium was pre-heated to 42°C. XL1-Blue competent cells were then thawed on 
ice and then gently mixed and aliquoted into each of the two pre-chilled tubes (50μL of 
cells per tube). A volume of 0.85μL of β-mercaptoethanol provided with the kit was added 
to each of the above cell aliquots. The contents of the tubes were gently swirled and then 
incubated on ice for 10 min, with gentle swirling every 2 min. Following the incubation 0.1–
50 ng of the pQE-30 vector (1μL) was added to one of the aliquots of cells and to the other 
1μL of the pUC18 control DNA was added. The tubes were then swirled gently again and 
incubated on ice for 30 min. The tubes were then heat-pulsed in a 42°C water bath for 45 
seconds and then incubated on ice for 2 min. The duration of the heat pulse is critical for 
maximum efficiency. A volume of 0.45mL of preheated SOC medium was then added two 
the tubes which were then incubated at 37°C for 1 h with shaking at 650 x g. A volume of 
100μL of the transformation mixture was then plated onto on LB agar plates containing 
ampicillin which were then incubated overnight for at least 17 h at 37°C. The following day 
2X5mL of LB broth was inoculated using a single colony from the above plate. This broth 
was then incubated for approximately 17 h at 37°C with shaking at 650 x g. DNA extraction 
was then performed using the QIAprep Spin Miniprep Kit (Qiagen, UK). 
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3.3.2.3 Vector Digestion with Restriction Enzymes 
Alpha Enolase and Aldolase C: BamHI and HindIII 
PK: KpnI and BamHI 
Gamma Enolase: KpnI and HindIII 
The restriction enzymes (New England Biolabs Inc., UK) were chosen for each of the four 
recombinant proteins using the NEBcutter V2.0 (New England Biolabs Inc., UK). The pQE30 
vector DNA was then digested using the restriction enzymes HindIII and BamHI for α-
enolase and aldolase-C, KpnI and BamHI for pyruvate kinase and KpnI and HindIII for γ- 
enolase as described below. 
A 20µL reaction mixture was prepared with 800 ng of the pQE30 vector DNA + 2µL of 10X 
BSA + 20 units (~ 1µL) of the first restriction enzyme + 2µL of 10X NE Buffer 1/2/3 (as 
appropriate to that restriction enzyme). This reaction was then incubated at 37°C for 1 h in 
a heat block following which the second restriction enzyme was added together with 
sodium chloride. The reaction mix was incubated for a further 1h at 37°C in a heat block. 
The restriction reaction was stopped by storing at -20°C. The following day the reaction was 
run on a 0.7% agarose gel containing SYBR® Safe (Invitrogen, UK). The DNA fragment was 
excised from the agarose gel with a clean, sharp scalpel using a trans-illuminator and gel 
extraction was performed as described below. 
3.3.2.4 Gel Extraction  
Gel extraction was carried out using the QIAQuick Gel Extraction Kit (Qiagen, UK). The gel 
slice was weighed in an eppendorf tube and to 1 volume of agarose gel (100mg ~ 100μL) 3 
volumes of Buffer QG was added. The maximum amount of gel slice per QIAquick column 
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was 400 mg. This was then incubated at 50°C for 10 min (or until the gel slice has 
completely dissolved). To help dissolve the gel, the tube was vortexed every 2–3 min during 
the incubation. After the gel slice has dissolved completely, it was checked that the colour 
of the mixture is yellow if the colour of the mixture was orange or violet, 10μL of 3 M 
sodium acetate, pH5.0, was added and mixed. Next 1 gel volume of isopropanol was added 
to the sample. This step increases the yield of DNA fragments <500 bp and >4 kb. The 
QIAquick spin column was then placed in a provided 2mL collection tube. To bind DNA, the 
sample was simply applied to the QIAquick column, and centrifuged for 1 min. Once the 
flow-though was discarded 0.5mL of Buffer QG was applied to the column which was then 
centrifuged for a further 1 min. Following this the column was washed with 0.75mL of 
Buffer PE and centrifuged again for 1 min. Once the flow-though was discarded QIAquick 
column was centrifuged for an additional minute at 17,000 x g. The DNA was then eluted in 
a clean eppendorf tube by addition of 50μL of Buffer EB (10 mM Tris·Cl, pH8.5) or dH2O (pH 
7.0–8.5) to the centre of the QIAquick membrane and centrifugation for 1 min.  The 
concentration was measured using Nanodrops and the DNA sample was then stored at -
20°C until used for ligation. 
3.3.2.5 Clones 
Clones for the four recombinant proteins were obtained from Source Bioscience 
Geneservice Cambridge, UK. The IMAGE IDs of the clones are: Homo sapiens Alpha Enolase- 
2906988/LLCM43-J13(M13R) cDNA clone MGC: 2414, Homo sapiens Aldolase C-
2987869/LLCM76-D14(M13R) cDNA clone MGC: 1449, Homo sapiens Gamma Enolase- 
3629603/IRAU21-F2(M13F) cDNA clone MGC: 2309 and Homo sapiens Pyruvate Kinase- 
3859987/IRQL4-E12(M13R) cDNA clone MGC:9369. 
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The four cDNA clones were streaked on to LB agar plates containing ampicillin (100µg/mL) 
and incubated at 37°C for 16-18 h.  Using a colony from each plate 5mL of LB broth 
containing ampicillin was inoculated and incubated at 37°C for 16-18 h with vigorous 
shaking at 600 x g. DNA was extracted using the QIAprep Spin Miniprep Kit (Qiagen, UK) as 
described below. 
3.3.2.6 DNA extraction  
The Qiaprep Spin Mini Prep kit (Qiagen, UK) was used for DNA extraction. The pelleted 
bacterial cells were resuspended in 250μL Buffer P1 and transferred to a microcentrifuge 
tube. 250μL Buffer P2 was then added and mixed thoroughly by inverting the tube 4–6 
times followed by addition of 350μL Buffer N3 and which was mixed immediately and 
thoroughly by inverting the tube 4–6 times again. The mixture was centrifuged for 10 min 
at 17,900 x g in a table-top microcentrifuge. The supernatants were then applied to the 
QIAprep spin column by decanting or pipetting. This was again centrifuge for 30–60s and 
the flow-though discarded.  The QIAprep spin column was then washed with 0.5mL Buffer 
PB and centrifuged for 30–60s. After discarding the flow-though the QIAprep spin column 
was washed with 0.75mL of Buffer PE and centrifuged for 30–60s. The column was then 
again centrifuged for an additional 1 min to remove residual wash buffer.  To elute the 
DNA, 50μL Buffer EB (10 mM Tris·Cl, pH8.5) or distilled water was added to the center of 
the QIAprep column placed in a clean 1.5mL microcentrifuge tube. The DNA concentration 
was measured using Nanodrops. 
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3.3.2.7 PCR  
Designing the primers 
Knowledge of the sequence to be amplified and the vector into which the resulting cDNA is 
to be ligated allowed us to design primers that amplify the desired sequence and introduce 
appropriate restriction sites into the cDNA. By incorporating a different restriction site at 
each end of the amplified sequence cloned products could be directionally inserted into an 
appropriate vector. This was achieved by extending the 5’ sequence of the oligonucleotide 
primers used in the PCR to introduce the appropriate restriction enzyme recognition 
sequence. Amplification of the DNA from the four clones was performed using the 
following primers: 
GGATCC- BamHI 
AAGTCC- HindIII 
GGTACC- KpnI 
 
Glycolytic Enzyme                             Primer Sequence 
Ald C (Forward) ATGTAGGATCCCCTCACTCGTACCCAGCCCT 
Ald C (Reverse) GATCTAAGCTTAGTAGGCATGGTTGGCAATG 
α-Eno (Forward) CATACGGATCCTCTATTCTCAAGATCCATGCAG 
α-Eno (Reverse) AGTCAAAGCTTTACTTGGCCAAGGGGTTTCTG 
γ-Eno (Forward) CAGTAGGTACCTCCATAGAGAAGATCTGGGC 
γ-Eno (Reverse) TGCTCAAGCTTTCACAGCACACTGGGATTAC 
PK (Forward) CATACGGATCCTCGAAGCCCCATAGTGAAGC 
PK (Reverse) TCTATGGTACCCACGGCACAGGAACAACAC 
 
Table 3.1: Primer sequences for glycolytic enzymes. Forward and reverse primer sequences 
with the appropriate restriction site for glycolytic enzymes ald C, α-enolase, γ-enolase and 
pyruvate kinase. 
5µL of 10x NH4 buffer, 2.5µL of 50 mM MgCl2, 5µL of dNTP, 1µL (20pmol) of each primer, 
was added to 1µL Q-BioTaq (5 units/µL, QBiogene Inc., UK) and 5µL of 1:100 DNA sample 
was added to a PCR tube and the final volume was adjusted to 50µL with PCR grade water. 
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The reaction mixture was then amplified using the following PCR cycle in a thermocycler. 
The PCR products were analyzed on a 2% agarose gel with ethidium bromide and DNA 
hyper ladder II (Bioline Reagents Ltd., UK). 
PCR Cycle 
Step Temperature (°C) Time  
1)Initialization  94 10 min  
25 Cycles 
2)Denaturing 
3)Annealing 
4)Extension/Elongation 
 
94 
46.5 
72 
 
30 s 
30 s 
120 s 
5)Final Elongation 
6)Final Storage 
72 
4 
10 min 
Short term storage 
 
 
Table 3.2: PCR cycle used for amplification of glycolytic enzymes aldolase C, α- enolase, γ-
enolase and pyruvake kinase. 
3.3.2.8 PCR Purification  
 
DNA fragments were purified using the QIAquick PCR Purification Kit (Qiagen, UK). 5 
volumes of Buffer PB was added to 1 volume of the PCR sample and mixed. The sample was 
then applied to the QIAquick column placed in a provided 2mL collection tube and 
centrifuged for 30–60 s to bind the DNA. After the flow- though was discarded the QIAquick 
column was placed back into the same tube and washed with 0.75mL of Buffer PE followed 
by centrifugation at 10,000 x g for 30–60 s. Again the flow-though was discarded and the 
column was centrifuged for an additional 1 min at maximum speed. After centrifugation 
the QIAquick column was placed in a clean 1.5mL microcentrifuge tube and DNA was 
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eluted by adding 50μL Buffer EB (10 mM Tris·Cl, pH8.5) or dH2O to the centre of the 
QIAquick followed by centrifugation for 1 min. The DNA concentration was then measured 
using Nanodrops. 
3.3.2.9 Restriction Reaction 
Digestion of the DNA from the four clones was carried out with the chosen restriction 
enzymes as described above for the pQE30 vector. 
Alpha Enolase and Aldolase C: BamHI and HindIII 
Gamma Enolase: KpnI and HindIII 
PK: KpnI and BamHI 
3.3.2.10 Ligations 
A ligation reaction consisting of 200ng of pQE30 expression vector + 30ng of insert (both 
digested by restriction enzymes) was prepared. To the above 1µL of T4 DNA ligase (New 
England Biolabs Inc., UK) and 2µL of 10X Buffer for T4 DNA ligase were added and the final 
volume was adjusted to 20µL with dH2O. T4 DNA ligase catalyzes the joining of two strands 
of DNA between the 5´-phosphate and the 3´-hydroxyl groups of adjacent nucleotides in 
either a cohesive-ended or blunt-ended configuration. The ligation reaction was then put in 
the PCR machine at 16°C for approximately 50 h.  Following the incubation transformation 
was carried out using XL1-Blue competent cells (as described previously). The transformed 
cells were plated onto LB agar plates containing ampicillin and incubated for 17 h at 37°C. 
Two colonies from each vector + insert plate were then used to inoculate 5mL LB broth 
which was then incubated for a further 16 h at 37°C with shaking at 550 x g. Plasmid DNA 
purification was carried out as per the instrutctions in the Qiagen plasmid maxi prep kit 
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(Qiagen, UK). The samples were then sequence verified at The Genome Centre, William 
Harvey Research Institute.   
3.3.2.11 Induction of proteins using Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
Once sequence verified protein expression was induced using Isopropyl β-D-1-
thiogalactopyranoside (IPTG) (Sigma-Aldrich, UK). IPTG is used in cloning procedures 
requiring induction of β-galactosidase activity. 10mL of culture medium containing 
ampicillin (100 μg/mL) was inoculated in a 50mL flask and the cultures were grown 
overnight at 37°C. The following day 100mL of prewarmed media (with antibiotics) was 
inoculated with 5mL of the overnight cultures and incubated  at 37°C with vigorous shaking 
until an optical density (OD600) of 0.6 was obtained which took approximately 30-60 min. 
1mL of sample for each protein was taken immediately before induction which served as a 
non-induced control. Expression was induced in the rest of the culture by addition of 1 mM 
IPTG. The cultures were incubated for an additional 4–5 h after which a second 1mL sample 
was collected which was the induced control sample. Both the non-induced and induced 
samples were pelleted and re-suspended in SDS-PAGE buffer and stored at -20°C until 
analysis by gel electrophoresis.  The remaining cells were then harvested by centrifugation 
at 4000 x g for 20 min. The solubility of the target proteins was then determined by re-
suspending the cell pellet in 5mL of lysis buffer for native purification. The samples were 
then snap frozen in dry ice and thawed in cold water followed by sonication 6 x 10s with 
10s pauses at 200–300 W. The lysate was kept on ice at all times. Centrifugation was then 
carried out at 10,000 x g at 4°C for 20–30 min. The supernatant was decanted (soluble 
protein) and saved on ice. The remaining pellet was then resuspended in 5mL lysis buffer. 
This formed the suspension of the insoluble matter (insoluble protein). Protein solubility 
was then determined by SDS-PAGE analysis and staining with Coomassie stain and 
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immunodetection using anti-His antibody as defined below. Once the solubility of the 
target proteins was confirmed appropriate protocol was followed for native or denaturing 
conditions (described). 
3.3.2.12 Anti-His Immunodetection  
The proteins were separated by SDS-PAGE using a 10% Tris-HCl ready gel (Bio-Rad, UK) and 
the membrane was stained with 0.5% Ponceau S + 0.1% acetic acid. Once the protein bands 
were visible the membrane was washed 3X10 min with TBS buffer following incubation for 
1 h in blocking buffer 3% BSA in TBS at RT. The membrane washed 2X10 min with TBS 
buffer before incubation with 1:1000 anti-His antibody (Qiagen, UK) prepared in blocking 
buffer at RT for 1h. Again the membrane was washed 2X10 min with TBS-tween. Incubation 
with horseradish peroxidase (HP) conjugated anti-mouse IgG (Sigma-Aldrich, UK) secondary 
antibody solution prepared in nonfat dried milk in TBS was carried out for 1h at RT.  The 
membrane was then washed 4X10 min in TBS-Tween buffer. Chemiluminescent detection 
reaction was then performed and expose to X-ray film according to the manufacturer’s 
recommendations. 
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Figure 3.1: Western blot confirming the expression of recombinant proteins. Western blot 
confirming the expression of the four recombinant proteins (aldolase C, α-enolase, γ-
enolase and pyruvate kinase) detected by anti-his antibody. Lane 1: soluble fraction; lane 2: 
insoluble fraction; lane 3: induced sample (IPTG induction); lane 4: non-induced sample. 
3.3.2.13 Protein Purification  
Native Conditions (Soluble Fraction) 
The pellet derived from 50mL cell culture volume was re-suspended in 6.3mL of lysis buffer 
(50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH8.0). 700μL lysozyme stock solution 
(10 mg/mL) and 3 Units/mL culture volume Benzonase® Nuclease (Novagen, 25 U/μl) was 
then added to the above. The mixture was then incubated on ice for 15–30 min followed by 
centrifugation at 12,000 x g for 15–30 min at 4°C. The supernatant was collected out of 
which 20μL of the cleared lysate was saved for SDS-PAGE analysis. The Ni-NTA spin column 
was equilibrated with 600μL the lysis buffer and centrifuged for 2 min at 890 x g. Upto 
600μL of the cleared lysate containing the 6xHis-tagged protein was loaded onto the pre-
equilibrated Ni-NTA spin column. Centrifugation for 5 min at 270 x g was then carried out 
Pyruvate Kinase                                                        Aldolase C 
   1                2                3           4                             1            2                  3                   4 
γ – Enolase                                     α- Enolase 
   1            2                3                      4                           1                  2                         3              4 
        60 kDa 
       45 kDa 
    40 kDa 
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and the flow-though collected. Again a small sample of the flow-though was saved for 
analysis by SDS-PAGE to check for binding efficiency. The Ni-NTA spin column was then 
washed twice with 600μL of wash buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM 
imidazole, pH8.0) and centrifuged for 2 min at 890 x g. Again the flow-though (wash 
fractions) was saved for analysis later by SDS-PAGE to check the stringency of the wash 
conditions. The proteins were then eluted twice with 300μL of elution buffer (50 mM 
NaH2PO4, 300 mM NaCl, 500 mM imidazole, pH8.0) by centrifugation for 2 min at 890 x g. 
Denaturing Conditions (Insoluble Fraction)  
The pellet was thawed and re-suspended in 700μL of Buffer A (7 M urea; 0.1 M NaH2PO4; 
0.01 M Tris·Cl; pH8.0) to which 3 Units/mL culture volume Benzonase® Nuclease (Sigma- 
Aldrich, UK) was also added. The cells were incubated with agitation for 15 min at RT. The 
solution should become translucent when lysis is complete. The lysate was then 
centrifuged at 12,000 x g for 15–30 min at RT (20–25°C) to pellet the cellular debris and the 
supernatant was collected. 20μL of the cleared lysate was stored for SDS-PAGE analysis. 
The Ni-NTA spin column was then equilibrated with 600μL of Buffer A and centrifuged for 2 
min at 890 x g. The cleared lysate supernatant containing the 6xHis-tagged protein was 
then loaded onto the pre-equilibrated Ni-NTA spin column. Again centrifugation was 
carried out for 5 min at 270 x g, and the flow-though collected. A small sample of the flow-
though was saved for analysis by SDS-PAGE to check binding. The Ni-NTA spin column was 
then washed with 600μl Buffer B (8M urea; 0.1M NaH2PO4; 0.01M Tris·Cl; pH6.3) and 
centrifuged for 2 min at 890 x g. Once again the flow-though was saved for analysis by SDS-
PAGE to check the stringency of the wash conditions. The protein was then eluted twice 
with 200μL Buffer C (8 M urea; 0.1M NaH2PO4; 0.01M Tris·Cl; pH4.5) by centrifugation for 2 
min at 890 x g. 
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3.3.3 Active Immunization Animal Model 
 
3.3.3.1 Strains and Treatment Groups  
Female Biozzi ABH and SJL mice purchased from Harlan, UK were used for these studies. 
The mice were approximately 10 weeks old and were housed for 2 weeks before the start 
of the experiment. Animals were maintained and studies were carried out in accordance 
with the Animals (Scientific Procedures) Act 1986. A total number of 8 animals per 
treatment group were used for both studies: This number was selected as previous studies 
attempting to find autoantigens have been successful (Amor S et al., 1994). 
Group 1: CFA only; Group 2: Recombinant proteins (200µg of each of the four recombinant 
proteins: aldolase C, α- enolase, γ-enolase and pyruvate kinase); Group 3: GABHS soluble + 
insoluble proteins (400µg per fraction)  
3.3.3.2 Active Immunization   
The immunization strategy was based on the protocol used to induce myelin targeted 
autoimmunity (Al-Izki et al., 2012).  
20mL syringes were used to make up the solution (i.e. multiples of 20mL). Firstly a stock 
solution was prepared (stock A), consisting  of 4mL incomplete Freund Adjuvant (Difco, 
Becton Dickinson, UK), 16mg Mycobacterium tuberculosis H37Ra and 2mg M. butyicum 
(Difco, Becton Dickinson, UK), in a 5mL Bijou. Complete adjuvant: Freunds complete 
adjuvant was prepared by adding 11.5mL incomplete Freund’s adjuvant to 1mL stock A that 
was vortex-mixed before use.  
The plunger from a 20mL syringe was removed and the barrel was plugged with a stopper 
cap. For the recombinant protein cocktail 200µg of each of the four proteins was added to 
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5mL sterile PBS. Similarly for the GABHS protein cocktail 400µg of both insoluble and 
insoluble protein fractions were added to 5mL sterile PBS. This was mixed and then 5mL of 
Complete Freunds adjuvant was added to both mixes. The syringes were sealed with 
parafilm and vortexed. A retort stand, boss and clamp was used to hold the 20mL syringes 
in place with the water level reaching the level of the adjuvant (containing a drop of 
detergent) in a waterbath sonicator (Bransonic Ultrasonicator, Sigma, UK) and sonicated for 
10 min to thicken the mixture. The adjuvant was vortexed and placed on ice to cool. A 1mL 
syringe (Becton Dickinson, UK) was inserted into the 20mL syringe and the adjuvant was 
pumped using the 1mL syringe until it had thickened sufficiently that the solution did not 
disperse when a drop was added to water. The plunger was inserted into the 20mL syringe 
and the syringe was tapped on the bench such that the content moved towards the plunger 
and then the syringe cap was removed. A long (6cm) large bore needle was fixed to the 
syringe and inserted into 1mL syringes with plungers pulled out to the 1mL mark.  The 
syringe was filled to 1mL and the barrel of the 1mL syringe was wiped with tissue paper to 
remove any excess adjuvant. A 16mm 25g needle (Becton Dickinson, UK) was fixed to the 
1mL syringe. With the tip of the needle cover on the bench, the syringe was pushed very 
firmly onto the needle. 
Mice were held at the nape of the neck between thumb and forefinger. The tail was held 
with the right hand with thumb and forefinger (tips facing the head) and the mouse was 
placed on the top of a wire mouse cage.  The skin of the dorsal surface of the flank was 
lifted with thumb and forefinger (left hand) and the needle was inserted (facing towards 
the head) subcutaneously into the mouse. A volume of 0.10mL of adjuvant was injected 
into the right flank and another 0.10mL was injected into the left flank. This was day 0. The 
procedure was repeated at day 7 and day 25. Injections at the latter time points were made 
more posterior to the original injections. 
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3.3.3.3 Assessment 
The mice were weighed before the start of the experiment and then every day after day 12. 
All animals were subjected to a baseline assessment using the open field activity chamber 
and rotorod for 300 s each. These tests were then repeated 5 days after every 
immunization i.e., day 5, 12 and 30.  
Open field activity chamber: The open field can be used to measure hyperactivity, 
exploratory activity, stereotyped rotation and locomotor impairment. It is also commonly 
used as a measurement of anxiety-related behavior (Belzung and Griebel, 2001). The test 
was carried out in an open field Plexiglas chamber equipped with multiple photocell 
receptors and emitters. The activity of the animal was then measured via a grid of invisible 
infrared light beams. The body of the mouse, when placed within the monitor, caused 
some of these beams to be broken, thus revealing its position in the (X-Y) plane. The 
analyzer collected the beam status information from the activity monitor and the computer 
software calculated multiple variables such as total distance travelled, horizontal activity, 
vertical activity, and movement time over a period of 5 min. 
Rotarod: This test was used to assess the animal’s motor coordination and balance. The 
mouse was placed on a cylinder that can rotate at constant or accelerating speeds for a 
period of 300 s.  Control and experimental subjects were compared for their ability to 
remain on the rod either by latency to drop off or the final speed achieved by the 
accelerating rod before they fall. 
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3.3.5 Intra-Cerebral Animal Model 
3.3.5.1 Sera Samples 
Antibodies (IgG) were purified from sera of a patient diagnosed (1) EL (2) dystonia (3) 
healthy control. The EL patient was a female in her mid-twenties. The purified antibodies 
from both patients and controls were then injected intra-cerebrally in Biozzi ABH mice as 
described later.  
3.3.5.2 Immunoglobulin G (IgG) Purification 
Collection tubes were prepared by adding 60-200µL of neutralisation buffer (1M Tris-HCl 
pH9.0) per mL of fraction to be collected. The pump was then filled with 10mL of binding 
buffer. HiTrap Protein G column (GE Healthcare, UK) was then attached to the pump 
tubing. Introduction of air into the column should be avoided. The snap-off end at the 
column outlet was then removed and the column was washed with 10mL of binding buffer 
(0.02M sodium phosphate pH7.0) at 1mL/min. The filtered sera sample was then applied to 
the column using the pump at 1-3mL/min. This was followed by washing the column with 
5-10mL of binding buffer until no material appears in the effluent. The antibodies were 
eluted with 2-5mL of elution buffer (0.1M citric acid pH4.5-5.5) and collected into tubes 
containing the neutralisation buffer as described in step 1. After elution the column was re-
equilibrated with 5-10mL of binding buffer. Before storage the column was washed with 
20% ethanol to prevent microbial growth and stored at 4- 8°C. 
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3.3.5.3 Animals and Treatment Groups 
Inbred female Biozzi ABH mice were used for this study .The mice were approximately 9-10 
weeks old before the start of the experiment. Animals were maintained and studies were 
carried out in accordance with the Animals (Scientific Procedures) Act 1986. A total number 
of three animals per treatment group were used: 
   GROUP                                     TREATMENT 
          1 Purified EL IgG (0.5 mg/mL) 
          2 Purified EL IgG (0.05 mg/mL) 
          3 Purified dystonia IgG (1 mg/mL) 
          4 Purified dystonia IgG (0.1 mg/mL) 
          5 mAb against NSE (1 mg/mL) 
          6 mAb against NSE (0.1 mg/mL) 
          7 Purified healthy controls IgG (1 mg/mL) 
          8 Purified healthy controls IgG (0.1 mg/mL) 
Table 3.3: Intra-cerebral animal model treatment groups. The table above summaries the 
various antibodies used for intra-cerebral injection in mice.3 animals were used per 
treatment group. 
3.3.5.4 Intra-cerebral injection 
Inbred Biozzi ABH mice were anaesthetised using isoflurane which is an inhalant 
anaesthetic. Surgical levels of anaesthesia of this general anaesthetic were maintained in 
oxygen/nitrous oxide. Once under general anaesthesia the mice were injected with 30µL of 
purified IgG from patient sera using 0.5mL Myjector U-100 insulin syringe with 29g x 0.5 
needle (Terumo, USA). The injection site was aimed at the forebrain (sight for the basal 
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ganglia) halfway along the sagittal suture before it meets the bregma suture. Although the 
injection site was aimed at the right frontal cortex but because of the volume injected this 
can spread around the brain and reach the spinal cord (Baker et al., 1992). Three mice per 
experimental group were employed for this study to see that the effects were 
reproducible. A short video of each animal was made once injected with the purified IgG. 
The animals were killed by dislocation of the neck as described in the Code of Practice for 
the Humane Killing of Animals under Schedule 1 to the Animals (Scientific Procedures) Act 
1986. 
  
Figure 3.2: Injection site of autoantibodies in the mouse brain. The injection site was 
aimed at the forebrain to target the basal ganglia approximately halfway along the sagittal 
suture (SS) before it meets the bregma suture (B). The other two sutures shown above are 
cranial suture (CS) and lambda suture (L). 
3.3.6 Enzyme Linkes Immunosorbent Assay (ELISA)  
Indirect ELISA was performed to analyse the reactivity of the serum from the test and CFA 
only animals against the four recombinant proteins and GABHS protein fractions. 10μg of 
the individual proteins and protein cocktail prepared in carbonate coating buffer were 
coated onto 96 well flat bottom culture plates. The plate was incubated overnight at 4°C. 
The following day the plate was blocked with 1% BSA prepared in PBS for 1 h at 37°C. The 
Injection Site
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plate was then washed 4-5 times with PBS+0.1% tween following which the primary 
antibody (serum from animals immunized with recombinant proteins/GABHS proteins and 
CFA) was added. The plate was incubated for a further 1.5 h at 37°C. Once again the plate 
was washed 5 times with PBS + 0.1% tween before the addition of HP conjugated anti-
mouse secondary antibody prepared at 1:1000 dilution. After 1 h of incubation at 37°C the 
washes were repeated and 100μL of TMB substrate was added to each well. After the 
reaction turned blue it was stopped by addition of 50μL of hydrochloric acid (HCl). The 
plate was then read at 450 nm in an ELISA plate reader using the KC-4 programme.  
3.3.7 Haematoxylin and Eosin (H&E) Staining 
Tissue Fixation and Embedding: 
The tissue collected from the animals was fixed using 4% paraformaldehyde for 48-72 h. 
Once fixed the tissue was transferred into plastic cassettes for overnight processing in 
Tissue-Tek VIP (Sakura). The following day the tissue was embedded in paraffin wax before 
being sectioned (5μm) using a microtome onto polysine slides (VWR, UK). The slides were 
allowed to dry overnight and the sections were stained as described below: 
Rehydration 
Xylene (2X) 5 min  
100% EtOH 3 min 
100% EtOH 3 min 
90% EtOH  3 min 
70% EtOH 3 min 
dH2O  5 min 
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Staining 
 
Haemotoxylin  1-5 min 
Rinse dH2O 
Acid Alcohol 1-6 quick dips.  
(0.1% HCL in 50% EtOH) 
Tap Water  5 min 
Eosin   3 min 
Rinse in a few quick changes of dH2O 
 
Dehydration 
 
70% EtOH  1 min  
90% EtOH  2 min 
100% EtOH 2 min 
100% EtOH 2 min 
Xylene (2X) 3 min 
 
The slides were cover slipped using DEPEX mounting medium and viewed under the light 
microscope. 
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3.4 ACTIVE IMMUNIZATION MODEL RESULTS 
 
3.4.1 Weight  
All animals were weighed before the start of the study and then every day after day 10. No 
significant drop was observed in the weight of the mice during the duration of the 
experiment. A slight drop was observed after every immunization but that is a normal 
phenomenon owing to the stress caused by immunization.  
3.4.2 Rotorod 
All animals were assessed for motor coordination and balance using a rotorod. The test was 
carried out before the start of the experiment i.e., pre-immunization and then 5 days after 
every immunization. No significant difference was observed between the mice immunized 
with GABHS proteins or recombinant proteins as compared to CFA only controls.  
3.4.3 Open Field Activity Chamber 
3.4.3.1 ABH Animal Model 
Behavioural and locomotor assessment of ABH mice was done using an open field activity 
chamber at various time points: pre immunization and then 5 days after every 
immunization carried out at day 5, 12 and 30. The data was collected in the dark and each 
animal was allowed to acclimatize to the chamber before the test was started. The results 
show a decrease in total distance travelled by animals immunized with recombinant 
protein after the third immunization as compared to pre-immunization (p=0.05). However, 
no significant difference was observed when they were compared to CFA immunized 
control animals. In contrast, ABH mice immunized with GABHS fractions showed a 
significant decrease in average total distance travelled when compared to CFA controls (p= 
0.02) and baseline measurement (p=0.005). 
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Figure 3.3: Average distance travelled by ABH mice immunized with GABHS proteins, RP 
and CFA using an open field activity chamber. Graphs A, B and C above depicts the average 
distance travelled by ABH mice immunized with GABHS protein fractions, recombinant 
proteins (ald C, α and γ-enolase and PK) and CFA in 300s using an open field activity 
chamber. (A) A combined graph of distance travelled by ABH mice in the test and control 
group. A two tailed T-test confirmed a significant decrease in distance travelled by test mice 
after the third immunization as compared to pre-immunization (recombinant proteins 
p<0.05; GABHS proteins p<0.005). Also a significant difference was observed in the distance 
travelled between the GABHS and CFA only mice (p<0.02) which was not seen in 
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recombinant protein mice. (B) Graph comparing the average distance travelled by 
recombinant protein mice to CFA only control mice. No significant difference in the distance 
travelled was observed between the test and control group. However, a significant decrease 
was observed between the pre-immunization and after the third immunization in the test 
group (p<0.05). (C) Graph comparing the average distance travelled by GABHS protein mice 
to CFA only control mice. A significant decrease in average distance travelled was observed 
in mice immunized with GABHS proteins as compared to controls after the third 
immunization (p<0.02). Similarly a significant difference in motor activity was seen in test 
mice between pre-immunization and after the third immunization (p<0.005). 
3.4.3.2 SJL Animal Model 
Behavioural and locomotor assessment of ABH mice was done using an open field activity 
chamber at various time points: pre immunization, and 5 days after every immunization 
carried out at day 5, 12 and 30. The data was collected in the dark and each animal was 
allowed to acclimatize to the chamber before the test was started. The results show a 
decrease in total distance travelled by animals immunized with recombinant protein after 
the third immunization as compared to pre-immunization (p<0.05). However, no significant 
difference was observed when they were compared to CFA immunized control animals. In 
contrast, ABH mice immunized with GABHS fractions showed a significant decrease in 
average total distance travelled when compared to CFA controls (p<0.02) and baseline 
measurement (p<0.005). 
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Figure 3.4: Average distance travelled by ABH mice immunized with GABHS proteins, RP 
and CFA using an open field activity chamber. The graphs A, B and C above depict the 
average distance travelled by SJL mice immunized CFA, GABHS protein fractions and 
recombinant proteins (ald C, α and γ-enolase and PK) in 300s using an open field activity 
chamber. (A)  A combined graph of distance travelled by SJL mice in the test and control 
group. A two tailed T-test confirmed a significant decrease in distance travelled by test mice 
after the third immunization as compared to pre-immunization only in the GABHS mice 
(p<0.02). Also a significant difference was observed in the distance travelled between the 
GABHS compared to CFA only mice (p<0.001) which was not seen in recombinant protein 
0 
1000 
2000 
3000 
4000 
5000 
6000 
Pre-Imm. 1st Imm. 2nd Imm. 3rd Imm. 
D
is
ta
n
ce
 T
ra
ve
lle
d
 in
 3
0
0
 s
e
cs
 
SJL (RP & GABHS) Open Field Activity Chamber 
CFA 
RP 
GABHS 
No CFA 
* 
A 
B  
 
 C 
127 
 
mice. (B) Graph comparing the average distance travelled by recombinant protein mice to 
CFA only control mice. No significant difference in motor was observed between the test 
and controls group or between the various immunization time points in the test group. (C) 
Graph comparing the average distance travelled by GABHS immunized mice to CFA only 
controls. A significant decrease in average was observed in mice immunized with GABHS 
proteins as compared to CFA controls after the third immunization (p<0.02). A significant 
difference was also observed in motor activity in test mice between the pre-immunization 
and after the third immunization recording (p<0.001). 
3.4.4 Serum reactivity to antigens 
 
ELISA was performed to test the serum reactivity of animals immunized with various 
antigens compared to CFA only controls. Sera of animals immunized with the a cocktail of 
the four recombinant proteins ald C, α- eno, γ- eno and PK was tested for reactivity against 
the four individual proteins to see if any particular protein elicited a higher immune 
response. Results showed a significantly higher serum reactivity of the test group as 
compared to CFA controls to all four proteins and the cocktail (p=0.01-0.001). Furthermore, 
serum reactivity to γ-enolase (p<0.001) and PK (p=0.01) was observed to be higher than to 
ald C and α-enolase in both strains of mice. 
Similar ELISA was performed for GABHS protein fraction comparing reactivity of the test 
animals with the controls. Once again a highly significant difference was observed between 
the serum reactivity of the animals immunized with GABHS soluble fraction (p=0.0002) and 
insoluble fraction (p=0.001) to the CFA controls. However, no significant difference was 
observed between the reactivity to insoluble and soluble protein fractions.  
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3.4.4.1 Recombinant Proteins 
         
 
 
        
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
Figure 3.5: ABH and SJL sera reactivity to recombinant proteins (autoantigens). The line 
graph above shows the reactivity of sera from ABH and SJL animals immunized with 
recombinant proteins (ald C, α and γ-enolase and PK) compared to CFA only control animals 
to individual proteins and a cocktail of all four recombinant proteins. A two-tailed t-test 
revealed a highly significant difference in reactivity of the sera from immunized animals as 
compared to CFA controls in both mouse species (p values ranging from 0.01 to 0.0001). 
Additionally higher sera reactivity was seen against γ-enolase (p<0.001) and PK (p<0.01) 
compared to ald C and α-enolase in both ABH and SJLs. 
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3.4.4.2 GABHS Proteins 
 
 
 
        
         
         
     
 
   
         
         
         
     
 
   
         
         
         
         
         
         
         
         
   
       
 
Figure 3.6: ABH and SJL sera reactivity to GABHS protein fractions. The graph above shows 
the reactivity of sera from ABH and SJL animals immunized with GABHS protein fractions as 
compared to CFA only control animals to individual GABHS fractions (insoluble and soluble) 
and a cocktail. A two tailed t-test revealed a highly significant difference in reactivity of the 
sear from immunized animals as compared to CFA controls in both mouse species (p<0.001 
to 0.0001). However, no difference was observed between the reactivity to insoluble and 
soluble fraction.  
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3.4.5 Assessment of Inflammation (H&E) 
H&E staining was carried out on both the heart and brain tissue from ABH and SJL mice 
immunized with GABHS proteins, recombinant proteins and CFA controls to examine them 
for any signs of inflammation. The brain tissue from ABH animals immunized with GABHS 
protein fractions showed massive leukocyte infiltration in the midbrain region. The cells are 
suspected to be neutrophils because if you look at higher power you can observe multilobal 
nuclei. However additional staining is required to confirm this. Similarly what appears to 
lymphocyte infiltration was seen in brain tissue of ABH mouse immunized with the four 
recombinant proteins (aldC, α-enolase, γ-enolase and PK). No infiltration was observed in 
the tissues recovered from SJL animals or heart tissue from ABH.  
 
Figure 3.7: H&E stained brain sections from ABH mice immunized with GABHS proteins 
and recombinant proteins. 20X Images A &B above show H&E stained brain sections from 
ABH mice immunized with GABHS proteins and  recombinant proteins (ald C, α and γ- 
enolase and PK). Infilteration was observed in brain sections from both groups and the deep 
staining cells might possibly be lymphocytes. (A) Midbrain section from ABH mouse 
immunized with GABHS protein fractions. (B) Midbrain section from ABH mice immunized 
with recombinant proteins.  
A B 
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3.5 Intra-Cerebral Animal Model Results  
 
The injection of the antibodies was done blinded to the nature of the antibody used.  Any 
animals with signs of brain damage as a result of the injection were excluded from the 
study. 
3.5.1 EL IgG 
Female Biozzi ABH mice were injected intra-cerebrally with a volume of 30 µL of purified 
IgG from EL patient sera at concentration of 0.5 and 0.05 mg/mL. Three mice were used per 
experimental group. Induction of antibodies at a concentration of 0.5 mg/mL produced 
pronounced signs like tremors and tail rigidity both of which are reminiscent of EL 
symptoms. These signs occurred with a rapid onset following administration, but were 
transient as many of these resolved within 1 h of treatment. However, to a lesser degree 
most of these stereotypical movements were still observed after induction of antibodies at 
a tenfold dilution (0.05 mg/kg). Injection of PBS and non CNS specific IgG falied to induce 
any signs in the animals. 
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Figure 3.8: Picture frames of ABH mouse injected with EL IgG (0.5 mg/mL). Images A to F 
show individual picture frames from a video of an ABH mouse injected intra-cerebrally with 
30 µL of purified EL IgG (0.5 mg/mL). (A) 2 s. (B) 10 s. (C) 30 s. (D) 40 s. (E) 1 min. (F) 1 min 
15 s. 
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Figure 3.9: Picture frames of ABH mouse injected with EL IgG (0.05 mg/mL). Images A and 
B show individual picture frames from a video of an ABH mouse injected intra-cerebrally 
with 30 µL of purified EL IgG (0.05 mg/mL). (A) 2 s. (B) 30 s. 
3.5.2 Dystonia 
Female Biozzi ABH mice were injected intra-cerebrally with a volume of 30 µL of purified 
IgG from a patient diagnosed with dystonia at concentration of 0.1 and 1mg/mL. Three 
mice were used per experimental group. Hind limb rigidity and an abnormal, twisted 
posture due to sustained muscle contraction were observed in mice injected with 1 mg/mL 
of IgG. At 0.1 mg/mL the animal remained motionless during the course of the experiment.  
The symptoms developed in the mice injected with autoantibodies from a dystonia patient 
varied from those seen in the EL model. Hind limb rigidity was much more pronounced in 
these animals as opposed to tail rigidity seen in the EL group. 
 B A 
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Figure 3.10: Picture frames of ABH mouse injected with dystonia IgG (1 mg/mL). Images 
A-D show individual frames from a video of an ABH mouse injected intra-cerebrally with 30 
µL of purified IgG from a patient diagnosed with dystonia (1 mg/mL. (A) 2 s. (B) 10 s. (C) 30 
s. (D) 1 min.  
   
Figure 3.11: Picture frames of ABH mouse injected with dystonia IgG (0.1 mg/mL). Images 
A and B show individual picture frames from a video of an ABH mouse injected intra-
cerebrally with 30µL of purified IgG from a patient diagnosed with dystonia (0.1 mg/mL). 
(A) 2 s. (B) 30 s. 
A B 
A B 
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3.5.3 Mouse mAb against NSE 
Female Biozzi ABH mice were injected intra-cerebrally with a volume of 30µL of mAb 
against enolase at concentration of 0.1 and 1mg/mL. This was carried out to confirm that 
enolase is indeed a target autoantigen in this group of disorders. At a concentration of 
0.1mg/kg the animals developed severe signs of rigidity and tremor and showed no signs of 
recovery. Although less severe both these classical symptoms of neuropsychiatric 
movement disorders were still observed in animals injected with the antibody diluted to 
0.01mg/mL.  
  
Figure 3.12: Picture frames of ABH mouse injected with mAb against NSE (0.5 mg/mL). 
Images A to C show individual picture frames from a video of an ABH mouse injected intra-
cerebrally with 30µL of mAb against NSE (0.5 mg/mL). (A) 2 s. (B) 20 s. (C) 1 min 15 s. 
3.5.4 Healthy Controls 
Female Biozzi ABH mice were injected intra-cerebrally with a volume of 30 µL of purified 
IgG from a healthy control at concentration of 0.1 and 1mg/mL. Three mice were used per 
experimental group. The mice showed no signs of rigidity, tremor or any other signs of 
distress as observed with the mice injected with patient IgG. Once the animal had 
recovered from the anaesthesia it showed normal behavioural and locomotor activity 
 
A B C 
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Figure 3.13: Picture frames of ABH mouse injected with healthy control IgG (1 mg/mL). 
Images A and B show individual picture frames from a video of an ABH mouse injected 
intra-cerebrally with 30µL of IgG purified from healthy control sera.. (A) 20 s. (B) 1 min. 
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3.6 DISCUSSION  
Animal models are a potential tool for developing or testing novel pharmacological 
therapies. They facilitate the study of genetic and environmental factors that contribute to 
the expression of behavioural and locomotor deficits which are the two most important 
parameters that help to define the phenotypes of mice.  
In the active immunization model the open field test conducted helped systematically 
assess a range of parameters like novel environment exploration, general locomotor 
activity, and an initial screen for anxiety-related behaviour in rodents (Prut et al., 2003). 
However, behaviour during the test can be influenced by genetic variation, sex, age and 
exposure to illumination in the chambers. Excess noise and human activity during testing 
period, excess odours in the room, and distracting visual signals were controlled to 
minimize variation in data collection. Animals with decreased muscle function will be less 
active (decreased horizontal and vertical activity, decreased movement time, and increased 
rest time), and the total distance travelled will be decreased, giving a sense of the level of 
ambulatory activity (Zhuang et al., 1999). Both SJL and ABH strains of mice showed a 
significant decrease in total distance travelled when injected with GABHS proteins as 
compared to CFA only controls. This could point towards neurobehavioral and locomotor 
abnormalities. It can also be indicative of anxiety-related behavior. Rearing and centre–
perimeter residence time are used as measures of anxiety and it is assumed that the mice 
feel safer in the perimeter regions of the open field chambers, close to the walls (Treit and 
Fundytus, 1988; Carli et al., 1989; Meng and Drugan, 1993; Steiner et al., 1997; Angrini et 
al., 1998; Heisler et al., 1998; Nasello et al., 1998). More ventures or exploratory excursions 
into the centre of the chamber are therefore interpreted as a decrease in anxiety (Schamm 
et al., 2001). It has been suggested that two factors influence anxiety-like behaviour in the 
open field. The first is social isolation resulting from the physical separation from cage 
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mates when performing the test. The second is the stress created by the brightly lit, 
unprotected, novel test environment (File, 1980; Prut et al., 2003). The measure of anxiety 
has been validated predictively by the demonstration that known anxiolytic agents 
(specifically diazepam, chlordiazepoxide, and pentobarbital) dose dependently decrease 
the amount of time spent in the perimeter of the open field (Treit and Fundytus, 1988), and 
genetically modified mice lacking particular 5-HT receptor subtypes (Heisler et al., 1998; 
Ramboz et al., 1998; Zhuang et al., 1999) or D3 dopamine receptor (Steiner et al., 1997) 
show the expected change in centre perimeter residence time based on their 
demonstrated roles in mediating or decreasing anxiety. Definitve conclusions can only be 
made by conducting additional behavioral tests. 
In the present study the mice were subjected to rotarod assessment and the length of time 
that the animal stays on the rotating rod is a measure of their balance, coordination, 
physical condition, and motor-planning. I failed to find any difference in motor 
coordination between mice immunized with GABHS or recombinant proteins and CFA 
controls. This contradicts the findings by Yaddanapudi et al. (2009) and Brimberg et al. 
(2012) where they depicted that GABHS immunized mice/rats remained on the rotorod for 
a shorter interval of time compared to PBS controls (Yaddanapudi et al., 2009; Brimberg et 
al., 2012).  
Out of the four speculated autoantigen enolase has been found to be the most prominent 
putative autoantigen in the literature (Dale et al., 2002). In our study higher sera reactivity 
was observed against γ-enolase as compared to α-enolase and ald C. This coincides with 
patient studies where most OCD sera tested positive for ABGA had antibodies specifically 
against enolase (Nicholson et al., 2012). Previous studies have reported the presence of 
enolase-specific autoantibodies in a range of psychiatric, degenerative and inflammatory 
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disorders, including discoid lupus erythematosus, autoimmune polyglandular syndrome 
type 1 primary and secondary  membranous nephopathy, cancer-associated retinopathy, 
autoimmune hepatitis type 1, mixed cryoglobulinemia with renal involvement, cystoid 
macular oedema, endometriosis (Gitlits et al., 2001; Witkowska et al., 2005). Based on the 
results from the animal model and previous findings, the development of an enolase 
enzymatic assay was attempted in order to test patient sera for antibodies against enolase.  
H&E staining showed infiltration in the brain tissue recovered from ABH mice. IgG deposits 
in several brain regions, including deep cerebellar nuclei (DCN), globus pallidus, and 
thalamus have been observed when sera from GABHS-immunized mice were tested for 
immunoreactivity to mouse brain (Hoffman et al., 2004). Similar findings have been 
reported by Brimberg et al. (2012) where once again streptococcal exposure in rats 
resulted in antibody deposition in the striatum, thalamus, and frontal cortex consistent 
with the known pathophysiology of SC and related neuropsychiatric disorders (Brimberg et 
al., 2012). Delineation of the characteristics of these autoantibodies like analysing the Ig 
class/subclass, specificity and affinity for specific epitopes in the CNS is critical in defining 
the pathogenesis immune-mediated neuropsychiatric syndromes. 
The science of neuropsychiatric movement disorders specially TS is advancing at multiple 
levels of analysis and is being enhanced though the use of animal models. Particularly hard 
challenges in the development of animal models of these disorders reflect its complex 
features. The lack of detailed behavioural testing in our study prevented us from picking-up 
behavioural and locomotor abnormalities reminiscent of these disorders. It is planned to 
develop this animal model further by injecting mice with purified M proteins (including 
specific serotypes) or/and superantigens which would help us establish a link between 
streptococcus and these disorders together with pin pointing the proteins causing the 
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virulence. Also the immunological effects of superantigens are generally species specific, 
therefore GABHS superantigens may need to be replaced with superantigens known to 
affect mice.  Mice challenged with superantigens primed with bacterial lipoproteins have 
showed higher levels of serum TNF- α and IL-6 compared to those exposed to either agent 
alone (Kearney et al., 2011). Also a number of behavioural tests need to be set up to better 
evaluate these animals. In addition subtle changes in stereotypies need to be picked up for 
which I plan to use blinded video tape analysis of these animal. These animal models may 
translate directly to human disease and may prove helpful in discovering autoantibody 
targets in TS and other postulated streptococcal-related neuropsychiatric disorders.  
Animal models might not be able to predict the immunogenicity of antigenic/therapeutic 
proteins in humans reliably. The mechanisms underlying immunogenicity differ between 
conventional animal models and humans, hence the value of these models is limited and 
studies have shown that conventional animal models over-estimate immunogenicity in 
patients (Koren et al., 2002). In non-human primate a variety of responses ranging  from 
weak, no antibody response, to a strong neutralizing response, or even a cross-reactive 
antibody response have been observed (Bussiere, 2003). These might not always correlate 
well with the immune response that is seen in humans. However, for proteins that are 
conserved across species, non-human primates might have some predictive value like 
enolase, an enzyme that presents a high evolutionary conservation among species 
(Carneiro et al., 2004; Pal-Bhowmick et al., 2007).  
Additionally the duration and schedule of dosing, route of administration, dosage of the 
protein, pharmacological properties of the protein, as well as the purity of the clinical 
material can influence its immunogenicity (Brinks et al., 2011). The use of transgenic mice 
or homologous proteins can be used to predict neo-epitopes, relative immunogenicity, and 
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breaking of tolerance. However, they are less suitable to predict the incidence of 
immunogenicity or clinical effect of antibody formation. HLA transgenics might serve as an 
interesting tool to study whether the immunogenic response is HLA restricted (Van Beers et 
al., 2010; Brinks et al., 2011). 
An important question is whether or not anti-neuronal antibodies are directly involved in 
the pathogenesis of the neuropsychiatric disorders or simply diagnostic markers. Two 
studies investigating the effects of infusing serum immunoglobulin from patients with 
PANDAS into rat striatum found an increase in stereotypical movements compared to 
control antibodies (Hallett et al., 2000; Taylor et al., 2002). However, another group using 
the same methods failed to reproduce the results (Loiselle et al., 2004) and more recently a 
collaborative study was also reported as being negative (Singer et al. 2005) although this 
study has been criticised for being methodologically flawed (Giovannoni, 2005).  
The present study is the first of its kind to create an intra-cerebral animal model of 
neuropsychiatric disorders like EL. The development of signs in mice after direct injection of 
antibodies representative of the disease in question confirms the pathogenicity of these 
antibodies. According to Witebsky's postulates (formulated by Ernst Witebsky and 
colleagues in 1957) (Rose and Bona, 1993) a disease to be regarded as an autoimmune 
disease has to fulfil the following three essential criteria (i) Direct evidence from transfer of 
pathogenic antibody or pathogenic T cells (ii) Indirect evidence based on reproduction of 
the autoimmune disease in experimental animals (iii) Circumstantial evidence from clinical 
clues. The animal model fulfils the first two criteria listed above. The clinical evidence of 
autoimmunity is subject to interpretation and may be fulfilled by evidence from a 
controlled trial of treatment with either plasma exchange or IVIg in children with PANDAS 
that demonstrated a significant improvement in motor and psychiatric symptoms for both 
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therapies compared to placebo (Perlmutter et al., 1999). These observations and insights 
from the proposed treatment effects of IVIG suggest that the autoantibodies are 
pathogenic in these disorders. In summary EL and other ABGA-associated disorders are an 
emerging entity, with major implications for neuropsychiatry. Establishing this group of 
disorders as “true” autoimmune diseases marks the first step towards understanding their 
pathogenesis which would in turn have therapeutic implications.  
The spectrum of post-streptococcal CNS disorders includes tics, chorea and dystonia 
(Church et al., 2004; Edwards et al., 2004). However the symptoms associated with each of 
these disorders is variable. EL symptoms include high fever, headache, double vision, 
delayed physical and mental response, tremors and lethargy. In acute cases, patients may 
enter a coma like state termed akinetic mutism (Dale et al., 2004; Lopez-Alberola, 
2009). On the other hand symptoms of dystonia include muscle spasms, abnormal muscle 
tone leading to progressive rigidity (Madhusudanan, 1999). Although part of the same 
disease spectrum, the different effect of these antibodies may be due to variable cellular 
and/or sub-cellular targets in this group of disorders.    
In the present study I wanted to determine the specificity of ABGA and hence compare the 
effects of antibodies from both EL and dystonia patients. A varied phenotype was observed 
in the all three cohorts with some common features, in particular rigidity. A less severe 
disease phenotype was reproducible in animals injected with a very low antibody 
concentration that enabled us to observe subtle phenotypical changes as opposed to a 
more pronounced effect observed with higher antibody concentration. In order to confirm 
whether enolase was one of the target autoantigen in this group of disorders antibody mAb 
against NSE was injected in mice. Injection of mAb against NSE did result in a phenotype 
very similar to that seen in mice injected with patient antibodies exhibiting classical signs of 
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tremor and rigidity. This effect again was reproducible even at low antibody 
concentrations. The preliminary results of this experiment point towards NSE being at least 
one of the antibody targets in this spectrum of neuropsychiatric movement disorders, with 
functional effect when injected intracerebrally bypassing the blood-brain-barrier.  
Given its novelty the present animal model forms the basis for a much larger set of 
experiments. Future work will involve injecting animals specifically in the basal ganglia 
which can be achieved by the use of a stereotactic frame. Additionally, antibodies from 
patients with TS could be used to see whether stereotypies and episodic utterances can be 
detected that have been proposed as a model of motor and vocal tics.  Also it would be 
interesting to determine if the use of affinity purified antibodies against the known 
autoantigens especially enolase from sera of patients will induce effects comparable with 
the commercial monoclonal antibody. Furthermore, electrophysiological experiments 
would be carried out to rule out the occurrence of epileptic seizures and confirm that the 
stereotypical movements seen in the mice are indeed representative of the disorders in 
question. 
All the above findings point towards a possible autoimmune origin of neuropsychiatric 
movement disorders that will have implications for both our understanding of the 
pathophysiology of these disorders and future therapeutic strategies. Future experiments 
should refine this existing animal model to create an animal model that replicates the 
behavioural, pharmacological, and immunological abnormalities seen in this group of 
neuropsychiatric disorders.  
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CHAPTER 4 
FUNCTIONAL ASSAYS 
 
4.1 INTRODUCTION 
 
4.1.1 Effect of Autoantibodies on Neuronal Function 
An important question is whether or not anti-neuronal antibodies detected in postulated 
post-streptococcal neuropsychiatric disorders are directly involved in the pathogenesis of 
these disorders or are simply a diagnostic marker. As described earlier these 
autoantibodies have been shown to recognize four main protein bands of 40, 45, 60 and 
98kDa which have been identified aldolase C (neurone specific), α and γ-enolase and 
pyruvate kinase (Dale et al., 2006). All three of the major candidate autoantigens proposed 
in this group of postulated post-streptococcal disorders have protein homologues in 
streptococci. Various hypotheses on the mode of action of these antibodies have been 
made based on the discovery of receptor or channel coupling of the antigens. Tests on 
cerebellar granular cells (CGC), have shown that incubation with commercial antibodies 
against the identified antigens enolase, pyruvate kinase and aldolase C increase the rate of 
apoptosis (Dale et al., 2006).  
Interestingly, streptococcal enolase is also found on the surface of the bacterium and 
appears to function as an efficient plasmin(ogen) binding protein which influences tissue 
invasiveness and pathogenicity (Pancholi and Fischetti, 1998). The streptococcal surface 
enolase antibodies appear to recognise a shared epitope with neuronal surface and 
cytoplasmic enolase. It was hypothesized that these antibodies may have a direct effect on 
neuronal function. Membrane neuronal aldolase provides local membrane energy and is 
enzymatically active (Bulliard et al., 1997). It also forms an oxidoreductase complex with 
enolase and other proteins on the neuronal membrane and is thought to monitor oxidative 
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stress and induce an appropriate cellular response (Bulliard et al., 1997). Aldolase binds 
tightly with ATPase protein pumps on the plasma membrane allowing direct coupling of 
glycolysis to the proton pump (Lu et al., 2001). The monomer of pyruvate kinase acts as 
thyroid hormone (T3) binding protein. Binding of T3 to pyruvate kinase inhibits enzymatic 
activity, suggesting that this process may be centrally involved in the control of some 
cellular metabolic effects induced by thyroid hormones (Kato et al., 1989). Interestingly, 
hyperthyroidism is a well-described cause of chorea. Membrane glycolysis provides a 
preferential source of ATP in order to maintain myocyte K+ channels (Weiss & Lamp, 1987), 
ATPase and calcium uptake (Hardin et al., 1992) and Na+/K+ pumps on intestinal cells 
(Dubinsky et al., 1998). The maintenance of these pumps may be directly linked to 
functionally compartmentalised ATP to ADP ratios on the cell membrane (Dubinsky et al., 
1998).  
Since all the above antigens are glycolytic enzymes involved in the preferential source of 
ATP, apoptosis was suggested to occur as a result of energy failure at the cell surface (Dale 
et al., 2006). Stress leads to an initiation of  intracellular apoptotic signalling process in 
cells. The binding of nuclear receptors by heat, radiation, glucocorticoids, nutrient 
deprivation, infection, hypoxia and increased intracellular calcium concentration for 
example, can trigger the release of intracellular apoptotic signals by a damaged cell (Mark 
et al., 2003). Ca2+ influx into cells activates enzymes, including phospholipases, proteases 
and endonucleases leading to damage of structures such as DNA and the cytoskeleton 
(McConkey and Nutt, 2001; Gronski et al., 2009). Cytoplasmic levels of Ca2+ can increase 
either from release from internal calcium stores such as the endoplasmic reticulum (ER) or 
entry from outside the cell via calcium channels, leading to the rapid activation of 
molecules that promote activation, proliferation and other functions in a cell (McConkey 
and Nutt, 2001). Mitochondria also are damaged by excessive surges of calcium (Gronski et 
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al., 2009). Mitochondria utilise the extra calcium and eventually swell and cease 
functioning (Gronski et al., 2009). Sodium channels are also disrupted at the time, 
aggravating and increasing the eventual cell death. Phagocytes are also known to utilize 
calcium flux. Activation of macrophages using LPS is shown to cause an increase in cytosolic 
calcium and the eventual production of TNF-α (Watanabe et al., 1996; Cuttell et al., 2008). 
In summary membrane glycolytic enzymes are closely involved in the energy provision and 
maintenance of ion channels on the neuronal membrane, trophic support and other 
functions. Therefore disrupting their activity is likely to lead neuronal dysfunction. 
4.2 HYPOTHESIS AND AIMS 
Serologic studies of children with post-streptococcal neuropsychiatric disorders have 
detected anti-neuronal antibodies but their role in the disease has not yet been explored. I 
hypothesized that these autoantibodies will have functional effects in vitro. 
 The main aim of this study was to investigate the functional effects (cytotoxicity, 
apoptosis, intracellular calcium flux) of anti-neuronal antibodies from patients diagnosed 
with postulated post-streptococcal disorders like TS, EL, SC and dystonia on both non-
neuronal and neuronal cells.  
4.3 MATERIALS AND METHODS 
4.3.1 Clinical Samples 
Serum samples from a mixed cohort of patients diagnosed with TS, EL, SC and dystonia 
were used in cytotoxicity, apoptosis and calcium flux assays as described below. Patient 
material was obtained with informed consent and appropriate ethical review.  
The samples used in this study were collected from Tertiary referral centres, Great Ormond 
Street Hospital (GOSH) and National Hospital of Neurology and Neurosurgery (NHNN), 
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therefore clinically they were in the severe end of spectrum. Consent for autoantibody and 
strep studies was obtained from the patients by Dr. R Dale (GOSH, now Sydney Children's 
Hospital, Australia) Prof. G Giovannoni (ION, now Royal London Hospital), Prof. N Quinn 
(NHNN) and  Prof. M Robertson (NHNN). These samples  were all known ABGA positive by 
Western Blot according to Church et al.,  2002. They were all ASOT and/or DNaseB positive 
by Behring Nephelometer (Siemens). Throat culture was not routinely performed as they 
were referral patients.  
The samples used were anonymized and stored at  -20oC. They were  typical positives in 
each clinical group that had sufficient volume of left to perform further experiment. There 
was nothing atypical about them regarding age, sex and streptococcal status. 
Chorea: Patients were referred between 1999 and 2002 by their general practitioner or 
paediatrician for investigation and management of an acute onset or relapsing movement 
disorder. All patients had disease onset shortly after streptococcal pharyngeal infections. 
Movement disorders were initially diagnosed by Dr. Russell Dale. Movement disorders 
were video-recorded and reviewed by expert child neurologists (Dr. Robert Surtees and 
Dr. Brian Neville, GOSH) to validate the movement disorder classification. Patients were 
diagnosed clinically using clinical scores i.e using Jone's criteria for rheumatic fever ( Jones 
et al., 1935; Jones, 1944) and chorea (evidence of streptococcal infection). 
Tourette’s: All TS patients were diagnosed by Prof. M. Robertson using standardised 
instruments, including the National Hospital Interview Schedule (Robertson et al., 1996), 
the Diagnostic Interview Schedule (Robertson et al., 1999) and the Yale Global Tic Severity 
Rating Scale (Leckman et al., 1989). In order to make a diagnosis of TS, patients had to 
satisfy DSM-IV-TR (APE, 2000) and ICD-10 (WHO, 1992) criteria. Thus all patients had to 
have multiple motor and one or more vocal tics, with symptoms lasting longer than 1 year. 
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Consent was obtained for each patient by Prof. Robertson and 1, 10mL, clotted blood 
sample was taken, centrifuged on the same day at 2000rpm for 10 minutes and stored in 2 
aliquots at -20°C. 
Encephalitis Lethargica:  All patients were referred to tertiary neurology centers between 
April 1999 and May 2002 with a new‐onset CNS dysfunction resulting in an EL‐like 
syndrome (sleep disorder and associated lethargy, parkinsonism and neuropsychiatric 
disorders). Movement disorders were video-recorded and reviewed by expert child 
neurologists (Dr. Robert Surtees and Dr. Brian Neville, GOSH). Psychiatric disturbances 
were often acute analyzed through DSM-IV criteria . 
Dystonia:  Dystonia patients all came from the Movement disorder clinic at the National 
Hospital for Neurology and Neurosurgery, diagnosed by Prof. N Quinn and Prof. K Bhatia 
(ION). The cases were identified during an ongoing study evaluating the prevalence of 
ABGA (Church et al., 2002). Generalized dystonia was observed in all patients.  
Healthy Controls: Serum from healthy controls were provided by Dr. Ruth Dobson at the 
Royal London Hospital, Queen Mary University of London. 
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           Cohorts                    Centre Age          
Range 
(Mean) 
Sex  
Ratio              
(F:M) 
    Publication 
Chorea Great Ormond Street 
Hospital for 
Children(GOSH), London. 
 
Institute of Neurology 
(ION), UCL. 
 
1.3 – 13 
yrs 
(7.15) 
      2:1 Dale et al., 2004 
Tourette’s 
Syndrome  
University of Bari, Italy. 
 
National Hospital for 
Neurology and 
Neurosurgery (NHNN), 
London. 
6- 14 yrs 
(10.4) 
     1:5 Dale et al., 2004 
Encephalitis 
Lethargica 
Great Ormond Street 
Hospital for 
Children(GOSH), London. 
 
Institute of Neurology 
(ION), UCL. 
 
The Royal London Hospital 
 
2- 69 yrs 
(17.85) 
    1.2:1 Dale et al., 2004 
Dystonia Institute of Neurology 
(ION), UCL. 
 
17- 57 yrs 
(39.75) 
      4:1 Edwards et al., 
2004 
 
Healthy Controls The Royal London Hospital 
 
22- 50      4:1         N/A 
Table 4.1: Clinical serum samples used for the functional assays in this study. The table 
above summarises the clinical cohorts used in the present study in terms of collection 
centre, age range and female: male (F:M) sex ratio. Clinical details of all samples have been 
previously published. 
In addition sera from ABH and SJL mice immunized with GABHS proteins and recombinant 
proteins (Ald C, enolase and pyruvate kinase) were also used for all the assays to compare 
their functional effects on cell function as opposed to CFA only immunized control animals. 
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All assay were carried out using purified IgG from sear from patients , controls And animal 
models as described on page 118. 
4.3.2 PC12 cells 
Background: 
PC12 is a cell line derived from a pheochomocytomais (neuroendocrine tumor) of the rat 
adrenal medulla (Greene and Tischler, 1976). When exposed to neurotrophins like the 
nerve growth factor (NGF) neoplastic PC12 cells undergo a series of biochemical and 
morphological changes thereby differentiating into neural cells (Walters et al., 2002). 
PC12 cells grown with or without NGF contain dense core chomaffin-like granules up to 350 
nm in diameter. The NGF-treated cells also contain small vesicles which accumulate in 
process varicosities and endings. PC12 cells synthesize and store the catecholamine 
neurotransmitters dopamine and norepinephine (Cunningham et al., 2001). 
PC12 cells were cultured in T75 culture flasks coated with Rat Tail Collagen I (Invitrogen Life 
Technologies, UK). The cells were maintained in RPMI 1640 medium (Sigma-Aldrich, Poole, 
Dorset, UK) supplemented with 50mL Horse serum (Lonza 14-403F), 25mL foetal calf serum 
(Sigma-Aldrich, Poole, Dorset, UK), 5mL penicillin/streptomycin (Sigma-Aldrich, Poole, 
Dorset, UK) and 5mL non-essential amino acid solution (Sigma-Aldrich, Poole, Dorset, UK) in 
a humidified incubator at 37°C and 4.5% CO2. The cells were passaged every 2-3 days in a 
ratio of 1:5. To induce differentiation into neurons the cells were treated with 50 ng/mL of 
nerve growth factor (Invitrogen Life Technologies, UK) every 2 days for upto a week.  
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Figure 4.1: 40X light microscope images of PC12 cells before and after differentiation. (A) 
Undifferentiated PC12 cells. (B) PC12 cells after differentiation into neurons. These cells now 
show neurite growth (marked with an arrow) after 7 days of treatment with nerve growth 
factor (NGF). 
4.3.3 Cytotoxicity Assay 
WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) 
colorimetric cytotoxicity assay (Roche Applied Science, Basel, Switzerland) was performed 
on differentiated and undifferentiated PC12 cells probed with serum samples from TS 
(n=10), EL, SC, dystonia (n=18), healthy controls (n=19) and the animal model (CFA only 
(n=8), recombinant proteins (n=8), GABHS proteins (n=8). The stable tetrazolium salt WST-1 
is cleaved to a soluble formazan by a complex cellular mechanism that occurs primarily at 
the cell surface. This bioreduction is largely dependent on the glycolytic production of 
NAD(P)H present in viable cells. Therefore, the amount of formazan dye formed directly 
correlates to the number of metabolically active cells in the culture. 
A B 
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Figure 4.2: The biochemical reaction occurring in the WST-1 assay. Conversion of 
tetrazolium salt WST-1 into soluble compound formazan occurs though NAD(P)H which is 
only present in viable cells. Hence the amount of formazan formed directly correlates to the 
number of metabolically active cells in the culture. 
1 x 104 cells (100μL/well) were grown in a 96-well tissue culture plate coated with rat tail 
collagen type I and incubated at 37°C for 24-48 h until desired confluency was achieved. 
Serum samples (1:100) were added to the cells and the plates were incubated for a period 
of 24 hours. 10μL of WST-1 reagent was then added to each sample and incubated at 37 °C 
under 7% CO2 in a humidified incubator for variable time periods (0.5 h to 4 h). The WST-1 
reagent incubation time of 1 h was found to be optimum since the color density did not 
change after this period. The formazan dye formed was quantitated with a scanning multi-
well spectrophotometer (ELISA plate reader). The absorbance was measured at 450 nm 
with a reference wavelength of 620 nm. The delta optical density directly correlates to the 
number of viable cells. All experiments were done in duplicates. 
 
 
 
 
WST-1 Formazan
NADHNAD+
EC-H                EC
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4.3.4 Annexin V Apoptosis Assay  
All FACS experiments were performed with Dr. Gary Warnes at the Flow Cytometry Core 
Facility, BICMS, Queen Mary, University of London.  
Apoptosis in response to exposure with serum samples was performed using FITC Annexin 
V apoptosis detection kit 1 (BD Biosciences, Oxford, UK). Apoptosis is characterized by 
certain morphologic features, including loss of plasma membrane integrity, condensation 
of the cytoplasm and nucleus, and DNA fragmentation. In apoptotic cells, the membrane 
phospholipid phosphatidylserine (PS) is translocated from the inner to the outer leaflet of 
the plasma membrane, thereby exposing PS to the external cellular environment. Annexin 
V  which is a 35-36 kDa Ca2+-dependent phospholipid-binding protein binds to cells with 
exposed PS. Annexin V conjugated to fluorochromes like fluorescein isothiocyanate (FITC) 
thus serves as a sensitive probe for flow cytometric analysis of apoptotic cells. Since 
externalization of PS occurs in the earlier stages of apoptosis, FITC Annexin V staining 
identifies apoptosis at an earlier stage than assays based on nuclear changes such as DNA 
fragmentation. Mitochondria plays a pivotal role in apoptosis therefore, MitoTracker dye 
was used in conjunction with annexin V to track mitochondrial function in the cells. 
MitoTracker probes are cell-permeant mitochondrion-selective dyes that contain a mildly 
thiol-reactive chloromethyl moiety.  
3x105 PC12 cells (undifferentiated and differentiated) were cultured onto collagen type I 
coated 24 well cell culture plates (1mL/well) and incubated for 48 hours at 37°C and 5% 
CO2 in a humidified chamber. Serum samples from TS patients (n=10), other 
neuropsychiatric disorders like SC, EL and dystonia (n=10), healthy controls (n=10) and ABH 
and SJL animal model (CFA only (n=8), recombinant proteins (n=8), GABHS proteins (n=8)) 
diluted 1:100 were then added to each well and the cells were incubated for a further 24 
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hours. A pan-kinase c inhibitor, staurosporine (STS) (1µg/mL) was used as a positive 
control. Following the incubation the cells were scraped and transferred into FACS tubes. 
The cell pellets were then washed with 3mL of PBS without Ca2+ and centrifuged at 250 x g 
for 5 min. The supernatant was then discarded and the cell pellets were re-suspended in 
100μl of PBS without Ca2+. A volume of 0.5μL of 1mM mitotracker dye (Invitrogen, UK) final 
concentration 40nM was added and the cells were incubated for 15 min at 37°C in a 
humidified chamber. The cells were again washed with 3mL of PBS without Ca2+ before 
being resuspended in 400μl of 1X Ca2+ rich buffer. 2μL of Annexin V- FITC (buffered in 50 
mM Tris (pH 8.0) with 80 mM NaCl, 0.2% BSA, 1 mM EDTA, and 0.09% sodium azid) and 
200ng/mL of propidium iodide staining solution (DAPI) was then added to all samples and 
incubated for 15 min at RT in dark. 10-20,000 events were then analyzed using BD LSRII 
flow cytometer (BD Biosciences, UK).  
4.3.5 Calcium Flux Assay 
Intracellular calcium flux in PC12 differentiated into neuronal cells when exposed to patient 
antibodies was determined using FACS. Intracellular calcium flux into the cell is 
representative of cell activation. The assay employed the use of Indo-1 which is a 
ratiometric calcium dye with a dual emission pattern: when bound to free intracellular 
calcium it emits at 390 nm (violet signal) and when unbound it emits at 530 nm (green 
signal) and the ratio of violet over the green signals is calculated as the ratio which is 
displayed as a parameter over time. Upon cell activation the dye should change from green 
to violet and hence the Indo-1 ratio should increase over time. 
1x105 PC12 cells/well were differentiated onto collagen type I coated 24 well cell culture 
plate. After differentiation the cells were scraped and transferred to BD Falcon™ round-
bottom tubes (BD Biosciences, UK) followed by washes with PBS (-Ca2+) and centrifugation 
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at 270 x g for 5 min. The cell pellet was re-suspended in 1mL PBS (-Ca2+) to which 2μl of 
Indo-1 dye was added to achieve a final concentration of 2µM. The samples were then 
incubated for 45 min at 37°C in a humidified chamber.  The samples were again washed 
with PBS (-Ca2+) and centrifuged at 270 x g for 5 min. The cell pellet was then resuspended 
in 1mL PBS (+Ca2+) and a baseline function level reading was taken for the first 30 seconds 
using BD FACS LSRII (BD Biosciences, UK). Serum samples from patients (n=8) healthy 
controls (n=8) and animal model (CFA only (n=3), RP (n=3), GABHS proteins (n=3)) at a 
dilution of 1:100 were then added to the suspension and each sample was read for a total 
of 5 min to see the changes in calcium flux. Ionomycin (10 μg/mL) was used as a positive 
control. Ionomycin is produced by the bacterium Streptomyces conglobatus and is used to 
raise the intracellular level of calcium (Yoshida and Plant, 1992). The data was analysed 
using the FlowJo v8.7.1 software.  
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4.4 RESULTS  
4.4.1 Cytotoxicity Assay  
4.4.1.1 Human Samples 
WST-1 cytotoxicity assay was performed to analyze the effect of patient antibodies on both 
PC12 undifferentiated and PC12 differentiated into neurons. Sera samples from patients 
diagnosed with TS, SC, EL and dystonia were used for this assay along with healthy controls. 
The assay involved quantitation of cleaved of tetrazolium salt WST-1 to a soluble formazan. 
This bioreduction is dependent on the production of NAD(P)H which is present only in 
viable cells. Therefore, the amount of formazan dye formed directly correlates to the 
number of metabolically active cells in the culture. The absorbance was measured at 450 
nm with a reference wavelength of 620nm. The delta OD directly correlates to the number 
of viable cells. A highly significant increase in cell cytotoxicity and decrease in the number 
of viable cells was observed in undifferentiated PC12 cells after exposure to antibodies 
from patients with TS and other neuropsychiatric movement disorders (SC, EL and 
dystonia) as compared to healthy controls (p<0.0001). The higher rate of cell cytotoxicity 
after exposure to patient antibodies as compared to controls was also seen in PC12 cells 
differentiated into neurons (p<0.0001).   
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Figure 4.3: Measurement of cell viability (WST-1 cytotoxicity assay) in undifferentiated 
and differentiated PC12 cells using sera from patients and controls. Graph representing 
the cytotoxicity induced in undifferentiated and differentiated PC12 cells exposed to sera 
from patients diagnosed with TS and other neuropsychiatric disorders (SC, EL and dystonia) 
and healthy controls. The absorbance was measured at 450 nm with a reference 
wavelength of 620nm. The delta OD directly correlates to the number of viable cells. 
Staurosporine was used as a positive control. (A) A two tailed unpaired t-test revealed a 
significant decrease in the number of viable cells hence increased cytotoxicity rate in 
undifferentiated PC12 cells treated with sera from patients with TS (p<0.0003) other 
neuropsychiatric disorders (p<0.0001) as compared to healthy controls. (B) A two tailed 
unpaired t-test revealed a significant decrease in the number of viable cells hence increased 
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cytotoxicity rate in differentiated PC12 cells treated with sera from patients with TS 
(p<0.0001) other neuropsychiatric disorders (p=0.0001) as compared to healthy controls. 
4.4.1.2 Animal Model Samples 
WST-1 cytotoxicity assay was performed to analyze the effect of antibodies from SJL and 
ABH mice immunized with GABHS proteins and recombinant proteins (aldolase C, α- 
enolase, γ- enolase, pyruvate kinase) as compared to CFA only control mice on both PC12 
undifferentiated and PC12 differentiated into neurons.  As described earlier the absorbance 
was measured at 450 nm with a reference wavelength of 620 nm. The delta OD directly 
correlates to the number of viable cells.  
A significant decrease in cell viability was observed in undifferentiated PC12 cells after 
exposure to antibodies from both ABH (p<0.008) and SJL (p<0.004) mice immunized with 
GABHS protein fractions. However, no difference in cell cytotoxicity was observed between 
sera sample from mice immunized with RP and CFA controls.  
 
 Figure 4.4: Measurement of cell viability in undifferentiated PC12 cells using sera from 
SJL and ABH animal models. Graphs representing the cytotoxicity induced in 
undifferentiated PC12 cells exposed to sera from ABH and SJL mice immunized with GABHS 
proteins, recombinant proteins (aldolase C, α- enolase, γ- enolase, pyruvate kinase). The 
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absorbance was measured at 450 nm with a reference wavelength of 620nm. The delta OD 
directly correlates to the number of viable cells. Staurosporine was used as a positive 
control. (A) A two tailed t-test revealed a significant decrease in the number of viable cells 
hence increased cytotoxicity rate in undifferentiated PC12 cells treated with sera ABH mice 
immunized with GABHS proteins (p<0.008) as compared to CFA only controls. (B) A two 
tailed t-test revealed a significant decrease in the number of viable cells hence increased 
cytotoxicity rate in differentiated PC12 cells treated with sera ABH mice immunized with 
GABHS proteins (p<0.004) as compared to CFA only controls. 
A significant decrease in cell viability was observed in PC12 cells differentiated into neurons 
after exposure to antibodies from both ABH (p<0.004) and SJL (p<0.005) mice immunized 
with GABHS protein fractions. Additionally a highly significant decrease in cell viability was 
also seen in cells treated with antibodies from ABH mice immunized with RP (p<0.009). This 
effect was not observed with sera antibodies from SJL mice immunized with RP.   
 
 Figure 4.5: Measurement of cell viability in differentiated PC12 cells using sera from SJL 
and ABH animal models. Graphs representing the cytotoxicity induced in PC12 neuronal 
cells exposed to sera from ABH and SJL mice immunized with GABHS proteins, recombinant 
proteins (aldolase C, α-enolase, γ-enolase, pyruvate kinase). The absorbance was measured 
at 450 nm with a reference wavelength of 620nm. The delta OD directly correlates to the 
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number of viable cells. Staurosporine was used as a positive control. (A) A two tailed t-test 
revealed a significant decrease in the number of viable cells hence increased cytotoxicity 
rate in differentiated PC12 cells treated with sera ABH mice immunized with GABHS 
proteins (p<0.004) and recombinant proteins (p<0.009) as compared to CFA only controls. 
(B) A two-tailed t-test revealed a significant decrease in the number of viable cells hence 
increased cytotoxicity rate in differentiated PC12 cells treated with sera ABH mice 
immunized with GABHS proteins (p<0.005) as compared to CFA only controls. 
4.4.2 Apoptosis Assay 
4.4.2.1 Human Samples 
An apoptosis assay involving measurement of Annexin V was performed on PC12 cells. This 
method is used to detect one of the earliest events in apoptosis—the externalization of 
phosphatidylserine (PS)—in living cells. Soon after apoptosis is induced, PS is translocated 
from the inner leaflet of the plasma membrane to the outer leaflet. FITC labelled Annexin 
V, has a strong and specific affinity for PS, to monitor the PS translocation that occurs due 
to apoptosis. Apoptosis was measured in both undifferentiated PC12 cells and cells 
differentiated into neurons after treatment with NGF after treatment with sera from 
patients with TS, EL, SC and dystonia and healthy controls. Staurosporin a known initiator 
of apoptosis was used a positive control. The results show a significant increase in 
apoptosis in undifferentiated PC12 cells after treatment with patient sera from TS patients 
(p<0.01) and those with other neuropsychiatric movement disorders (p<0.0001) as 
compared to healthy controls. Similar effect was observed with PC12 differentiated into 
neurons where antibodies from TS patients (p<0.0001) and those with other 
neuropsychiatric movement disorders (p<0.0001) caused a marked increase in apoptosis. 
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 Figure 4.6: Measurement of cell apoptosis in undifferentiated and differentiated PC12 
cells using sera from patients and controls. The graphs above depict the apoptosis induced 
in both undifferentiated and differentiated PC12 cells after the addition of sera samples 
from patients diagnosed with TS, other neuropsychiatric movement disorders (SC, EL and 
dystonia) as compared to healthy controls. The apoptosis assay involved measurement of 
Annexin V which detects one of the earliest events in apoptosis. Staurosporin was used as a 
positive control. (A) A two tailed t-test revealed a significant difference between the 
apoptosis induced by the addition of sera from patients with TS (p<0.01) and non-TS 
disorders (p<0.0001) as compared to healthy controls. (B) A two-tailed t-test showed a 
highly significant difference between apoptosis induced by the addition of sera from 
patients with TS (p<0.0001) and non-TS disorders (p<0.0001) as compared to healthy 
controls. 
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4.4.2.2 Animal Model Samples 
An apoptosis assay involving measurement of Annexin V method to detect one of the 
earliest events in apoptosis—the externalization of phosphatidylserine (PS)—in living cells 
was performed. FITC labelled Annexin V, has a strong and specific affinity for PS, to monitor 
the PS translocation that occurs due to apoptosis. Apoptosis was measured in both 
undifferentiated PC12 cells and cells differentiated into neurons after treatment with sera 
from ABH and SJL mice immunized with GABHS proteins, RP (ald C, enolase and PK) and 
CFA as described in Chapter 3. The results from undifferentiated PC12 cells show a 
significant increase in apoptosis after treatment with sera from ABH immunized with 
GABHS and RP as opposed to mice immunized with CFA alone. However in case of SJL 
samples a significant increase in apoptosis is only observed after after treating the cells 
with sera from mice immunized with GABHS and not RP. 
  
Figure 4.7: Measurement of cell apoptosis in undifferentiated PC12 cells using sera from 
SJL and ABH animal models. Graphs representing apoptosis induced in undifferentiated 
PC12 exposed to sera from SJL and ABH mice immunized with GABHS proteins, recombinant 
proteins (ald C, α- enolase, γ- enolase and pyruvate kinase) and CFA controls. The apoptosis 
assay involved measurement of Annexin V which detects one of the earliest events in 
apoptosis.Staurosporine was used as a positive control. (A) A two tailed t-test revealed a 
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significant increase in apoptosis in cells treated with sera SJL mice immunized with GABHS 
proteins (p<0.008) as compared to CFA only controls. (B) A two tailed t-test revealed a 
significant increase in apoptosis in cells treated with sera from ABH mice immunized with 
GABHS proteins (p<0.0003) and RP (p<0.05) as compared to CFA only controls. 
A significant increase in apoptosis was observed in PC12 cells differentiated into neurons 
after the addition of sera from both SJL and ABH mice immunized with GABHS and RPs as 
compared to CFA only controls.   
  
Figure 4.8: Measurement of cell apoptosis in differentiated PC12 cells using sera from SJL 
and ABH animal models. Graphs representing apoptosis induced in undifferentiated PC12 
exposed to sera from SJL and ABH mice immunized with GABHS proteins, recombinant 
proteins (ald C, α- enolase, γ- enolase and pyruvate kinase) and CFA controls. The apoptosis 
assay involved measurement of Annexin V which detects one of the earliest events in 
apoptosis. Staurosporine was used as a positive control. (A) A two tailed t-test revealed a 
significant increase in apoptosis in cells treated with sera SJL mice immunized with GABHS 
proteins (p<0.006) and RPs (p<0.02) as compared to CFA only controls. (B) A two tailed t-
test revealed a significant increase in apoptosis in cells treated with sera from ABH mice 
immunized with GABHS proteins (p<0.0009) and RP (p<0.01) as compared to CFA only 
controls. 
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4.4.3 Calcium Flux 
4.4.3.1 Human Samples 
Intracellular calcium flux that represents cell activation was measured in PC12 cells 
differentiated into neurons after being exposed to patient antibodies. The FACS assay was 
performed using Indo-1 which is a ratiometric calcium dye with a dual emission pattern i.e., 
when bound to free intracellular calcium it emits a violet signal and when unbound it emits 
green signal and the ratio of violet over the green is calculated as the Indo-1 ratio which is 
displayed as a parameter over time. Ionomycin was used as a positive control. The figures 
below show the real-time calcium flux into the cells after the addition of the sera samples 
from patients and healthy controls. PC12 neuronal cells exhibited a significant increase in 
intracellular flux after the addition of sera from patients with TS, SC, EL and dystonia as 
compared to healthy controls.   
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Figure 4.9: Real time intracellular calcium flux in differentiated PC12 cells after addition 
of of sera from patients and controls. The above image is illustrative of the real time 
changes in intracellular calcium levels in PC12 neuronal cells after the addition of sera from 
patients (S) and healthy controls (C). The FACS assay involved measurement of Indo-1 
(calcium dye) ratio over time. Ionomycin was used as a positive control. A baseline 
measurement was done for the first 30 s after which the serum sample was added and the 
changes in intracellular calcium were measured for 5 min. An increase in calcium flux can be 
observed after the addition of ionomycin and sera samples at 30 s.  
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Figure 4.10: Intracellular calcium flux in PC12 neuronal cells following treatment with 
patient and control sera. The graph above depicts the real time intracellular calcium flux as 
a measure of Indo-1 ratio over time in PC12 neuronal cells after treatment with patient 
(n=8) and control (n=8) sera samples. A baseline reading was done for the first 30 s after 
which the serum sample was added and the changes in calcium flux monitored for 5 min. 
The Indo-1 ratio was measured just before (30 s) and after the addition of sera samples 
when it reached its peak. A two-tailed t-test revealed a significant increase in intracellular 
calcium flux after the addition of patient sera as opposed to healthy controls (p<0.03).  
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4.4.3.2 Animal Model Samples 
Intracellular calcium flux that represents cell activation was measured in PC12 cells 
differentiated into neurons after addition of sera antibodies from active immunization 
animal model described in Chapter 3. The FACS assay was carried out using Indo-1 which is 
a ratiometric calcium dye with a dual emission pattern i.e., when bound to free intracellular 
calcium it emits a violet signal and when unbound it emits green signal and the ratio of 
violet over the green is calculated as the Indo-1 ratio which is displayed as a parameter 
over time. Ionomycin was used as a positive control. The figures below shows the real-time 
calcium flux into the cells after the addition of the sera samples from SJL and ABH 
immunized with GABHS proteins, RP (ald C, enolase and PK) and CFA only. PC12 neuronal 
cells exhibited an increase in intracellular flux after the addition of sera antibodies. The flux 
was significant when sera from SJL (p<0.02) and ABH (p<0.04) mice immunized with GABHS 
proteins was added to differentiated PC12 cells as compared to CFA only controls.  The 
effect on calcium flux wasn’t pronounced in response to sera from mice immunized with 
RPs (putative autoantigens) as compared to CFA controls. 
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Figure 4.11: Real time intracellular calcium flux in differentiated PC12 cells after addition 
of sera from ABH and SJL mice immunized with GABHS proteins, RP and CFA. The above 
images A and B are illustrative of the real time changes in intracellular calcium levels in 
PC12 neuronal cells after the addition of sera from mice immunized with GABHS proteins, 
A) ABH 
B) SJL 
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RP and CFA. The FACS assay involved measurement of Indo-1 (calcium dye) ratio over time. 
Ionomycin was used as a positive control. A baseline measurement was done for the first 30 
s after which the serum sample was added and the changes in intracellular calcium were 
measured for 5 min. An increase in calcium flux can be observed after the addition of 
ionomycin and sera samples at 30 s. (A) Real time intracellular calcium flux in differentiated 
PC12 cells after addition of sera from ABH mice immunized with GABHS (a-g1), RP (a-r1) 
and CFA only (a-c1) at 30 s. (B) Real time intracellular calcium flux in differentiated PC12 
cells after addition of sera from SJL mice immunized with GABHS (s-g1), RP (s-r3) and CFA 
only (s-c1) at 30 s.  
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Figure 4.12: Intracellular calcium flux in differentiated PC12 cells following treatment 
with sera from test and control ABH mice. The graph above depicts the real time 
intracellular calcium flux as a measure of Indo-1 ratio over time in PC12 neuronal cells after 
treatment sera from ABH mice immunized with GABHS (n=3), RP (n=3) and CFA controls 
(n=3). A baseline reading was done for the first 30 s after which the serum sample was 
added and the changes in calcium flux monitored for 5 min. The Indo-1 ratio was measured 
before and after the addition of sera samples when it reached its peak. A two-tailed t-test 
revealed a significant increase in intracellular calcium flux after the addition of patient sera 
as opposed to healthy controls (p<0.04). 
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Figure 4.13: Real time intra-cellular calcium flux in PC12 neuronal cells after treatment 
with test and control sera from SJL mice. The graph above depicts the real time 
intracellular calcium flux as a measure of Indo-1 ratio over time in PC12 neuronal cells after 
treatment with sera from SJL mice immunized with GABHS (n=3), RPs (n=3) and CFA controls 
(n=3). A baseline reading was done for the first 30 s after which the serum sample was 
added and the changes in calcium flux monitored for 5 min. The Indo-1 ratio was measured 
before and after the addition of sera samples when it reached its peak. A two-tailed t-test 
revealed a significant increase in intracellular calcium flux after the addition of patient sera 
as opposed to healthy controls (p<0.02). 
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4.5 DISCUSSION 
It was hypothesized that there was an antibody-mediated autoimmune mechanism as well 
as bacterial infection contributing to the pathogenesis of neuropsychiatric movement 
disorders like TS and SC. Apart from clinical evidence and a disease replicating animal 
model another proof of an autoimmune aetiology comes from demonstrating the 
autoaggressive action of circulating autoantibodies on living cells. The pathogenic effect of 
these antibodies was studied in both neuronal and non-neuronal cells in terms of 
cytotoxicity, apoptosis and intracellular calcium flux.  
Using the WST-1 cytotoxicity assay a clear decrease in the number of viable cells was seen 
in response to patient autoantibodies as compared to those from healthy controls. 
Similarly a significant increase in apoptosis was observed in both differentiated and 
undifferentiated cells after treatment with patient antibodies. Patient sera samples were 
bifurcated into two categories TS and non-TS (SC, EL and dystonia) and both groups were 
seen to exert the same pathogenic effect on PC12 cells. This finding strengthens the 
hypothesis that these disorders are likely to be autoantibody mediated and could be part of 
the same spectrum. A recent study however exhibited that serum autoantibodies only from 
SC, but not PANDAS or TS patients bound to neuronal surface antigens (Brilot et al., 2011). 
The cytotoxic and apoptotic effect of patient antibodies was consistent in both 
undifferentiated and PC12 differentiated into neurons. The main form of enolase dimer on 
undifferentiated cells is the αα-homodimer (non-neuronal enolase) (Vinores et al., 1981). A 
change from non-neuronal to neuron specific enolase (αγ and γγ –dimer) during PC12 
differentiation into neurons has also been documented (Schemedel et al., 1980). This 
confirms that anti-neuronal antibodies found in patients with neuropsychiatric disorders 
target both α and γ enolase isoforms.  
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In the present study it was not possible to perform an ATP assay due to technical 
difficulties. As part of the future studies I will determine the ATP/ADP ratios using a 
luciferase chemiluminescence assay (Pocock & Nicholls, 1998) to determine whether 
energy metabolism is altered. ATP levels need to be assessed since apoptosis may be 
triggered upstream by perturbations in ATP, in particular a fall in ATP. It is also possible that 
an increase in ATP in some instances given current suggestions that cell surface glycolytic 
enzymes may actually serve to generate energy at the membrane (Dubinsky et al., 1998). In 
line with this there is preliminary data using a commercial anti-enolase monoclonal 
antibody, which causes a marked increase in neuronal ATP but a fall in ADP relative to 
controls. The time course of such ATP increases needs to be described since an initial 
stimulation may be followed by a fall, triggering apoptosis, particularly if energy substrate 
sources are depleted. 
There are a number of possible ways in which these autoantibodies can act. Increased 
signal transduction is one mechanism proposed to alter neuronal cell physiology leading to 
neurological dysfunction. In 2003, Kirven et al., demonstrated cross-reactive antibodies in 
SC that deposit in the basal ganglia and lead to calcium/calmodulin-dependent protein 
kinases (CaM kinase II) activation in neuronal cells (Kirvan et al., 2003). The CaM kinases 
are a family of related kinases that are activated in response to increased intracellular 
calcium concentrations. As seen in my results patient antibodies led to a marked increase in 
intracellular calcium flux as compared to those from healthy controls. Ca2+ influx into cells 
activates a number of enzymes, including phospholipases, endonucleases, and proteases 
which lead to damage of structures like DNA and the cytoskeleton (McConkey and Nutt, 
2001; Gronski et al., 2009). Although an effect of autoantibodies from patients on calcium 
flux was demonstrated the nature of the target receptor/channel still needs to be identified 
which would further help us understand the downstream alterations in signal transduction.  
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Some initial studies with patient IgG have indicated decreased calcium responses in 
cultured neurones to a depolarising stimulus. In cultured neurones, enhanced intracellular 
free calcium provides trophic functions for neuritogenesis and gene transcription, 
particularly via the NMDA receptor and L-type calcium channel (Helton et al., 2005). The L-
type calcium channels preferentially localize to soma and dendrites of neurons (Hell et al., 
1993; Simon et al., 2003), but their contribution to action potential-dependent calcium 
entry in these regions is still unclear. Blocking these pathways with the NMDA receptor 
antagonist MK801 or the L-type calcium channel antagonist Nifedipine (a dihydropyridie), 
might trigger apoptosis. In our future experiments The effects of purified monospecific 
antibodies on KCl-evoked calcium responses will be determined together with NMDA 
stimulated calcium responses. Single cell calcium (Ca2+) responses can then be measured by 
fluorescence imaging as previously described (Evans & Pocock, 1999; Pocock and Evans 
2000). 
Additionally an in vitro GABHS infection model possibly should be developed using cultured 
phagocytes to study dose-dependent apoptosis. Some previous studies of GABHS 
interactions with epithelial cells assessed apoptosis as an outcome variable. In respiratory 
epithelial cell lines, internalization of the bacteria was observed to be critical for induction 
of the apoptotic phenotype (Nakagawa et al., 2001; Timmer et al., 2009).  GABHS have 
been seen to induce apoptosis in human neutrophils (Kobayashi et al., 2003) although the 
specific virulence factor(s) involved and effects on caspase activation have not yet been 
explored. Purified SAg and M proteins could be used to study their individual pathogenic 
effect on cellular and sub-cellular targets.  
All functional assays were also carried out using sera from SJL and ABH mice immunized 
with GABHS proteins, recombinant proteins and CFA. Both SJL and ABH mice are known to 
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be susceptible to induction of experimental allergic encephalomyelitis (EAE) (Levine and 
Sowinski, 1973; Goverman and Brabb, 1996). ABH additionally was later found to be highly 
susceptible to other autoimmune conditions like autoimmune neuritis, autoimmune 
uveitis, as well as virus-induced demyelination and have therefore been the key strain to 
study human inflammatory neurological diseases (Amor et al., 2005). High levels of cell 
cytotoxicity and apoptosis were observed after the addition of sera from mice immunized 
with GABHS and RP from both strains. However a significant increase in calcium flux was 
only seen with sera from SJL and ABH immunized with GABHS proteins and not RP. As 
described previously I could not observe a disease phenotype in these mice due to lack of 
adequate behavioural testing. At least in an in vitro setting it was possible to determine the 
pathogenic effect of the antibodies raised against the putative autoantigens. The results 
obtained are promising such that this animal model will be developed further by 
immunization with individual recombinant proteins to raise mono-specific antibodies.  
 
 
 
 
 
 
 
 
 
 
 
 
176 
 
CHAPTER 5 
ENOLASE AS A TARGET AUTOANTIGEN 
 
5.1 INTRODUCTION 
5.1.1 Enolase 
5.1.1.1 Background 
The enzyme enolase also known as phosphopyruvate dehydratase was discovered by 
Lohmann and Meyerhof in 1934 (Lohman.K 1934). It is responsible for the catalysis of 2-
phosphoglycerate (2-PG) to phosphoenolpyruvate (PEP), the penultimate step of glycolysis.  
There are three subunits of enolase, α, β, and γ, each encoded by a separate gene that can 
combine to form five different isoenzymes: αα, αβ, αγ, ββ, and γγ. Alpha-enolase (also 
called non-neuronal enolase) is ubiquitously expressed in the early stage of embryonic 
development, beta-enolase is expressed in adult skeletal and cardiac muscles, and gamma-
enolase (also called neuron-specific enolase) is expressed in mature neuron and 
neuroendocrine cells (Marangos and Schmechel, 1987, Deloulme et al., 1997). Using 
sensitive immunoassays, significant levels of γ enolase have been found  in differentiated 
tissues other than nervous tissues (Haimoto et al., 1985). The structure is highly conserved 
with a homology of 40-90% between different species (Pancholi, 2001). In mammals there is 
82% homology between the amino acid sequences of -, -, and -enolase monomers 
(Pancholi, 2001). Studies with discoid lupus erythematosus have demonstrated that the 
reactive autoepitopes in enolase are also highly conserved from “yeast to man.” This study 
observed that autoantibodies reacted most strongly with -enolase but also predicted that 
-enolase would show some reactivity with -enolase producing the least (Gitlits et al., 
1997).  
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5.1.1.2 Function 
Enolase has also been show to act as a plasminogen receptor on neuronal membranes 
(Nakajima et al., 1994a) mediating interactions between microglia and dopaminergic 
neurons (Nakajima et al., 1994b). The enolase binding to plasminogen induces plasminogen 
transformation into plasmin and is thought to be a virulence factor by preventing the 
generation of fibrin clots and thus enabling tissue invasion, as described for S. pyogenes and 
S. Pneumonia (Fontan et al., 2000). Plasminogen is critical in the host’s defence as it 
dissolves fibrin clots, maintaining homeostasis and vascular potency; however GABHS 
subverts this fibrinolytic activity, increasing pathogenesis (Pancholi and Fischetti, 1998). 
Eukaryotic haematopoietic cells – B cells, T cells, neutrophils, and monocytes also express 
-enolase on their surface but streptocococcal surface enolase SEN has a higher affinity for 
plasminogen and has been proposed to be the major plasminogen binding protein on the 
surface of GABHS (Pancholi and Fischetti, 1998; Pancholi, 2001; Witkowska et al., 2005). 
NSE can form complexes with other glycolytic enzymes (e.g. aldolase C) which monitor 
oxidative stress levels at the cell surface (Bulliard et al., 1997). In addition, α-enolase when 
located in the nucleus is a Myc-binding protein (MBP-1) playing a vital and crucial role in cell 
growth and differentiation (Terrier et al., 2007). In addition, heat shock protein, Myc-
binding protein, eye -crystallin protein, and an endothelial stress protein (Pancholi, 2001).  
Proteins that are structurally similar to human enolase have also been observed on the 
surface of other bacteria including Streptococcus pneumoniae, Escherichia coli, Klebsiella 
pneumoniae, Hafnia, Citrobacter, Enterobacteriaceae and Psuedomonas aeruginosa 
(Witkowska et al., 2005). In E.coli, enolase is an integral component of the RNA 
degradosome (Kuhnel and Luisi, 2001; Carpousis, 2002). Its role has been hypothesized to 
direct subcellular compartmentalization of degradosome to the membrane (Liou et al. 2001; 
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Morita et al. 2004).  These enolase-like proteins have been shown to react with rabbit 
antibodies specific for human -enolase and have been observed in patients with Buerger 
disease and atherosclerosis (Witkowska et al., 2005). The aetiology of these conditions is 
unknown but previous studies have suggested a bacterial cause (Witkowska et al., 2005). 
What is also unclear is exactly how -enolase and enolase-like proteins are present on the 
surface of these cells.  These proteins have no signal sequence or hydrophobic domain to 
translocate the protein from the cytoplasm to the cell membrane (Pancholi, 2001). It has 
therefore been suggested that enolase and other proteins with these characteristics should 
be classed as a special variety of surface protein (Pancholi, 2001). 
5.1.1.3 Associated Disorders 
Studies have reported the presence of enolase-specific autoantibodies in a range of 
psychiatric, degenerative and inflammatory disorders, including discoid lupus 
erythematosus (Terrier et al., 2007), autoimmune polyglandular syndrome type 1 primary, 
and secondary membranous nephopathy, cancer-associated retinopathy, primary biliary 
cirrhosis (Akisawa et al., 1997), mixed cryoglobulinemia with renal involvement, cystoid 
macular edema, endometriosis (Gitlits et al., 2001).  In addition, autoantibodies which cross 
react with GABHS and human -enolase have been observed in ARF patients (Fontan et al., 
2000). ARF is one of the most important sequelae of upper respiratory tract infection 
occurring due to GABHS (McDonald et al., 2004). 
Antibodies against glycolytic enzymes have also been observed in optic neuritis. Out of 209 
samples tested for anti-optic nerve autoantibodies, 55% showed specific neuronal 
autoantibodies. Autoantibodies specific to classical glycolytic enzymes involved in energy 
production (α and γ enolases, glyceraldehyde 3-phosphate dehydrogenase) also reacted 
with retinal antigens (Adamus et al., 2011). 
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In a recent study ninety-six participants with OCD were tested for the presence of anti-
streptolysin-O titres (ASOT) and the presence ABGA. The findings were compared with 
those in a control group of individuals with depression (n= 33) and schizophenia (n= 17). 
ABGA were tested for with western blots using three recombinant antigens; aldolase C, 
enolase and pyruvate kinase. Positivity for ABGA was observed in 19/96 (19.8%) 
participants with OCD compared with 2/50 (4%) of controls (Fisher’s exact test P= 0.012). 
The majority of positive OCD sera (13/19) had antibodies against the enolase antigen 
(Nicholson et al., 2012).  
5.1.2 Sodium Potassium ATPase (Na+/K+-ATPase) 
5.1.1.2 Background 
Sodium Potassium ATP-ase (Na+/K+ -ATPase) is a heterodimeric integral membrane protein 
responsible for carrying out coupled extrusion and uptake of Na+ and K+ ions across the 
plasma membrane of cells (Kaplan JH, 2002). The Na+/K+- ATPase is composed of a 100 kDa 
α-subunit with ten transmembrane segments and a glycosylated β-subunit of about 55 kDa. 
Four distinct α-subunits and the β subunit isoforms have been identified, and there appears 
to be no preferential association of particular subunits with each other (Peng et al., 1997; 
Mao et al., 2005).  
The pump is composed of multiple isoforms and the isoform distribution varies with the 
tissue and during development (Kaplan, 2002). The alpha 1 isoform is the major isoform in 
the kidney and the alpha2 isoform is the predominant one in skeletal muscle (Lingrel et al. 
2007). While all three isoforms are found in the brain, the alpha 3 isoform is located 
essentially in neurons while the alpha 2 isoform is found in astrocytes and some limited 
neuronal populations. Interestingly the alpha 4 isoform is found exclusively in the mid 
region of the sperm tail (Lingrel et al. 2007). 
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5.1.2.2 Function 
The pump plays a central role in a variety of physiological processes like differentiation 
(Smith et al., 1982), proliferation (Rozengurt and Heppel, 1975), propagation of action 
potential of nerves and muscles (Thomas E, 1972) and regulation of cellular volume (Rolfe 
and Brown, 1997). It also functions as signal transducer/integrator to regulate the mitogen-
activated protein kinase pathway (MAPK), mitochondrial reactive oxygen species (ROS) 
production, as well as intracellular calcium (Liu et al., 2000; Aizman and Aperia, 2003). In 
neurons, the Na+/K+-ATPase can account for up to two-thirds of the cell's energy 
expenditure (Howarth et al., 2012). 
Lipid rafts are cholesterol- and shingolipid-enriched membrane microdomains implicated in 
membrane signalling and trafficking (Calder and Yaqoob, 2007). These specialized 
microdomains serve as organizing centres and compartmentalize cellular processes like the 
assembly of signalling molecules, regulating neurotransmission and receptor trafficking and 
membrane protein trafficking (Thomas et al., 2004; Calder and Yaqoob, 2007). Although 
recent reports have begun to describe molecules associated with rafts, their protein 
composition remains largely unknown, especially in neuronal cells (Ledesma et al., 2003). 
Proteomic analysis of the low-density fraction of lipid rafts  revealed the α-subunit of Na+-
K+-ATPase as the protein with the highest significance score (Welker et al., 2007). Na+/K+- 
ATPase forms a signalling complex composed of multiple receptors (EGFR, IP3R), structural 
proteins (ankyrin, caveolin) and protein and lipid kinases (Src-kinase, PI3K) (Brady et al., 
2011) 
Enolase being a glycolytic enzyme, as expected, is found in the cytosol. However as 
mentioned above it is also located on the neuronal surface, where it serves alternate 
functions like acting as a receptor for plasmin/plasminogen and has also been shown to be 
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a trophic factor for dopaminergic neurons (Liu et al., 2007; Plow and Das, 2009). Enolase 
along with the other glycolytic enzymes might be positioned in the lipid rafts and may 
interact with other membrane proteins, e.g. ion channels like the Na+/K+ -ATPase. Bi-
dimensional gel analysis and pharmacological raft lipid manipulation of purified detergent-
insoluble raft fractions from primary cultures of hippocampal neurons have led to the 
identification of neuronal raft proteins. Enolases were found amongst these proteins and 
functional studies demonstrate their participation in plasminogen binding (Ledesma et al., 
2003; Camoletto et al., 2009). The rafts were found enriched with several other 
plasminogen binding molecules and the exclusive activation of plasminogen to the 
protease plasmin in these microdomains (Ledesma et al., 2003). These observations 
indicate that neuronal rafts may not only play a role in intracellular signalling but might also 
be involved in extracellular/membrane protein proteolysis (Ledesma et al., 2003). The 
active extrusion of Na+ ions from human erythocytes is inhibited by low concentrations of 
fluoride ion (Maizels, 1951). This has been attributed to glycolytic inhibition caused by 
fluoride ion (Embden and Haymann, 1924), which leads to a decline in cellular 
concentration of adenosine triphosphate (ATP), the presumed energy source for the Na+ 
pump (Gardos and Straub, 1957; Eckel, 1958; Millmann and Omachi, 1972). 
5.2 HYPOTHESIS AND AIMS 
The membrane glycolytic enzymes are closely involved in the energy provision and 
maintenance of ion channels on the neuronal membrane, trophic support and other 
functions. Based on previous findings that have identified enolase as a potential 
autoantigen in the present study it was hypothesized that antibodies from patients with 
neuropsychiatric movement disorders like TS, SC and EL will inhibit the enzymatic activity of 
this glycolytic enzyme.  
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In addition the hypothesis that all ion channel proteins exist in the plasma membrane in a 
regulatory complex with one or more proteins and enolase might be part of that complex 
that participate in the modulation of channel activity has been pursued. Hence inhibition of 
enolase activity might be resulting in dysregulation of Na+/K+ -ATPase thereby leading to 
disruption of normal cellular processes. 
The main aim of this study was analyse the effect of autoantibodies from patients 
diagnosed with postulated post-streptococcal disorders neuropsychiatric disorders like TS, 
EL and SC on the enzymatic activity of cell surface enolase using PC12 neuronal cells. To 
study the expression of Na+/K+ -ATPase and NSE in PC12 neuronal cells and see if they are 
co-expressed using fluorescence confocal microscopy.  
5.3 MATERIALS AND METHODS 
5.3.1 Sera Samples 
A total of 49 patient sera samples were used for the enolase activity assay. The cohort 
included sera samples from patients diagnosed with TS (n=22) and other disorders 
including SC, EL and dystonia (n=27). The TS patient sera samples were kindly provided by 
Dr. Davide Martino, University of Bari, Italy. Sera samples from patients with SC, EL and 
dystonia were provided by Dr. Andrew Church, Institute of Neurology, London. 
Furthermore sera from healthy controls (n=20) kindly provided by Dr. Ruth Dobson, 
Department of Neuroscience and Trauma, Queen Mary University of London were also 
tested in the assay.  Pateint material was obtained with informed consent and appropriate 
ethical review.  
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5.3.2 PC12 cells  
PC12 is a cell line derived from a pheochomocytoma (neuroendocrine tumour) of the rat 
adrenal medulla (Greene and Tischler, 1976). When exposed to neurotrophins like the 
nerve growth factor  (NGF) neoplastic PC12 cells undergo a series of biochemical and 
morphological changes thereby differentiating into neural cells (R.J.Walters, 2002). 
PC12 cells grown with or without nerve growth factor (NGF) contain dense core chomaffin-
like granules up to 350 nm in diameter. The NGF-treated cells also contain small vesicles 
which accumulate in process varicosities and endings. PC12 cells synthesize and store the 
catecholamine neurotransmitters dopamine and norepinephine (Cunningham et al., 2001). 
PC12 cells were cultured in T75 culture flasks coated with Collagen I, Rat Tail (Invitrogen 
Life Technologies, UK). The cells were maintained in RPMI 1640 medium (Sigma-Aldrich, 
UK) supplemented with 50mL horse serum (Lonza 14-403F), 25mL foetal calf serum (Sigma-
Aldrich, Poole, UK), 5mL penicillin/streptomycin (Sigma-Aldrich, UK) and 5mL Non-Essential 
amino acid solution (Sigma-Aldrich, UK) in a humidified incubator at 37°C and 4.5% CO2. 
The cells were passaged every 2-3 days in a ratio of 1:5. To induce differentiation into 
neurons the cells were treated with 50 ng/mL of NGF (Invitrogen Life Technologies, UK) 
every 2 days for upto a week.  
5.3.3 Cell Fractionation  
PC12 cell fractions were prepared using the complete cell fractionation kit (Promokine, 
Germany) to carry out enolase activity assay on whole cells and fractions. PC12 cells (4-8 x 
10⁶) were collected by centrifugation at 700 x g for 5 minutes. The cells were then washed 
with 5-10mL of ice-cold PBS (Invitrogen Life Technologies, UK) and centrifuged at 700 x g 
for 5 mins. The cell pellet was then resuspended in 1mL of ice-cold PBS and transferred to 
an eppendorf tube. A spin for 5 min at 700 x g was done and the supernatant was removed. 
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The pellet was then resuspended in 400μL of Cytosol Extraction Buffer-Mix (CEB-mix 
containing dithiotheitol (DTT) and protease inhibitor cocktail) and incubated on ice for 20 
min with gentle tapping (3-4 times) every 5 min. Once again the cell samples were 
centrifuged at 700 x g for 10 min and the supernatant was collected (Cytosolic Fraction).  
For the membrane fraction the pellet was re-suspended in 400μl of ice-cold Membrane 
Extraction Buffer-A Mix (MEB-A Mix containing DTT and protease inhibitor cocktail) to 
which 22μL of Membrane Extraction Buffer-B, was added. The samples were vortexed for 5 
seconds and incubated on ice for 1 min before centrifugation for 5 min at 1000 x g. The 
supernatant was immediately transferred to a clean pre-chilled tube 
(Membrane/Particulate Fraction).  
5.3.4 Enolase activity assay  
Enolase isoforms and their dimers are some of the known target of anti-neuronal 
antibodies (Dale et al., 2004). An assay for enolase was carried out on whole adhered 
growing cells to determine if the activity of enolase is affected by though binding of anti-
neuronal antibodies. It is more likely that antibodies bind to targets on cell surface, 
therefore, the cells were not permeabilized when measuring the enzymatic activity of 
enolase. However analysis of the enolase activity was performed on whole PC12 neuronal 
cells and various cell fractions including membrane and cytosol to identify the targets of 
these autoantibodies.  
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Figure 5.1: Enzymatic reaction in the enolase assay. Enolase converts 2-Phosphoglycerate 
(DPG) to phosphoenolpyruvate (PEP), which is further converted to pyruvate through 
pyruvate kinase (PK). The enzyme lactate dehydrogenase (LDH) converts pyruvate to lactate 
by oxidation of NADH. Enolase acitivity is revealed by the decrease in NADH that can be 
measured through changes in absorbance at 340 nm.   
PC12 cells were cultured onto rat tail, collagen I (Invitrogen life technologies, UK) coated 
flat bottomed 96 well cell culture plates. The cells were differentiated into neurons by 
treatment with NGF (50 ng/mL) every alternate day over a period of 7 days. After the cells 
had fully differentiated into neurons 1:100 diluted serum samples from patients with TS, 
EL, SC and dystonia along with healthy controls were added to the cells which were then 
incubated with the antibodies for 24 hs. Two positive controls were used in this assay- 
1:100 diluted monoclonal antibody (mAb) against neuron specific enolase (NSE) (1 mg/mL) 
(Abcam, UK) and 0.5 mM sodium fluoride (Abcam, UK). Flouride inhibits the activity of 
enolase by binding Mg2+ thereby hindering interactions between Mg2+ and the substrate 2-
PG (Hoorn et al., 1974).  
 50 µL reaction mixture containing 4mM 2-phosphoglycerate barium salt, 1mM β-
nicotinamide (NADH), 50mM magnesium sulphate (MgSO4), 200mM potassium chloride 
(KCl), 2.6mM adenosine di-phosphate (ADP), 0.3 unit of lactate dehydrogenase (LDH) and 
2- Phosphoglycerate + H2O   Phosphoenolpyruvate 
 
Phosphoenolpyruvate + ADP      Pyruvate + ATP 
 
Pyruvate + β-NADH    L-Lactate +  β-NAD+ 
  Enolase 
Pyruvate Kinase 
            L-Lactate Dehydrogenase 
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0.2 units of pyruvate kinase (PK) dissolved in medium was added and the plate which was 
incubated at 37°C. Absorbance was measured at 340 nm every 15 min for up to 1 h 30 min. 
The data plotted shows reading upto an hour as no significant changes in absorbance were 
observed after that. The absorbance measured was directly proportional to the levels of 
NADH which in turn was inversely proportional to enolase activity. Hence higher the 
absorbance, lower the enolase activity.  
5.3.5 Immunocytochemistry (ICC) 
PC12 cells were grown and differentiated on coverslips coated with type I rat tail collagen 
as described above. Once fully differentiated into neuronal cells they were fixed in 4% 
paraformaldehyde (PFA) pH7.4 for 15 min at RT followed by washes with ice cold PBS. The 
samples were then blocked with 1% BSA in PBS containing 0.1% tween for 30-60 min to 
block unspecific binding of the antibodies followed by incubation in the diluted primary 
antibodies prepared in the blocking solution at a dilution of 1:500 for 1 h at RT or overnight 
at 4°C. Three primary antibodies were used in the study as listed in the table below: anti- 
neuron specific enolase (NSE) (Abcam, UK), anti-sodium potassium ATPase (Na+/K+ ATPase) 
(Abcam, UK) and anti-neurofilament (NFL) (Abcam, UK). The antibody solution was then 
decanted and the cells were washed 3X PBS, 5 min per wash. The cells were then incubated 
with the appropriate secondary antibody prepared in 1% BSA for 1 h at RT in dark. 
Secondary antibody solution was then decanted and the cells were washed three times 
with PBS for 5 min each in the dark. The cells were then incubated with 0.1-1 μg/mL 
Hoechst or DAPI (DNA stain) for 1 min and rinsed with PBS. The coverslips were mounted 
onto superfrost slides (VWR, UK) with a drop of DEPEX mounting medium and sealed with 
nail varnish to prevent drying and movement under microscope. The slides were then 
stored at +4°C. The slides were viewed using the Zeiss LSM 510s laser scanning confocal 
microscope. 
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Primary Antibody Secondary antibody Product Source 
Mouse monoclonal to neuron 
specific enolase (NSE) 
Fluorescein isothiocyanate 
(FITC) conjugated goat anti-
mouse (Green) 
Abcam, UK 
Rabbit polyclonal to sodium 
potassium ATPase (Na
+
/K
+
 
ATPase) 
Tetramethylrhodamine-5-(and 
6)-isothiocyanate(TRITC) 
conjugated sheep anti-rabbit 
(Red) 
Abcam, UK 
Chicken polyclonal to 68kDa 
neurofilament 
 
DyLight
TM
 405-Conjugated  
 
donkey anti-chicken (Blue) 
 
Abcam, UK  
Jackson ImmunoResearch 
Laboratory, USA 
Table 5.1: Table summarising the primary and secondary antibodies used for staining 
PC12 neuronal cells. The antibodies listed above were used to study the expression of 
neuron specific enolase (NSE), sodium potassium ATPase (Na+/K+ -ATPase) and 
neurofilament (NFL) in PC12 neuronal cells using confocal microscopy.  
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5.4 RESULTS  
5.4.1 Enolase Activity Assay 
Enolase is one of the autoantigen implicated in postulated post-streptococcal disorders 
mentioned above. Enolase activity was measured in PC12 neuronal cells: whole cells, 
cytosol and membrane fraction after the addition of sera samples from patients diagnosed 
with TS and EL (n=6) and healthy controls (n=5). The assay was carried out on both 
membrane and cytosol fractions to investigate where the antibody binding occurs. The 
enzymatic assay entailed measurement of NADH which bears an inverse relation with 
enolase activity i.e., the higher the NADH the lower the enolase activity and vice versa. The 
production of NADH concentration was measured at an absorbance of 340 nm. From the 
graphs below it can be concluded that sera antibodies bind to enolase present on the cell 
membrane and inhibit its activity.  The statistical analysis shows a significant inhibition of 
enolase activity in both PC12 whole neuronal cells (p<0.04) and its membrane fraction 
(p<0.001) after the addition of sera from patients as compared to healthy controls. 
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Figure 5.2: Enolase activity assay conducted on PC12 neuronal cell fractions. Graphs A, B 
& C above depict the changes in levels of NADH (absorbance @340 nm) measured over a 
period of 1 hour in PC12 neuronal whole cells and fractions (membrane and cytosol) after 
treatment with sera samples from patients diagnosed with TS and EL as compared to 
healthy controls. Levels of NADH bear an inverse relation to levels of enolase activity i.e., 
higher the NADH lower the enolase activity and vice versa. Both mAb against NSE and 
sodium fluoride were used as positive controls. (A) Shows the levels of NADH in PC12 
neuronal cells after the addition of sera from patients with TS and EL versus healthy 
controls. A two- tailed T-test revealed a significant inhibition of enolase activity after the 
addition of patient sera as compared to control (p<0.04). (B) Shows the levels of NADH in 
the cytosolic fraction of PC12 neuronal cells after the addition of sera from patients with TS 
and EL versus healthy controls. No significant difference in enolase activity was observed 
between the patients and controls. (C) Shows the levels of NADH in the membrane of PC12 
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neuronal cells after the addition of sera from patients with TS and EL versus healthy 
controls. A two- tailed t-test revealed a significant inhibition of enolase activity after the 
addition of patient sera as compared to control (p<0.001). 
Once determined that antibodies target the enolase present on the plasma membrane sera 
samples from additional samples from patients diagnosed with TS, EL, SC and dystonia 
along with healthy controls were tested for their action on the enzymatic activity of 
enolase in non-permeabilized PC12 neuronal cells. Statistical tests show a significant 
decrease in enolase activity after the addition of sera from patients as compared to 
controls. Two- tailed t-test comparing patients and controls at each time point confirmed a 
significant inhibition of enolase activity of patient sera as compared to control (p<0.0001). 
             
Figure 5.3: Enolase activity assay conducted on PC12 neuronal cells using patient and 
control sera. The graph above shows the changes in levels of NADH (absorbance @340 nm) 
measured over a period of 1 hour in PC12 neuronal cells after treatment with sera samples 
from patients diagnosed with TS, Non-TS disorders (SC, dystonia and EL) and healthy 
controls. Level of NADH is inversely proportional to enolase activity i.e., higher the NADH 
lower the enolase activity and vice versa. Sodium fluoride and mAb against neuron-specific 
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enolase were used as positive controls. Statistical analysis revealed increased inhibition of 
enolase activity (higher NADH) in PC12 neuronal cells at every time point (15, 30, 45 and 60 
min) after the addition of patient sera as compared to controls. Two- tailed T-tests 
comparing patients and controls at each time point (15, 30, 45 and 60 min) yielded 
significantly stronger inhibition of patient sera compared to control sera at each of the time 
points explored (p<0.0001). 
5.4.2 Co-expression Na+ /K+ -ATPase – Neuron specific enolase 
The expression of Na+/K+ -ATPase and NSE in PC12 cells was studied both before and after 
differentiation into neurons using fluorescent and confocal microscopy was examined. 
Undifferentiated cells were counterstained with DAPI that stains the nuclei while for 
differentiated cells a third antibody against NFL was used which serves as a neuronal 
marker. 40x images of undifferentiated PC12 cells show the co-expression of Na+/K+ -
ATPase (red), NSE (green). Although the staining seems diffused the expression of the both 
Na+/K+- ATPase and NSE can be seen in the plasma membrane of the cells. 100x images of 
PC12 neuronal cells stained with show similar co-expression of Na+/K+ -ATPase (red), NSE 
(green) and NFL (blue). 
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5.4.2.1 Undifferentiated PC12 Cells 
 
Figure 5.4: Flourescent images of undifferentiated PC12 cells stained for Na+/K+ -ATPase 
and NSE. 40X images A to D of PC12 undifferentiated stained with fluorescent tagged 
antibodies against Na+/K+ -ATPase and NSE and counterstained with DAPI. (A) TRITC 
conjugated Na+/K+ -ATPase. (B) FITC conjugated mAb against NSE. (C) DAPI stained nuclei. 
From the staining pattern above both Na+/K+- ATPase and NSE appear to be co-expressed. 
Although the staining seems diffused they are expressed primarily in the plasma membrane 
of undifferentiated PC12 cells.   
 
 
193 
 
5.4.2.2 Differentiated PC12 Cells 
  
Figure 5.5: Confocal images of differentiated PC12 cells stained for NFL, NSE and Na+/K+ -
ATPase. 100X confocal images A to D above show PC12 cells differentiated into neurons 
stained with antibodies against NFL, NSE and Na+/K+ -ATPase respectively.(A) DyLightTM 405 
conjugated antibody against 68kDa NFL.  (B) FITC conjugated mAb against NSE. (C) TRITC 
labelled polyclonal antibody against Na+/K+ -ATPase. (D) An overlay of images A, B and C. 
From the staining pattern observed above Na+/K+ -ATPase and NSE seem to be co-expressed 
in PC12 neuronal cells. Once again the expression seems to be primarily in the membrane of 
the neuronal cells. 
A B 
C D 
194 
 
5.5 DISCUSSION  
In the present study the role of enolase as a target autoantigen in postulated post-
streptococcal CNS disorders was investigated further. Enolase isoforms α and γ and their 
dimers are some of the known targets of anti-neuronal antibodies (Dale et al., 2004; 2006). 
Enolase has been implicated as a target autoantigen in a range of non- CNS autoimmune 
disorders. Autoantibodies directed against a pituitary cytosolic protein identified as α-
enolase were detected in 70% of patients with biopsy- proven lymphocytic hypophysitis 
compared with 9.8% of normal subjects (Crock, 1998; O’Dwyer et al., 2002). Antibodies to 
alpha enolase have also been found in sera from patients with SLE, particularly those with 
renal disease (Moodie et al., 1993). An evaluation of antibody titers from patients with ARF 
has shown the serum to have higher levels of antibodies that react with the human and 
bacterial enolases compared to serum samples from patients with streptococcal 
pharyngitis or healthy control subjects (Fontan et al., 2000).  
As a glycolytic enzyme enolase is found in the cytoplasm, but it is also found on the cell 
surface especially on the synaptic membrane (Ueta et al., 2004). The function of enolase on 
the synaptic membrane is not fully understood but it is known to possess enzymatic activity 
(Pancholi V., 2001). Fluorocytometric analysis has also revealed that anti-streptococcal 
enolase antibodies react with the enolase expressed on the surface of haematopoietic cells 
(Fontan et al., 2000). There is only a poor influx of the enolase educt 2-phosphoglycerate 
(DPG) into the cells (Hamasaki et al., 1978) so that the main enolase activity measured in 
this assay comes from the surface enolase and released enolase. So in this study it was 
attempted to determine if the activity of cell surface enolase present in PC12 neuronal cells 
was directly affected though binding of anti-neuronal antibodies present in sera of patients 
diagnosed with TS, SC, EL and dystonia. This method differed from the assay protocols 
previously described which measured the transformation of NADH to NAD after the 
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addition of a test solution containing enolase (Pancholi and Fischetti, 1998; Whiting et al., 
2002). 
A marked inhibition of the enzymatic activity of enolase was after the addition of sera 
antibodies from patients as opposed to healthy controls. This confirms cell surface enolase 
as a target autoantigen in this group of neuropsychiatric movement disorders. Future work 
revolves around further refining the enolase enzymatic assay and defining the threshold 
values for both patient and control populations such that it can be introduced as a 
diagnostic test to detect the presence of anti-enolase antibodies.  
The α1 subunit of Na+/K+- ATPase contains multiple structural motifs that interact with 
soluble, membrane and structural proteins including Src, caveolin-1, phospholipase C-γ, PI3 
kinase, IP3 receptor, BiP, calnexin, cofilin, and ankyrin (Barwe et al., 2005). Binding to these 
proteins not only regulates the ion-pumping function of the enzyme, but it also conveys 
signal-transducing functions to the Na+/K+-ATPase (Kaplan, 2005; Li and Xie, 2009). As seen 
in the previous chapter anti-neuronal antibodies present in sera from patients diagnosed 
with TS and other postulated post-streptococcal antibodies result in cell cytotoxicity, 
apoptosis and increased calcium flux. Also in the present chapter enolase has been 
demonstrated as one of the targets for these antibodies. I postulated that enolase might be 
one of the proteins associated with the  Na+/K+-ATPase that regulates numerous cell 
functions in various types of organs and cells including cell motility, cell proliferation, 
glycogen synthesis, apoptosis, hypertension, intracellular calcium signalling, cardiac 
hypertrophy, renal and  cardiac  remodelling, epithelial cell tight junction, vascular tone 
homeostasis, and sodium homeostasis (Liu et al., 2012). Following this hypothesis 
undifferentiated and PC12 cells differentiated into neurons were stained for enolase and 
Na+/K+ -ATPase and found the two to be co-expressed. Diffused staining was repeatedly 
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observed despite using various methods of cell fixation and blocking. Hence this 
experiment needs to be optimised with a further set of antibodies and other neuronal cell 
lines.  
As mentioned earlier it was postulated that enolase and Na+/K+-ATPase might be present 
on lipid rafts that are glycolipoprotein microdomains present in the plasma membrane of 
the cell. The size of the lipid rafts are ranges from 10–200 nm (Pike, 2008). Their size being 
below the classical diffraction limit of a light microscope has made it difficult to visualize 
them. Future experiments would involve staining the rafts with fluorophores conjugated to 
cholera-toxin B-subunit, which binds to the raft constituent ganglioside GM1. 
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CHAPTER 6 
NMDAR AND VGKC ASSAY 
 
6.1 INTRODUCTION 
6.1.1 N-Methyl-D-Aspartate Receptor (NMDAR) 
6.1.1.1 Background 
L-Glutamate is a major excitatory neurotransmitter in the mammalian CNS acting via two 
classes of receptors, ligand gated ion channels (ionotropic) and G-protein coupled 
(metabotropic) receptors (Dongen, 2009). The N-methyl-D-aspartate receptor (NMDAR) is a 
specific type of ionotropic receptor belonging to the glutamate receptor superfamily 
together with AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) and kainate 
receptors (Dingledine et al., 1999). Both NMDA and non-NMDA receptors are activated by 
the endogenous transmitter, L-glutamate, however, L-aspartate, a putative endogenous 
transmitter appears to activate NMDA only (Patneau and Mayer, 1990). Glycine, which was 
first reported to potentiate NMDAR activation at submicromolar levels (Johnson and 
Ascher, 1987), was later shown to be an essential co-agonist for this receptor (Kleckner and 
Dingledine, 1988). NMDA receptors are inactive at resting membrane potential this is due 
to a voltage dependent block of the pore by magnesium ions (Mayer et al., 1984). Their 
activation is secondary to kainate or AMPA receptor activation that leads to depolarization 
of the neuron causing the release of the Mg2+ blockade (Ascher and Nowak, 2009). The 
NMDAR is most abundant in the cortex, basal ganglia, and sensory pathways of the nervous 
system, but have also been identified in a variety of non-neuronal and peripheral locations 
(Bolton and Paul, 2006). 
Electrophysiological studies using recombinant receptors suggest that functional NMDA 
receptors consist of heteromers containing combinations of two subunits (1) NR1, which is 
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essential for channel activity (2) NR2 which modulates the properties of the channels 
(Dunah et al., 1999). Individual subunits and multiple receptor isoforms that arise by 
selective splicing of the NR1 transcripts and differential expression of the NR2 subunits 
have been well characterized and found to have distinct brain distributions and diverse 
functional properties (Flores Soto et al., 2012). The binding sites for the two NMDA 
agonists, glutamate and glycine are found on different subunits - glycine binds to the NR1 
subunit while glutamate binds to the NR2 subunit. Both binding sites interact allosterically 
and this is one of the reasons why both subunit types are required to generate a fully 
functioning receptor (Lester et al., 1993). A related gene family of NR3 subunits is the most 
recently discovered members of the NMDAR family. They form excitatory glycine receptors 
when co-assembled with NR1 that are calcium-impermeable and unresponsive to 
glutamate (Chatterton et al., 2002). The lack of agonists or antagonists selective for a given 
subunit of NMDA receptors has made it difficult to understand the subunit expression, 
composition, and post-translational modification mechanisms. 
The NMDAR is highly permeable to calcium ions and plays a key role in the plasticity of 
synapses, which is believed to underlie memory and learning, as well as the development 
of the nervous system (Yamazaki, 1992). It works together with metabotropic glutamate 
receptors, ensuring the establishment of long-term potentiation (LTP), a process thought to 
be responsible for learning and memory (Zhuo et al., 2009). These functions are mediated 
by calcium entry though the NMDA receptor-associated channel which activates a number 
of Ca2+-dependent enzymes that influence a wide variety of cellular components like 
cytoskeletal proteins or second messenger synthases like Ca2+/calmodulin kinase II (CaMKII) 
(Strack et al., 1997; Bayer et al., 2001). However, over activation at NMDA receptors, 
triggers an excessive entry of Ca2+, initiating a series of cytoplasmic and nuclear processes 
that promote neuronal cell death (Churn et al., 1995, Wroge et al., 2012). 
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6.1.1.2 NMDAR Encephalitis and other Disorders 
The NMDAR have been associated with a variety of neurological disorders including 
ischemic brain damage and epilepsy, and, more speculatively with neurodegenerative 
disorders such as Alzheimers, Huntingtons chorea, and ALS (Waxman and Lynch, 2005; 
Ghasemi and Schachter, 2011). 
Anti-NMDA receptor encephalitis has been recently identified as treatment responsive 
encephalitis associated with anti-NMDA receptor antibodies (Iizuka and Sakai, 2008). These 
antibodies bind to the NR1/NR2 heteromers of the NMDA receptors and antibody levels 
are known to correlate with the clinical severity of the disease (Irani and Vincent, 2011).  
Recent studies have demonstrated that these antibodies cause a reversible reduction in the 
numbers of cell-surface NMDA receptor clusters in post-synaptic dendrites, suggesting 
antibody mediated decreased NMDA receptor function (Iizuka, 2009).  
NMDAR encephalitis is highly characteristic occurring in five stages: the prodromal phase 
with viral infection like symptoms, psychotic phase, unresponsive phase, hyperkinetic 
phase, and gradual recovery phase (Iizuka et al., 2010). Psychiatric manifestations are 
observed that upon progression lead to decrease of verbal output, catatonia, seizures, 
dyskinesias, hypoventilation and frequent autonomic instability (Ryan-N et al., 2011). In 
some cases it is a paraneoplastic syndrome usually affecting childbearing-age female with 
ovarian tumours, however, recent reports suggest a much higher incidence of 
nonparaneoplastic cases in males and children (Lebas et al., 2010; Hung et al., 2011). 
Treatment of anti-NMDAR encephalopathy includes immunotherapy and/or tumour 
removal. Anecdotal reports have revealed that recovery may be spontaneous without 
tumour resection but early tumour resection along with aggressive immunotherapy 
facilitates early functional recovery and 65% of patients with anti-NMDAR encephalopathy 
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exhibit full or near-full recovery (Suzuki et al., 2008). Most patients receive corticosteroids, 
IVIg or plasma exchange as first-line of immunotherapy (Dalmau et al., 2011). It is likely that 
patients who do not respond to one form of immunotherapy might respond to others 
regimens including plasmaphoresis, cyclophosphamide, and rituximab (Irani and Vincent, 
2011). 
Clinical features seen in EL coincide with the NMDAR receptor encephalitis which might 
make it a part of the spectrum of anti-NMDAR disorders. Dale et al. (2009) studied sera 
from paediatric patients with contemporary EL and found 10 sera out of 20 (from 2 males 
and 8 females, aged 1.3–13 years) and 6/6 cerebrospinal fluid samples positive for 
antibodies against the NMDA receptor. Different disease phenotypes were observed 
between the NMDA receptor positive and negative patients suggestive of different 
pathogenic targets. The antibody concentration in all cases was found to be higher in the 
serum than CSF (Dale et al., 2009).  
Other studies have shown NMDAR hypofunction as a central component of the functional 
dysconnectivity as the most accepted model of symptoms seen in schizophenia, a complex 
disorder with unknown aetiology.  Zandi et al. (2010) tested the serum of 46 patients (63% 
schizophenia, 15% psychosis not otherwise specified, 13% bipolar affective disorder, 4% 
schizoaffective disorder, 2% major depression with psychosis and 2% delusional disorder) 
for antibodies against NMDA receptor and found 4 schizophenia patients positive for these 
antibodies (Zandi et al., 2010).   
Studies have also implicated the NMDA receptor in the development of EAE the 
representative model of multiple sclerosis, with a particular role in the loss of blood brain 
barrier (BBB) function and recruitment of inflammatory cells (Paul and Bolton, 1995). A 
recent case study has also reported the presence of anti-NMDA antibody-positive limbic 
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encephalitis in a patient with multiple sclerosis. The simultaneous manifestation of both 
diseases has never been reported before and is suggestive of a possible link between these 
diseases or underlying, autoimmune responses that may be important for the development 
of autoimmune encephalitis (Uzawa et al., 2011). 
6.1.2 Voltage Gated Potassium Channels (VGKC) 
6.1.2.1 Background 
Potassium channels are a ubiquitous and diverse family of membrane proteins present in 
both excitable cells such as neurons and nonexcitable cells (Heinemann and Hoshi, 2006). 
Members of this channel family play critical roles in cellular signalling processes regulating 
neurotransmitter release, heart rate, neuronal excitability, epithelial electrolyte transport, 
insulin sretion, smooth muscle contraction, and cell volume regulation (Shieh et al., 2000). 
Voltage-gated potassium channels (Kv channels) are transmembrane channels that allow 
rapid and selective flow of potassium ions across the cell membrane thereby generating 
and propagating electrical impulses in the nervous system (Sands et al., 2005).  
Typically, vertebrate voltage-gated K+ channels are tetramers of two functionally and 
structurally independent domains: an ion conduction pore, and voltage-sensor domains. 
The ion conduction pore is composed of four subunits arranged symmetrically as a ring 
around the conduction pathway (Jiang et al., 2002; Khalili-Araghi et al., 2006). Voltage-
sensor domains are positioned at the periphery of the channel and consist of four 
transmembrane segments (S1-S4) (Gandhi et al., 2002). The structural element responsible 
for the high selectivity of the channel is a sequence of five amino acids, TVGYG that is 
highly conserved among potassium channels ,this forms the narrowest part of the channel, 
also known as the selectivity filter (Lu et al., 2001). 
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6.1.2.2 VGKC and Autoimmune disorders 
Anti-voltage-gated potassium channel antibodies (anti-VGKC-Ab) are known to cause 
hyperexcitability of the CNS and peripheral nerve (Arimura et al., 2007). These antibodies 
are known to cause three rare neurological syndromes: neuromyotonia, limbic encephalitis 
and Morvan’s syndrome although an increasing array of other associated neurological 
symptoms are now becoming recognised (Molloy et al., 2011). 
Limbic encephalitis typically presents with subacute cognitive decline, seizures and 
behavioral disturbances like disorientation, anxiety, depression and hallucination (Derry et 
al., 2011). Paraneoplastic cases are rare unlike other anti-VGKC-Ab-associated neurological 
disorders. Current diagnostic criteria is based on neuropathological/neuroradiological 
evidence of a malignancy, usually small-cell lung cancer, testicular cancer, or thymoma 
(Graus et al., 2004). However, it is now recognised that in a small proportion of cases this 
syndrome is not paraneoplastic in nature (Buckley et al., 2001). Morvan syndrome is 
characterized by neurological symptoms involving the autonomic system (hyperhidrosis, 
urinary incontinence, and cardiac arrhythmia), peripheral nervous system (neuromyotonia), 
and the CNS (severe insomnia, hallucinations, impairment of short-term memory and 
epilepsy) (Vincent et al., 2004; Misawa  and Mizusawa, 2010). Both VGKC-Ab-associated 
limbic encephalitis and Morvan syndrome are treatable conditions responding well to 
responding well to cortico-steroid therapy, plasma exchange and intravenous 
immunoglobulin (Vincent et al., 2004; Misawa and Mizusawa, 2010). Until recently, 
children with encephalitis were not routinely tested for VGKC antibodies and testing 
typically occurred only after an year or more of symptoms (Dale and Vincent, 2010).  
Detection and measurement of VGKC Abs are useful in the diagnosis and management of 
autoimmune VGKC channelopathies and related neurological disorders. It has recently 
203 
 
become evident that the actual antigens involved in antibody binding are in fact proteins 
closely complexed with VGKC namely LGI-1 (leucine-rich glioma inactivated 1) and Caspr-2 
(contactin-associated protein-like 2) and less frequently Contactin-2 (Irani and Vincent, 
2011). Early clinical descriptions suggest that LGI-1 antibodies are mostly associated with 
the classic limbic encephalitis (Dalmau et al., 2010), whereas Caspr-2 antibodies are 
associated with both limbic encephalitis and neuromyotonia (Lancaster et al., 2011).  
6.2 HYPOTHESIS AND AIMS: 
The spectrum of neurologic manifestations and neoplasms associated with voltage-gated 
potassium channel autoimmunity is broader than previously recognized. Similarly 
pathogenic antibodies against the NMDAR have been implicated in a range of disorders; 
however, the full clinical spectrum and treatment responses are still unclear. Therefore, in 
the present study I analysed serum samples from a mixed cohort of patients with a range of 
neuropsychiatric movement disorders for the presence of anti-NMDAR and anti-VGKC 
antibodies. 
6.3 MATERIALS AND METHODS 
6.3.1 Patient Samples 
A total of 46 patients samples were used for both NMDAR and VGKC assay. The cohort 
included sera from patients with TS (n=21), EL (n=11), chorea (n=6), dystonia (n=4) and 
PANDAS (n=4). The mean age of patients with TS was 11 years with an age range of 7-14 
years. Only 2 out of the 21 TS patients were females. Patient material was obtained with 
informed consent and appropriate ethical review. 
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6.3.2 NMDAR Assay  
The NMDAR assay is a cell based assay used for detection of anti-NMDA antibodies present 
in serum/CSF employing human embryonic kidney 293 cells (HEK293) transfected with NR1 
and NR2B NMDAR subunits and co-transfected with EGFP (enhanced green fluorescent 
protein). The assay was carried out with Dr. Leslie Jacobson at the Weatherall Institute of 
Molecular Medicine, University of Oxford.  
Day 1 
3 coverslips of 13 mm diameter were put into each well of a 6 well plates using fine 
forceps. Approximately 2mL of poly-L-lysine (0.01% in PBS) was added to each well and 
incubated for 15-20 min. Following the incubation the supernatant was taken off and the 
plates were left to dry in the tissue culture hood with the lid open. 3 x 105 HEK293 cells in 
2mL of Dulbecco’s modified Eagle’s medium (DMEM) with 10% foetal calf serum (FCS) and 
penicillin, streptomycin and amphotericin (DMEM+FCS+P/S) were seeded into each well 
and the plates were incubated for 24 hours at 37°C in a humidified chamber. 
Day 2  
Transfection of HEK cells with the NR1:NR2B glutamate receptor subunits was carried out 
with untagged-NR1 and NR2B cDNA at a ratio of 3:1. An EGFP expression vector was co-
transfected to visualize cells taking-up cDNAs. DNA and polyethylenimine (PEI) mixture was 
prepared as described below: 
4 μg DNA/well (NR1:NR2B in a ratio of 3:1)  
1.5μL PE/well 
50μL DMEM medium without supplements 
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The above mixture was incubated at RT for 10 min before adding it to the cells. 
Day 3 
500 μM of ketamine was added to the cells 16 hs post- transfection. Ketamine is one of the 
most common glutamate receptor antagonists and therefore it blocks the NR1/NR2 
subunits which become functional when transfected into cells. These functional subunits 
lead to cell apoptosis. 
Day 4 
Serum samples were diluted 1:20 in DMEM+HEPES+1% BSA (2.3 gms HEPES/500mL DMEM) 
to make up a total volume of 200 μL/sample. The serum samples were then transferred to 
24-well cell culture plates and a coverslip coated with NR1/NR2 transfected HEK cells was 
then placed in each well with a serum sample. The plates were then incubated for 60 
minutes at RT in the dark. Following the incubation the supernatant was taken off and the 
wells were washed 2 x with DMEM with HEPES and 1 x with PBS. The cells were then fixed 
using 4 % paraformaldehyde (PFA) and incubated for 10 min at RT followed by 3X washes 
with DMEM+HEPES. 250μL of goat anti-human IgG, AlexaFluor 568 secondary antibody 
diluted 1:750 in DMEM+HEPES+BSA was then added and the samples were incubated for 
45 min at RT in the dark. The samples were then washed 2X in DMEM+HEPES and 3X in 
PBS. Each coverslip (cell side down) was placed on a drop mounting medium containing 
DAPI (~ 20 μL) on superfrost microscopic slides. The slides were then left to dry in the dark 
for atleast 3 h before viewing them under Leica DM 2000 fluorescent microscope. Pictures 
were taken using QCapturePro programme. The slides were then stored at 4°C.  
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6.3.3 VGKC Assay 
The VGKC assay was carried out by Dr. Bethan Lang at the Weatherall Institute of Molecular 
Medicine, University of Oxford. In the VGKC autoantibody assay, antibodies in patient sera 
and controls are allowed to interact with detergent solubilised VGKCs extracted from rabbit 
brain tissue and complexed with 125I-labelled α-dendrotoxin. 
6.3.3.1 Preparation of whole rabbit brain homogenate 
Whole rabbit brain was homogenised with 6X volumes of the solubilisation buffer 
containing protease inhibitors. An electric homogeniser was used for 3 x 10 seconds, 
returning the tissue/homogenate to ice in between pulses. The homogenate was then 
centrifuged at 17,000 x g at 4°C for 10 min following which the supernatant was discarded 
and the precipitate was re-suspended in an equal volume of SB (+ PIs) as the original tissue 
weight. The aliquots were stored at -80°C until required. 
6.3.3.2 Preparing the VGKCs  
2mLs dendrotoxin buffer pH7.12 
500µL whole rabbit brain homogenate 
0.05g Calbiochem high purity digitonin 
5µL 0.1M PMSF 
The buffer was warmed in a glass universal in a 37°C water bath and digitonin was added 
onto the surface of the buffer. Whole rabbit brain homogenate was then added together 
with PMSF and mixed carefully following incubation in the water bath at 37°C for a further 
15 MIN . This mixture was then transferred to clear eppendorf/microcentrifuge tubes 
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without making bubbles and microfuged at 17,000 x g for 15 min at RT. The supernatant 
was then removed, which contained the soluble VGKC and the pellet discarded. The VGKCs 
in the supernatant were used directly to make the assay mix with the 125I α-dendrotoxin 
(prepared as directed by the manufacturer). Generally, 2mLs VGKC from supernatant + 
2mLs PTX buffer + 125I α-Dendrotoxin to give ~ 45 – 50,000 cpm (measured counts per 
minute) for 50µL of the final mixture is used. This was done only when the VGKC 
supernatant was ready and was followed by direct incubation at RT for 15 min, and then 
transferred to 4°C. The samples were vortexed and then microfuged at 17,000 x g for 5 min 
just before aliquoting the appropriate amount (50µL) into the final assay incubation tube. 
At least 3 healthy control sera and a variety of known positive VGKC sera were used in each 
VGKC assay. 
6.3.3.3 Setting up the assay  
The diluted and microfuged control and test samples were aliquoted into the final assay 
tubes following the addition of the assay mix. For screening the serum samples a 1:1 
dilution was used: 50µL diluted serum + 50µL assay mix. The mixture was incubated 
overnight at 4°C. 
6.3.3.4 Precipitation with anti-human IgG  
50μL of sheep anti-human IgG (Fc) was used with 5 μL serum and incubated at room 
temperature for approximately 80 min. Once precipitated, 500µL PTX was added to each 
tube immediately before microfugation at 17,000 x g for 5 min. The supernatants were 
then aspirated immediately and the pellets washed twice with 500µL PTX.  
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6.3.3.5 Counting the radioactivity in the pellet  
For screening an assay of 5µL the mean cpm of the healthy controls was subtracted from 
the cpm of all other samples, divided by 10 and this equalled concentration of anti-VGKC 
antibodies present in the sample. 
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6.4 RESULTS  
6.4.1 Anti-NMDAR Antibodies 
The NMDAR assay was performed to analyse serum samples for presence of antibodies 
against the NMDA receptor using HEK293 cells transfected with NR1:NR2B subunits and co-
transfected with EGFP. According to the number of cells stained and intensity of staining 
the samples were scored between 0-4 (0= negative, 1= weakly positive, 4= strongly 
positive). The samples were used at a 1:20 dilution with repeats at various titrations like 
1:100 and 1:500. The sera were analysed against the glycine receptor as a positive control. 
4 out of the 46 serum samples used in this study tested positive for antibodies against the 
NMDAR receptor. All 4 serum samples came from male patients diagnosed with TS with 
ages ranging from 8 to 14 years.  
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Figure 6.1: Fluorescent 40x images of serum found positive for anti-NMDAR antibodies. 
The NMDAR assay was performed using HEK293 cells transfected with NR1:NR2B NMDAR 
subunits and co-transfected with EGFP. The images above are from a serum sample found 
positive for antibodies against the NMDAR. The serum came from a 14 year old male 
diagnosed with TS. (A) EGFP staining. (B) Positive staining for NR1:NR2B NMDAR subunits. 
(C) Merged image of A&B showing co-localization of EGFP and NMDAR subunits. (D) 
Merged image with DAPI stained nuclei showing co-localization of NR1:NR2B subunits, 
EGFP and DAPI. 
A 
C D 
B 
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Figure 6.2:  Fluorescent 40x images of serum found negative for anti-NMDAR antibodies. 
The NMDAR assay was performed using HEK293 cells transfected with NR1:NR2B NMDAR 
subunits and co-transfected with EGFP. The images above are from a serum sample found 
neagitve for antibodies against the NMDAR. (A) EGFP staining. (B) Negative staining for 
NR1:NR2B NMDAR subunits. (C) Merged image of A&B showing co-localization of EGFP and 
NMDAR subunits. (D) Merged image with DAPI stained nuclei showing co-localization of 
NR1:NR2B subunits, EGFP and DAPI. 
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6.4.2 Anti-VGKC Antibodies 
All 46 serum samples were also tested for antibodies against the voltage gated potassium 
channel. In the VGKC autoantibody assay, antibodies in patient sera and controls are 
allowed to interact with detergent solubilised VGKCs extracted from rabbit brain tissue and 
complexed with 125I-labelled α-dendrotoxin. High titres of anti-VGKC were seen in serum 
from 2 patients with measured counts per minute of 2566 and 215. Both these patients 
were diagnosed with chorea. 
6.5 DISCUSSION  
In the last decade significant advances have been made in understanding the spectrum of 
probable antibody-mediated central nervous system diseases. With the development of 
assays for detection of antibodies against cell surface neuronal proteins like the NMDA 
receptor and VGKC the diagnosis of these disorders has now become feasible. The full 
clinical spectrum of antibody mediated CNS disorders is now only likely to widen with their 
increasing recognition. 
 Antibodies against the NMDA receptor have now been implicated in a range of disorders 
like classical limbic encephalitis, psychosis and epilepsy and more recently also found in 
patients with multiple sclerosis, EL and schizophrenia. In the present study the presence of 
anti-NMDAR antibodies in the sera of 4 TS patients has been demonstrated. This finding to 
the best of our knowledge is the first to show the presence of anti-NMDAR antibodies in a 
minority of subjects with TS. TS is comorbid with multiple conditions like OCD, ADHD, 
depression and anxiety disorders (Martino et al., 2009) so an understanding into its 
pathogenic mechanism would have major implications in the field of neuropsychiatry. 
Previously TS and OCD were considered to be disorders mediated by serotonin and 
dopamine mechanisms but now the role of glutamate is becoming important given its 
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pivotal role in neurotransmission and neuronal development (Pittenger et al., 2006). A 
study by McGrath et al. (2000) has demonstrated using D1CT model of comorbid  TS+OCD, 
that glutamatergic drugs such as MK-801, a non-competitive NMDA receptor antagonist, 
indirectly stimulate the cortical-limbic glutamate output and aggravate abnormal behaviour 
(repetitive climbing and leaping) (McGrath et al., 2000). Further evidence implicating 
glutamatergic transmission in OCD has come from rat model of OCD in which Albelda et al. 
(2010) have shown that D-cycloserine (15mg/kg), a partial NMDA agonist can selectively 
decrease compulsive lever pressing suggesting that activation of NMDA receptors may have 
an anti-compulsive effect in OCD patients (Albelda et al., 2010).  
VGKC given their pivotal role in various physiological processes including neuronal 
signalling are increasingly being elucidated as molecular targets in a number of 
pathophysiologic states, and they continue to trigger considerable enthusiasm as drug 
targets. Anti-VGKC antibodies have been suggested to cross the BBB and act centrally, 
binding predominantly to thalamic and striatal neurons causing encephalopathic and 
autonomic features (Irani and Vincent, 2011). In the present study anti-VGKC antibodies 
were detected in 2 serum samples, both of which came from patients with chorea. 
Interestingly, testing for anti-VGKC antibodies have become part of the investigation of 
patients with unexplained subacute onset of epilepsy, memory or cognitive problems, or 
peripheral nerve hyperexcitability syndrome. 
Increasing amount of evidence both in vitro and in vivo is pointing towards the 
pathogenicity of antibodies against cell surface proteins. The production of these 
antibodies is probably the result of a combination of factors such as genetic pre-
disposition, presence of a systemic tumor or molecular mimicry caused by a prodromal 
infection. Irrespective of the cause, until now in most cases, the associated syndromes have 
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been responsive to immunotherapy, which highlights the importance of their detection in 
patients with otherwise unexplained encephalopathic symptoms. Autoimmune diseases 
have previously been studied on the basis of the affected organ, looking for a single 
causative factor, however, in the recent years the focus has changed to a more cross-
disciplinary approach of these multifactorial diseases, with a view to providing a better 
understanding of the common mechanisms underlying their pathogenesis. The aim now is 
to tailor diagnosis and treatment by establishing these syndromes in terms of their full 
range of clinical presentations, frequency, means of early recognition, and optimal 
immunotherapy. 
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CHAPTER 7 
CONCLUSIONS AND FUTURE WORK 
 
7.1 OVERVIEW  
In the last decade significant advances have been made in understanding the spectrum of 
probable antibody-mediated central nervous system diseases.  A complex interplay 
between an array of both environmental and genetic factors underlie these disorders. The 
present study is focussed on unravelling the complex pathogenesis of neurological and 
neuropsychiatric disorders that have been linked to GABHS like SC, TS, and EL.  
Although the pathophysiology of post-streptococcal disorders is not completely 
understood, antigenic mimicry is proposed to be the triggering cause of autoimmunity 
(Hahn et al., 2005, David Greenwood, 2007). It is a possibility that GABHS needs to be the 
initial autoimmunity-inciting event but that subsequent symptom exacerbations might be 
triggered by viruses, other bacteria, or non-infectious immunologic responses. In the 
pathogenesis of these diseases, host factors may also be of critical importance.  Gender 
appears to be a risk factor, as three-quarters of the PANDAS are males whereas SC  is more 
prevalent amongst females. The age of the host also may determine susceptibility as it is 
known that rheumatic fever and SC are quite rare after puberty. It is also possible that the 
post-pubertal decrease in incidence is related to the fact that the rate of GABHS infections 
falls dramatically around the age of 12, presumably because the child has developed 
antibodies against the conserved portion of the M-protein. Genetic control of the immune 
response may contribute to differential vulnerability to PANDAS. Mouse genetic models 
suggest that the response to infectious pathogens is strain specific. Different strains have 
different qualitatively and quantitatively  response that leads to very different clinical 
outcomes.  
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To conclude the entity of CNS diseases falling under the post-streptococcal umbrella is still 
controversial. A multidimensional approach was undertaken to understand the complex 
dynamics of these disorders as briefly summarised below. 
 
Figure 7.1: An overview of the work carried out during the PhD 
This PhD provides a brief insight into this spectrum of disorders. The synopsis of the results 
obtained is briefly described below together with the potential future work I would like to 
perform working as a post-doctoral scientist.  
7.2 GABHS  
7.2.1 Patient Vs Control Phenotype 
Among the various factors involved in the virulence of GABHS, the M protein and 
streptococcal superantigens have been the focus of interest because of their potential role 
in both autoimmunity and manifestations in acute infections. In the present study GABHS 
samples from both patients and controls were typed for the emm gene and the presence of 
SAg. One aim was to determine whether emm types and SAg were more prevalent in 
patients diagnosed with suspected post-streptococcal neuropsychiatric disorders as 
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compared to neurological controls and if there was any co-relation between the two 
virulence factors. Our results showed that certain emm types were found only in the 
patient population like emm4, emm11 and emm3. Different emm types tend to 
predominate in different age groups and geographical locations. The combination of 
factors results in a complex epidemiologic situation for GABHS infections requiring a 
deeper understanding of geographic and temporal variation in emm types. Once again a 
range of superantigens were observed to be present only in the patient isolates like speA, 
H, I, J, K, L and M which might be enhancing the pathogenicity of these isolates. Whilst 
studying the link between the two factors a few observations were made like speL and M 
were found only in emm type 4 patient samples and not controls. Certain combinations of 
superantigen genes are found to be more common and the majority of emm types showed 
restricted superantigen profiles.  
The pattern seen in our study has been consistent with previous findings in the field making 
it possible for us to draw certain definitive conclusions about the co-relation between the 
two virulence factors. However, the importance and relevance of these relationships needs 
further investigation by clarifying their role in the outcome of infection with GABHS. The 
data presented will be taken forward by analysing a large cohort of both patient and 
control samples as it could be of value for preventive work, including ongoing attempts at 
creating vaccine prophylaxis against GABHS disease.  
7.2.2 Is GABHS linked to this group of disorders? 
Only a limited number of animal models have been set up using GABHS to confirm its link 
with the onset of a spectrum of neuropsychiatric disorders in children. Animal models to 
test the hypothesis that an immune response to GABHS can result in behavioural 
abnormalities was carried out by Hoffman et al. (2004), Yaddanapudi et al. (2009) and 
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Brimber et al.  (2012). They observed deficits in motor coordination, learning/memory and 
social interaction in PANDAS mice, replicating more complex aspects of human disease. In 
our active immunization mouse model the animals exhibited decreased activity in the open 
field activity chamber. Although no motor deficits were observed using the rotor rod 
testing. The lack of detailed behavioural testing in our study may have prevented us from 
picking up subtle behavioural and locomotor abnormalities reminiscent of these disorders.  
7.2.2.1 Future Work 
This animal model would be taken further by injecting mice with purified M proteins 
(perhaps specific serotypes) or/and superantigens which would help us establish a link 
between streptococcus and these disorders together with pin pointing the proteins causing 
the virulence. Also a number of behavioural tests will be set up to better evaluate these 
animals. In addition videotaping th animals would help observe subtle signs and changes in 
behaviour. 
In an in vitro setting I would like to create a GABHS infection model using cultured 
phagocytes to study dose-dependent apoptosis. GABHS have been seen to induce 
apoptosis in human neutrophils (Kobayashi et al., 2003) although the specific virulence 
factor(s) involved and effects on caspase activation have not yet been explored. I could 
therefore use purified SAg and M proteins to study their individual pathogenic effect on 
cellular and sub-cellular targets.  
7.3 AUTOANTIBODIES  
7.3.1 In vivo effect  
Previous studies have shown the effects of infusing serum immunoglobulin from patients 
with PANDAS into rat striatum found an increase in stereotypical movements compared to 
control antibodies (Hallett et al., 2000; Taylor et al., 2002). However, another group using 
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the same methods failed to reproduce the results (Loiselle et al., 2004). The present study 
is the first of its kind to create an intra-cerebral animal model of neuropsychiatric disorders 
like EL. In the present study it was aimed to determine the specificity of anti-basal ganglia 
antibodies and hence compare the effects of antibodies from both EL and dystonia 
patients. A varied phenotype was observed in the two cohorts with some common features 
like rigidity. The development of symptoms in mice after induction of autoantibodies 
representative of the disease in question confirms the pathogenicity and specificity of 
these antibodies. Although part of the same disease spectrum antibody we are possibly 
dealing with variable cellular and sub-cellular targets in this group of disorders. Given its 
novelty the present animal model only forms the basis for a much larger experiment. 
7.3.1.1 Future work  
Future work will involve injecting animals specifically into the basal ganglia which will be 
achieved by using a stereotactic frame. Additionally, antibodies from patients with TS 
would be use to determine the development of any stereotypies and episodic utterances 
that have been proposed as a model of motor and vocal tics.  Also affinity purified 
antibodies against the known autoantigens especially enolase from sera of patients would 
be used to compare its effect with those seen with the commercial monoclonal antibody. 
electrophysiological experiments would be performed to rule out the occurrence of 
epileptic seizures, and confirm that the stereotypical movements seen in the mice are 
indeed representative of the disorders in question.  
7.3.2 In vitro effect 
 
It was hypothesized that an antibody-mediated autoimmune mechanism as well as 
bacterial infection contributed to the pathogenesis of neuropsychiatric movement 
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disorders like TS and SC. Hence the effect of patient and control antibodies was studied on 
both neuronal and non-neuronal cells in terms of cytotoxicity, apoptosis and intracellular 
calcium flux. A significant increase in both cytotoxicity and apoptosis was observed in 
response to patient antibodies highlighting their pathogenic effect. The cytotoxic and 
apoptotic effect of patient antibodies was consistent in both undifferentiated and PC12 
differentiated into neurons. The main form of enolase dimer on undifferentiated cells is the 
αα-homodimer (non-neuronal enolase) (Vinores et al., 1981). A change from non-neuronal 
to neuron specific enolase (αγ and γγ –dimer) during PC12 differentiation into neurons has 
also been documented (Schemedel et al., 1980). Additionally patient antibodies caused a 
significant increase in intracellular calcium flux in neuronal cells which could  be responsible 
for activation of a number of enzymes, including phospholipases, endonucleases, and 
proteases which lead to damage of structures like the components of DNA and the 
cytoskeleton (McConkey and Nutt, 2001; Gronski et al., 2009) thereby leading to neuronal 
dysfunction. 
7.3.2.1 Future work 
In the present study it was not possible to perform an ATP assay due to technical 
difficulties. As part of the future studies I would like to determine the ATP/ADP ratios using 
a luciferase chemiluminescence assay (Pocock & Nicholls. 1998) to determine whether 
energy metabolism is also altered. ATP levels need to be assessed since apoptosis may be 
triggered upstream by perturbations in ATP, in particular a fall in ATP. It is also possible that 
an increase in ATP in some instances given current suggestions that cell surface glycolytic 
enzymes may actually serve to generate energy at the membrane (Dubinsky et al., 1998).  
Although an effect of autoantibodies from patients on calcium flux was demonstrated, an 
identification of target receptor/channel is still pending that would help understand the 
downstream alterations in signal transduction. Some initial studies with patient IgG have 
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indicated decreased calcium responses in cultured neurones to a depolarising stimulus. In 
cultured neurones, enhanced intracellular free calcium provides trophic functions for 
neuritogenesis and gene transcription, particularly via the NMDA receptor and L-type 
calcium channel (Helton et al., 2005). In my future experiments I would determine the 
effects of purified monospecific antibodies on KCl-evoked calcium responses as well as 
NMDA stimulated calcium responses. Single cell Ca2+ responses can then be measured by 
fluorescence imaging as previously described (Evans & Pocock, 1999; Pocock and Evans 
2000). 
7.3.3 Other Potential Targets 
Antibodies against the NMDA receptor have now been implicated in a range of disorders 
like classical limbic encephalitis, psychosis and epilepsy and more recently also found in 
patients with multiple sclerosis, EL and schizophrenia. In the present study I have 
demonstrated the presence of anti-NMDAR antibodies in the serum of 4 Tourette’s 
patients. Previously TS and OCD were considered to be disorders mediated by serotonin 
and dopamine mechanisms but now the role of glutamate is becoming plausible given its 
pivotal role in neurotransmission and neuronal development (Pittenger et al., 2006). Also 
since testing for anti-VGKC antibodies have become part of the investigation of patients 
with unexplained subacute onset of epilepsy, memory or cognitive problems, or peripheral 
nerve hyperexcitability syndrome I tested our samples for anti-VGKC antibodies which were 
detected in 2 serum samples, both of which came from patients diagnosed with chorea.  
7.3.3.1 Future work 
Future studies involve testing this cohort of samples for presence of anti-dopamine 
receptor antibodies since in a rat model of PANDAS described recently alterations in 
dopamine and glutamate levels were seen in the cortex and basal ganglia. Furthermore, the 
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motor symptoms were found to improve by the D2 blocker haloperidol and the selective 
serotonin reuptake inhibitor paroxetine, respectively, these are the drugs used to treat 
motor symptoms and compulsions in streptococcal-related neuropsychiatric disorders 
(Brimberg et al., 2012).  
7.4 ENOLASE 
Enolase isoforms α and γ and their dimmers are some of the known targets of anti-
neuronal antibodies (Dale et al., 2004; 2006). In the present study the role of enolase as a 
target autoantigen in postulated post-streptococcal CNS disorders was confirmed. A two 
way approach was adopted to confirm this, firstly though an animal model where I direct 
infusion of mAb against enolase into mice and secondly in an in vitro setting by assessing 
the action of antibodies from patients on the functioning of this enzyme.  
7.4.1 In vivo proof 
I worked on the hypothesis that if enolase indeed is a one of the autoantigen in this group 
of disorders then injecting mice with monoclonal antibody (mAb) against the protein 
should also result in stereotypical movements similar to those seen in human subjects. 
Intra-cerebral induction of mAb against NSE did result in a phenotype very similar to that 
seen in mice injected with patient antibodies exhibiting classical symptoms of tremor and 
rigidity. The pathogenic effect was consistent even at ten-fold lower antibody 
concentration. The results of this experiment strongly implicate NSE as being one of the 
antibody targets in this spectrum of neuropsychiatric movement disorders.  
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7.4.1.1 Future work 
Future work will involve affinity purification of antibodies from patient sera using the 
recombinant protein enolase. These antibodies would then be sterotactically injected into 
the mouse basal ganglia.  
7.4.2 In vitro proof 
Fluorocytometric analysis has also revealed that anti-streptococcal enolase antibodies react 
with the enolase expressed on the surface of hematopoietic cells (Fontan et al., 2000). 
Keeping our results from the animal model and previous findings in mind I developed an 
enolase enzymatic assay to test sera for antibodies against enolase. There is only a poor 
influx of the enolase educt 2-phosphoglycerate (DPG) into the cells (Hamasaki et al., 1978) 
so that the main enolase activity measured in this assay comes from the surface enolase 
and released enolase. A marked inhibition of the enzymatic activity of enolase was 
observed after the addition of sera antibodies from patients as opposed to healthy 
controls.  
7.4.2.1 Future work 
Future work revolves around further refining the enolase enzymatic assay where I need to 
better define threshold values for both patient and control populations such that it can be 
introduced as a diagnostic screening test to detect the presence of anti-enolase antibodies.  
7.4.3 Membrane expression of enolase 
After confirmation that autoantibodies target cell surface enolase my next working 
hypothesis was where could this enzyme be expressed? It was postulated that since Na+/K+- 
ATPase interacts with soluble, membrane and structural proteins that regulate the ion-
pumping function and signal-transducing functions to the Na+/K+-ATPase (Kaplan JH, 2005; 
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Li and Xie, 2009) enolase might be one of the associated proteins. Following this hypothesis 
undifferentiated and PC12 cells differentiated into neurons were stained for enolase and 
Na+/K+ -ATPase and found the two to be co-expressed.  
7.5.3.1 Future Work 
Diffused staining was repeatedly observed despite using various methods of cell fixation 
and blocking. Hence these experiment need to be repeated with a new set of antibodies 
and other neuronal cell lines. As mentioned earlier I also postulated that both enolase and 
Na+/K+-ATPase might be present on lipid rafts which are glycolipoprotein microdomains 
present in the plasma membrane. Future experiments would involve staining the rafts with 
fluorophores conjugated to cholera-toxin B-subunit, which binds to the raft constituent  
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7.5 CONCLUSIONS 
In summary TS, SC, EL and other ABGA-associated disorders are still an emerging clinical 
entity, with major implications for neuropsychiatry. Establishing this group of disorders as 
“true” autoimmune diseases marks the first step towards future therapeutic strategies. All 
experiments conducted during the course of this PhD form the initial steps to understand 
the complex aetiology of these disorders. Further work needs to be done to disentangle the 
interplay between environmental factors and genetic background and translate these 
findings into clinical applications by developing disease prediction models and investigation 
of a treatment strategy. All the future work will be covered as part of a grant received by 
European Multicentre Tics in Children Studies (EMTICS) which is project funded by the EU 
programme FP7 combining 27 partners from 11 different countries. This programme aims 
to identify the genetic and environmental susceptibility factors of tic disorders leading to a 
better understanding of the underlying mechanisms, especially by elucidating the role of 
autoimmunity and infections.  
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FACS: ANNEXIN V APOPTOSIS  
Undifferentiated PC12 cells: Human Samples 
 
Supplementary Figure 1: FACS image for live and apoptotic undifferentiated PC12 cells 
after treatment with staurosporin (positive control). The above flow cytometry images 
show the percentage of live and apoptotic undifferentiated PC12 cells after treatment with 
staurosporin (1 μg/mL) a known inducer of apoptosis. 56.2% of cells were found to undergo 
apoptosis after addition of STS. Only 21.7% cells were found to be alive out of which 69.2% 
had intact mitochondrial function.  
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Supplementary Figure 2: FACS image for live and apoptotic undifferentiated PC12 cells 
after treatment with sera from a TS patient. The above flow cytometry images show the 
percentage of live and apoptotic undifferentiated PC12 cells after treatment with 1:100 sera 
from a TS patient. 46.6% of cells were found to undergo apoptosis after addition of sera 
antibodies. Only 31.1% cells were found to be alive out of which 81.5% had intact 
mitochondrial function. 
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Supplementary Figure 3: FACS image for live and apoptotic undifferentiated PC12 cells 
after treatment with sera from a healthy control. The above flow cytometric images show 
the percentage of live and apoptotic undifferentiated PC12 cells after treatment with 1:100 
sera from a healthy control. Only 17.6% of cells were found to undergo apoptosis after 
addition of control sera antibodies. 68.7% cells were found to be alive out of which 86.4% 
had intact mitochondrial function. 
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Differentiated PC12: Human Samples 
 
                
 
 
Supplementary Figure 4: FACS image for live and apoptotic differentiated PC12 cells after 
treatment with staurosporin (positive control). Supplementary figure 4: The above flow 
cytometry images show the percentage of live and apoptotic PC12 cells differentiated into 
neurons after treatment with staurosporin (1 μg/mL) a known inducer of apoptosis. 20.3% 
of cells were found to undergo apoptosis after addition of STS. 18.6% cells were found to be 
alive out of which only 18.9% had intact mitochondrial function. 
268 
 
 
 
A                                                                                                                                                                                                                
                                                            
 
 
 
 
Supplementary Figure 5: FACS image for live and apoptotic differentiated PC12 cells after 
treatment with sera from a TS patient. The above flow cytometry images show the 
percentage of live and apoptotic PC12 cells differentiated into neurons after treatment with 
1:100 sera from a TS patient. 15.5% of cells were found to undergo apoptosis after addition 
of sera antibodies. Only 5.2% cells were found to be alive out of which 19.4% had intact 
mitochondrial function. 
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Supplementary Figure 6: FACS image for live and apoptotic differentiated PC12 cells after 
treatment with sera from a healthy control. The above flow cytometry images show the 
percentage of live and apoptotic PC12 cells differentiated into neurons after treatment with 
1:100 sera from a healthy control. Only 6.1% of cells were found to undergo apoptosis after 
addition of control sera antibodies. 16.1% cells were found to be alive out of which 13% had 
intact mitochondrial function. 
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Undifferentiated PC12: ABH Animal Model 
 
Supplementary Figure 7: FACS image for live and apoptotic undifferentiated PC12 cells 
after treatment with sera from ABH (CFA only) animal model. The above flow cytometry 
images show the percentage of live and apoptotic undifferentiated PC12 cells after 
treatment sera from ABH mouse immunized with CFA only. 10.9% of cells were found to 
undergo apoptosis after addition of sera antibodies. Only 48.4% cells were found to be alive 
out of which 94.9% had intact mitochondrial function.  
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Supplementary Figure 8: FACS image for live and apoptotic undifferentiated PC12 cells 
after treatment with sera from ABH (GABHS) animal model. The above flow cytometry 
images show the percentage of live and apoptotic undifferentiated PC12 cells after 
treatment sera from ABH mouse immunized with GABHS protein fractions. 23.8% of cells 
were found to undergo apoptosis after addition of sera antibodies. Only 27.4% cells were 
found to be alive out of which 81.8% had intact mitochondrial function.  
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Supplementary Figure 9: FACS image for live and apoptotic undifferentiated PC12 cells 
after treatment with sera from ABH (RP) animal model. Supplementary figure 9: The 
above flow cytometry images show the percentage of live and apoptotic undifferentiated 
PC12 cells after treatment sera from ABH mouse immunized with recombinant proteins 
(aldC, enolase and PK). 45.1% of cells were found to undergo apoptosis after addition of 
sera antibodies. 39% cells were found to be alive out of which 70.3% had intact 
mitochondrial function.  
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Undifferentiated PC12: SJL Samples  
 
Supplementary Figure 10: FACS image for live and apoptotic undifferentiated PC12 cells 
after treatment with sera from SJL (CFA only) animal model. The above flow cytometry 
images show the percentage of live and apoptotic undifferentiated PC12 cells after 
treatment sera from SJL mouse immunized with CFA alone. 14.8% of cells were found to 
undergo apoptosis after addition of sera antibodies. 67.9% cells were found to be alive out 
of which 95.4% had intact mitochondrial function.  
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Supplementary Figure 11: FACS image for live and apoptotic undifferentiated PC12 cells 
after treatment with sera from SJL (GABHS) animal model. The above flow cytometry 
images show the percentage of live and apoptotic undifferentiated PC12 cells after 
treatment with sera from SJL mouse immunized with GABHS protein fractions. 20.7% of 
cells were found to undergo apoptosis after addition of sera antibodies.37.9% cells were 
found to be alive out of which 72.9% had intact mitochondrial function.  
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Supplementary Figure 12: FACS image for live and apoptotic undifferentiated PC12 cells 
after treatment with sera from SJL (RP) animal model. The above flow cytometry images 
show the percentage of live and apoptotic undifferentiated PC12 cells after treatment sera 
from SJL mouse immunized with recombinant proteins (ald C, enolase and PK). 14.1% of 
cells were found to undergo apoptosis after addition of sera antibodies. 46.8% cells were 
found to be alive out of which 84.8% had intact mitochondrial function.  
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Differentiated PC12: ABH Samples 
Supplementary Figure 13: FACS image for live and apoptotic differentiated PC12 cells 
after treatment with sera from ABH (CFA only) animal model. The above flow cytometry 
images show the percentage of live and apoptotic PC12 cells differentiated into neurons 
after treatment with sera from ABH mouse immunized with CFA alone. 4.9% of cells were 
found to undergo apoptosis after addition of sera antibodies .Only 6.6% cells were found to 
be alive out of which 26.7% had intact mitochondrial function.  
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Supplementary Figure 14: FACS image for live and apoptotic differentiated PC12 cells 
after treatment with sera from ABH (GABHS) animal model. The above flow cytometry 
images show the percentage of live and apoptotic PC12 cells differentiated into neurons 
after treatment with sera from ABH mouse immunized with GABHS protein fractions. 16.6% 
of cells were found to undergo apoptosis after addition of sera antibodies .Only 6.6% cells 
were found to be alive out of which 9.7% had intact mitochondrial function.  
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Supplementary Figure 15: FACS image for live and apoptotic differentiated PC12 cells 
after treatment with sera from ABH (RP) animal model. The above flow cytometry images 
show the percentage of live and apoptotic PC12 cells differentiated into neurons after 
treatment with sera from SJL mouse immunized with recombinant proteins (aldC, enolase 
and PK). 16% of cells were found to undergo apoptosis after addition of sera antibodies. 
Only 4.7% cells were found to be alive out of which 26.6% had intact mitochondrial function.  
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Differentiated PC12: SJL Samples 
 
Supplementary Figure 16: FACS image for live and apoptotic differentiated PC12 cells 
after treatment with sera from SJL (CFA only) animal model. The above flow cytometry 
images show the percentage of live and apoptotic PC12 cells differentiated into neurons 
after treatment with sera from SJL mouse immunized with CFA alone. 12.1% of cells were 
found to undergo apoptosis after addition of sera antibodies. Only 3.2% cells were found to 
be alive out of which 24.1% had intact mitochondrial function.  
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Supplementary Figure 17: FACS image for live and apoptotic differentiated PC12 cells 
after treatment with sera from SJL (GABHS) animal model. The above flow cytometry 
images show the percentage of live and apoptotic PC12 cells differentiated into neurons 
after treatment with sera from SJL mouse immunized with GABHS protein fractions. 18.5% 
of cells were found to undergo apoptosis after addition of sera antibodies. Only 4.2% cells 
were found to be alive out of which 8.7% had intact mitochondrial function.  
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Supplementary Figure 18: FACS image for live and apoptotic differentiated PC12 cells 
after treatment with sera from SJL (RP) animal model. The above flow cytometry images 
show the percentage of live and apoptotic PC12 cells differentiated into neurons after 
treatment with sera from SJL mouse immunized with recombinant proteins (aldC, enolase 
and PK). 16% of cells were found to undergo apoptosis after addition of sera antibodies. 
Only 4.7% cells were found to be alive out of which 26.6% had intact mitochondrial function.  
 
 
